76 results on '"Capici, S"'
Search Results
2. The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data
- Author
-
Capici S, Sala L, Galimberti S, Valsecchi MG, Squillace N, Gustinetti G, Cazzaniga ME, and Bonfanti P
- Subjects
sars-cov-2 ,covid-19 ,pneumonia ,tocilizumab ,Infectious and parasitic diseases ,RC109-216 - Abstract
Serena Capici,1,* Luca Sala,1,* Stefania Galimberti,2 Maria Grazia Valsecchi,2 Nicola Squillace,3 Giulia Gustinetti,3 Marina Elena Cazzaniga,1,4 Paolo Bonfanti3,4 1Phase 1 Research Unit, ASST Monza, Monza, Italy; 2Bicocca Bioinformatics Biostatistics and Bioimaging B4 Center, School of Medicine and Surgery, University of Milano - Bicocca, Monza, Italy; 3Infectious Disease Unit, ASST Monza, Monza, Italy; 4School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy*These authors contributed equally to this workCorrespondence: Marina Elena CazzanigaPhase 1 Research Unit, ASST Monza, Monza, ItalyTel +390392339037Email marina.cazzaniga@asst-monza.itAbstract: The severe acute respiratory syndrome coronavirus 2 pandemic has dominated the global health scenario from the beginning of 2020 and still represents a major health emergency. Cytokine inhibitors as tocilizumab have been used to treat COVID-19 severe pneumonia with conflicting results. We performed a retrospective study whose results can contribute to the general overview regarding the role of these agents in severe COVID-19 pneumonia, suggesting an interesting, even not statistically significant evidence of the effectiveness of tocilizumab treatment in this disease and sow a seed of reflection about their use in future waves of pandemic. We compared two cohorts of patients treated with local standard of care and with tocilizumab in the experimental one. With a median follow-up of 92 days, deaths were 6 and 16 in the tocilizumab and the standard of care group, respectively. With a longer follow-up than previous studies, a trend in difference with regards to mortality of the groups was observed.Keywords: Sars-Cov-2, COVID-19, pneumonia, tocilizumab
- Published
- 2021
3. GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial
- Author
-
Capone, S, Fusco, F, Milleri, S, Borre, S, Carbonara, S, Lo Caputo, S, Leone, S, Gori, G, Maggi, P, Cascio, A, Lichtner, M, Cauda, R, Dal Zoppo, S, Cossu, M, Gori, A, Roda, S, Confalonieri, P, Bonora, S, Missale, G, Codeluppi, M, Mezzaroma, I, Capici, S, Pontali, E, Libanore, M, Diani, A, Lanini, S, Battella, S, Contino, A, Piano Mortari, E, Genova, F, Parente, G, Dragonetti, R, Colloca, S, Visani, L, Iannacone, C, Carsetti, R, Folgori, A, Camerini, R, Ziviani, L, Malescio, F, Turrini, I, Lawlor, R, Romano, A, Nunziata, M, Armato, S, Mazzeo, N, Carleo, M, Dell'Isola, C, Pisapia, R, Pontarelli, A, Olivani, A, Grasselli, S, Laccabue, D, Leoni, M, Paolillo, F, Mancini, A, Ruaro, B, Confalonieri, M, Salton, F, Mancarella, G, Marocco, R, De Masi, M, Belvisi, V, Lamonica, S, Cingolani, A, Seguiti, C, Brambilla, P, Ferraresi, A, Lupi, M, Ludovisi, S, Renisi, G, Massafra, R, Pellicciotta, M, Armiento, L, Vimercati, S, Piacenza, M, Bonfanti, P, Columpsi, P, Cazzaniga, M, Rovelli, C, Ceresini, M, Previtali, L, Trentini, L, Alcantarini, C, Rugge, W, Biffi, S, Poletti, F, Rostagno, R, Moglia, R, De Negri, F, Fini, E, Cangialosi, A, Bruno, S, Rizzo, M, Niglio, M, Stritto, A, Matano, A, Petruzziello, A, Valsecchi, P, Pieri, T, Altamura, M, Calamo, A, Giannelli, A, Menolascina, S, Di Bari, S, Mauro, V, Aronica, R, Segala, D, Cultrera, R, Sighinolfi, L, Abbott, M, Gizzi, A, Marascia, F, Valenti, G, Feasi, M, Bobbio, N, Del Puente, F, Nicosia, A, Frasca, M, Mazzoleni, M, Garofalo, N, Ammendola, V, Grazioli, F, Napolitano, F, Vitelli, A, Marcellini, V, Capone S., Fusco F. M., Milleri S., Borre S., Carbonara S., Lo Caputo S., Leone S., Gori G., Maggi P., Cascio A., Lichtner M., Cauda R., Dal Zoppo S., Cossu M. V., Gori A., Roda S., Confalonieri P., Bonora S., Missale G., Codeluppi M., Mezzaroma I., Capici S., Pontali E., Libanore M., Diani A., Lanini S., Battella S., Contino A. M., Piano Mortari E., Genova F., Parente G., Dragonetti R., Colloca S., Visani L., Iannacone C., Carsetti R., Folgori A., Camerini R., Ziviani L., Malescio F., Turrini I., Lawlor R., Romano A., Nunziata M., Armato S., Mazzeo N., Carleo M. A., Dell'Isola C., Pisapia R., Pontarelli A., Olivani A., Grasselli S., Laccabue D., Leoni M. C., Paolillo F., Mancini A., Ruaro B., Confalonieri M., Salton F., Mancarella G., Marocco R., De Masi M., Belvisi V., Lamonica S., Cingolani A., Seguiti C., Brambilla P., Ferraresi A., Lupi M., Ludovisi S., Renisi G., Massafra R., Pellicciotta M., Armiento L., Vimercati S., Piacenza M., Bonfanti P., Columpsi P., Cazzaniga M. E., Rovelli C., Ceresini M., Previtali L., Trentini L., Alcantarini C., Rugge W., Biffi S., Poletti F., Rostagno R., Moglia R., De Negri F., Fini E., Cangialosi A., Bruno S. R., Rizzo M., Niglio M., Stritto A. D., Matano A., Petruzziello A., Valsecchi P., Pieri T., Altamura M., Calamo A., Giannelli A., Menolascina S., Di Bari S., Mauro V., Aronica R., Segala D., Cultrera R., Sighinolfi L., Abbott M., Gizzi A., Marascia F. G., Valenti G., Feasi M., Bobbio N., Del Puente F., Nicosia A., Frasca M., Mazzoleni M., Garofalo N., Ammendola V., Grazioli F., Napolitano F., Vitelli A., Marcellini V., Capone, S, Fusco, F, Milleri, S, Borre, S, Carbonara, S, Lo Caputo, S, Leone, S, Gori, G, Maggi, P, Cascio, A, Lichtner, M, Cauda, R, Dal Zoppo, S, Cossu, M, Gori, A, Roda, S, Confalonieri, P, Bonora, S, Missale, G, Codeluppi, M, Mezzaroma, I, Capici, S, Pontali, E, Libanore, M, Diani, A, Lanini, S, Battella, S, Contino, A, Piano Mortari, E, Genova, F, Parente, G, Dragonetti, R, Colloca, S, Visani, L, Iannacone, C, Carsetti, R, Folgori, A, Camerini, R, Ziviani, L, Malescio, F, Turrini, I, Lawlor, R, Romano, A, Nunziata, M, Armato, S, Mazzeo, N, Carleo, M, Dell'Isola, C, Pisapia, R, Pontarelli, A, Olivani, A, Grasselli, S, Laccabue, D, Leoni, M, Paolillo, F, Mancini, A, Ruaro, B, Confalonieri, M, Salton, F, Mancarella, G, Marocco, R, De Masi, M, Belvisi, V, Lamonica, S, Cingolani, A, Seguiti, C, Brambilla, P, Ferraresi, A, Lupi, M, Ludovisi, S, Renisi, G, Massafra, R, Pellicciotta, M, Armiento, L, Vimercati, S, Piacenza, M, Bonfanti, P, Columpsi, P, Cazzaniga, M, Rovelli, C, Ceresini, M, Previtali, L, Trentini, L, Alcantarini, C, Rugge, W, Biffi, S, Poletti, F, Rostagno, R, Moglia, R, De Negri, F, Fini, E, Cangialosi, A, Bruno, S, Rizzo, M, Niglio, M, Stritto, A, Matano, A, Petruzziello, A, Valsecchi, P, Pieri, T, Altamura, M, Calamo, A, Giannelli, A, Menolascina, S, Di Bari, S, Mauro, V, Aronica, R, Segala, D, Cultrera, R, Sighinolfi, L, Abbott, M, Gizzi, A, Marascia, F, Valenti, G, Feasi, M, Bobbio, N, Del Puente, F, Nicosia, A, Frasca, M, Mazzoleni, M, Garofalo, N, Ammendola, V, Grazioli, F, Napolitano, F, Vitelli, A, Marcellini, V, Capone S., Fusco F. M., Milleri S., Borre S., Carbonara S., Lo Caputo S., Leone S., Gori G., Maggi P., Cascio A., Lichtner M., Cauda R., Dal Zoppo S., Cossu M. V., Gori A., Roda S., Confalonieri P., Bonora S., Missale G., Codeluppi M., Mezzaroma I., Capici S., Pontali E., Libanore M., Diani A., Lanini S., Battella S., Contino A. M., Piano Mortari E., Genova F., Parente G., Dragonetti R., Colloca S., Visani L., Iannacone C., Carsetti R., Folgori A., Camerini R., Ziviani L., Malescio F., Turrini I., Lawlor R., Romano A., Nunziata M., Armato S., Mazzeo N., Carleo M. A., Dell'Isola C., Pisapia R., Pontarelli A., Olivani A., Grasselli S., Laccabue D., Leoni M. C., Paolillo F., Mancini A., Ruaro B., Confalonieri M., Salton F., Mancarella G., Marocco R., De Masi M., Belvisi V., Lamonica S., Cingolani A., Seguiti C., Brambilla P., Ferraresi A., Lupi M., Ludovisi S., Renisi G., Massafra R., Pellicciotta M., Armiento L., Vimercati S., Piacenza M., Bonfanti P., Columpsi P., Cazzaniga M. E., Rovelli C., Ceresini M., Previtali L., Trentini L., Alcantarini C., Rugge W., Biffi S., Poletti F., Rostagno R., Moglia R., De Negri F., Fini E., Cangialosi A., Bruno S. R., Rizzo M., Niglio M., Stritto A. D., Matano A., Petruzziello A., Valsecchi P., Pieri T., Altamura M., Calamo A., Giannelli A., Menolascina S., Di Bari S., Mauro V., Aronica R., Segala D., Cultrera R., Sighinolfi L., Abbott M., Gizzi A., Marascia F. G., Valenti G., Feasi M., Bobbio N., Del Puente F., Nicosia A., Frasca M., Mazzoleni M., Garofalo N., Ammendola V., Grazioli F., Napolitano F., Vitelli A., and Marcellini V.
- Abstract
The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and heterologous immunization approaches implemented worldwide for booster doses call for diversified vaccine portfolios. GRAd-COV2 is a gorilla adenovirus-based COVID-19 vaccine candidate encoding prefusion-stabilized spike. The safety and immunogenicity of GRAd-COV2 is evaluated in a dose- and regimen-finding phase 2 trial (COVITAR study, ClinicalTrials.gov: NCT04791423) whereby 917 eligible participants are randomized to receive a single intramuscular GRAd-COV2 administration followed by placebo, or two vaccine injections, or two doses of placebo, spaced over 3 weeks. Here, we report that GRAd-COV2 is well tolerated and induces robust immune responses after a single immunization; a second administration increases binding and neutralizing antibody titers. Potent, variant of concern (VOC) cross-reactive spike-specific T cell response peaks after the first dose and is characterized by high frequencies of CD8s. T cells maintain immediate effector functions and high proliferative potential over time. Thus, GRAd vector is a valuable platform for genetic vaccine development, especially when robust CD8 response is needed.
- Published
- 2023
4. GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial
- Author
-
Capone S., Fusco F. M., Milleri S., Borre S., Carbonara S., Lo Caputo S., Leone S., Gori G., Maggi P., Cascio A., Lichtner M., Cauda R., Dal Zoppo S., Cossu M. V., Gori A., Roda S., Confalonieri P., Bonora S., Missale G., Codeluppi M., Mezzaroma I., Capici S., Pontali E., Libanore M., Diani A., Lanini S., Battella S., Contino A. M., Piano Mortari E., Genova F., Parente G., Dragonetti R., Colloca S., Visani L., Iannacone C., Carsetti R., Folgori A., Camerini R., Ziviani L., Malescio F., Turrini I., Lawlor R., Romano A., Nunziata M., Armato S., Mazzeo N., Carleo M. A., Dell'Isola C., Pisapia R., Pontarelli A., Olivani A., Grasselli S., Laccabue D., Leoni M. C., Paolillo F., Mancini A., Ruaro B., Confalonieri M., Salton F., Mancarella G., Marocco R., De Masi M., Belvisi V., Lamonica S., Cingolani A., Seguiti C., Brambilla P., Ferraresi A., Lupi M., Ludovisi S., Renisi G., Massafra R., Pellicciotta M., Armiento L., Vimercati S., Piacenza M., Bonfanti P., Columpsi P., Cazzaniga M. E., Rovelli C., Ceresini M., Previtali L., Trentini L., Alcantarini C., Rugge W., Biffi S., Poletti F., Rostagno R., Moglia R., De Negri F., Fini E., Cangialosi A., Bruno S. R., Rizzo M., Niglio M., Stritto A. D., Matano A., Petruzziello A., Valsecchi P., Pieri T., Altamura M., Calamo A., Giannelli A., Menolascina S., Di Bari S., Mauro V., Aronica R., Segala D., Cultrera R., Sighinolfi L., Abbott M., Gizzi A., Marascia F. G., Valenti G., Feasi M., Bobbio N., Del Puente F., Nicosia A., Frasca M., Mazzoleni M., Garofalo N., Ammendola V., Grazioli F., Napolitano F., Vitelli A., Marcellini V., Capone, Stefania, Fusco, Francesco M, Milleri, Stefano, Borrè, Silvio, Carbonara, Sergio, Lo Caputo, Sergio, Leone, Sebastiano, Gori, Giovanni, Maggi, Paolo, Cascio, Antonio, Lichtner, Miriam, Cauda, Roberto, Dal Zoppo, Sarah, Cossu, Maria V, Gori, Andrea, Roda, Silvia, Confalonieri, Paola, Bonora, Stefano, Missale, Gabriele, Codeluppi, Mauro, Mezzaroma, Ivano, Capici, Serena, Pontali, Emanuele, Libanore, Marco, Diani, Augusta, Lanini, Simone, Battella, Simone, Contino, Alessandra M, Piano Mortari, Eva, Genova, Francesco, Parente, Gessica, Dragonetti, Rosella, Colloca, Stefano, Visani, Luigi, Iannacone, Claudio, Carsetti, Rita, Folgori, Antonella, Camerini, Roberto, Capone, S, Fusco, F, Milleri, S, Borre, S, Carbonara, S, Lo Caputo, S, Leone, S, Gori, G, Maggi, P, Cascio, A, Lichtner, M, Cauda, R, Dal Zoppo, S, Cossu, M, Gori, A, Roda, S, Confalonieri, P, Bonora, S, Missale, G, Codeluppi, M, Mezzaroma, I, Capici, S, Pontali, E, Libanore, M, Diani, A, Lanini, S, Battella, S, Contino, A, Piano Mortari, E, Genova, F, Parente, G, Dragonetti, R, Colloca, S, Visani, L, Iannacone, C, Carsetti, R, Folgori, A, Camerini, R, Ziviani, L, Malescio, F, Turrini, I, Lawlor, R, Romano, A, Nunziata, M, Armato, S, Mazzeo, N, Carleo, M, Dell'Isola, C, Pisapia, R, Pontarelli, A, Olivani, A, Grasselli, S, Laccabue, D, Leoni, M, Paolillo, F, Mancini, A, Ruaro, B, Confalonieri, M, Salton, F, Mancarella, G, Marocco, R, De Masi, M, Belvisi, V, Lamonica, S, Cingolani, A, Seguiti, C, Brambilla, P, Ferraresi, A, Lupi, M, Ludovisi, S, Renisi, G, Massafra, R, Pellicciotta, M, Armiento, L, Vimercati, S, Piacenza, M, Bonfanti, P, Columpsi, P, Cazzaniga, M, Rovelli, C, Ceresini, M, Previtali, L, Trentini, L, Alcantarini, C, Rugge, W, Biffi, S, Poletti, F, Rostagno, R, Moglia, R, De Negri, F, Fini, E, Cangialosi, A, Bruno, S, Rizzo, M, Niglio, M, Stritto, A, Matano, A, Petruzziello, A, Valsecchi, P, Pieri, T, Altamura, M, Calamo, A, Giannelli, A, Menolascina, S, Di Bari, S, Mauro, V, Aronica, R, Segala, D, Cultrera, R, Sighinolfi, L, Abbott, M, Gizzi, A, Marascia, F, Valenti, G, Feasi, M, Bobbio, N, Del Puente, F, Nicosia, A, Frasca, M, Mazzoleni, M, Garofalo, N, Ammendola, V, Grazioli, F, Napolitano, F, Vitelli, A, and Marcellini, V
- Subjects
immunological memory ,phase 2 clinical trial ,safety ,Sars-CoV-2 vaccine ,COVID-19 ,CD8 ,T cell response ,simian adenoviral vector ,General Biochemistry, Genetics and Molecular Biology ,CD4 ,neutralizing antibodie - Abstract
The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and heterologous immunization approaches implemented worldwide for booster doses call for diversified vaccine portfolios. GRAd-COV2 is a gorilla adenovirus-based COVID-19 vaccine candidate encoding prefusion-stabilized spike. The safety and immunogenicity of GRAd-COV2 is evaluated in a dose- and regimen-finding phase 2 trial (COVITAR study, ClinicalTrials.gov: NCT04791423) whereby 917 eligible participants are randomized to receive a single intramuscular GRAd-COV2 administration followed by placebo, or two vaccine injections, or two doses of placebo, spaced over 3weeks. Here, we report that GRAd-COV2 is well tolerated and induces robust immune responses after a single immunization; a second administration increases binding and neutralizing antibody titers. Potent, variant of concern (VOC) cross-reactive spike-specific Tcell response peaks after the first dose and is characterized by high frequencies of CD8s. Tcells maintain immediate effector functions and high proliferative potential over time. Thus, GRAd vector is a valuable platform for genetic vaccine development, especially when robust CD8 response is needed.
- Published
- 2023
5. Baseline 18FDG-PET Metabolic Tumour Volume (MTV) as a Potential Predictive Factor of Response to Metronomic Chemotherapy (mCHT) in HR+/HER2- Metastatic Breast Cancer (MBC) Patients (pts). Preliminary Results of the Metro-pet Study
- Author
-
Meazza Prina, M, Gotuzzo, I, Cazzaniga, M, De Bernardi, E, Cafaro, P, Capici, S, Cogliati, V, Fulvia Pepe, F, Cicchiello, F, Riva, F, Cordani, N, Cerrito, M, Turolla, E, Landoni, C, Elisei, F, Crivellaro, C, Virdone, L, Monaco, L, Guidi, A, Guerra, L, Meazza Prina, M, Gotuzzo, I, Cazzaniga, M, De Bernardi, E, Cafaro, P, Capici, S, Cogliati, V, Fulvia Pepe, F, Cicchiello, F, Riva, F, Cordani, N, Cerrito, M, Turolla, E, Landoni, C, Elisei, F, Crivellaro, C, Virdone, L, Monaco, L, Guidi, A, and Guerra, L
- Subjects
mCHT, 18FDG-PET, MBC - Published
- 2023
6. Exceptional disease control with neratinib monotherapy in HER2-positive advanced breast cancer: A case report
- Author
-
Di Mauro, P, Capici, S, Cogliati, V, Pepe, F, Maggioni, C, Riva, F, Cicchiello, F, Cazzaniga, M, Di Mauro P., Capici S., Cogliati V., Pepe F. F., Maggioni C., Riva F., Cicchiello F., Cazzaniga M. E., Di Mauro, P, Capici, S, Cogliati, V, Pepe, F, Maggioni, C, Riva, F, Cicchiello, F, Cazzaniga, M, Di Mauro P., Capici S., Cogliati V., Pepe F. F., Maggioni C., Riva F., Cicchiello F., and Cazzaniga M. E.
- Abstract
Human epidermal growth factor receptor 2 (HER2) represents a crucial drug target in breast cancer treatment. Currently, several agents that target HER2 are available, including monoclonal antibodies, antibody-drug conjugates, and tyrosine kinase inhibitors (TKIs). Despite major research efforts, no validated biomarker exists to identify patients who respond to anti-HER2 therapy alone and could be spared the toxicity of chemotherapy. Here we report the case of a 45-years-old patient with recurrent, hormone receptor-positive, and HER2-positive advanced breast cancer who had progressed various lines of treatment but showed an exceptional and prolonged response to neratinib monotherapy. A next-generation sequencing (NGS) analysis on her tumor showed a CDK12-PLXDC1 truncation and amplification of several genes, including CDK12. This case illustrates the activity of neratinib monotherapy and suggests its clinical potential without chemotherapy in a certain subtype of HER2-positive breast cancer, that may possess distinct molecular features, such as CDK12 expression.
- Published
- 2022
7. How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
- Author
-
Cogliati, V, Capici, S, Pepe, F, Di Mauro, P, Riva, F, Cicchiello, F, Maggioni, C, Cordani, N, Cerrito, M, Cazzaniga, M, Cogliati V., Capici S., Pepe F. F., Di Mauro P., Riva F., Cicchiello F., Maggioni C., Cordani N., Cerrito M. G., Cazzaniga M. E., Cogliati, V, Capici, S, Pepe, F, Di Mauro, P, Riva, F, Cicchiello, F, Maggioni, C, Cordani, N, Cerrito, M, Cazzaniga, M, Cogliati V., Capici S., Pepe F. F., Di Mauro P., Riva F., Cicchiello F., Maggioni C., Cordani N., Cerrito M. G., and Cazzaniga M. E.
- Abstract
CDK4/6 inhibitors in association with endocrine therapy represent the best therapeutic choice for either endocrine-sensitive or resistant hormone-receptor-positive advanced breast cancer patients. On the contrary, the optimal therapeutic strategy after the failure of CDK4/6 inhibitors-based treatment still remains an open question worldwide. In this review, we analyze the most studied mechanisms of resistance to CDK4/6 inhibitors treatment, as well as the most significant results of retrospective and prospective trials in the setting of progression after CDK4/6 inhibitors, to provide the reader a comprehensive overview from both a preclinical and especially a clinical perspective. In our opinion, an approach based on a deeper knowledge of resistance mechanisms to CDK4/6 inhibitors, but also on a careful analysis of what is done in clinical practice, can lead to a better definition of prospective randomized trials, to implement a personalized sequence approach, based on molecular analyses.
- Published
- 2022
8. Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study
- Author
-
Pepe, F, Cazzaniga, M, Baroni, S, Riva, F, Cicchiello, F, Capici, S, Cogliati, V, Maggioni, C, Cordani, N, Cerrito, M, Malandrin, S, Pepe F. F., Cazzaniga M. E., Baroni S., Riva F., Cicchiello F., Capici S., Cogliati V., Maggioni C., Cordani N., Cerrito M. G., Malandrin S., Pepe, F, Cazzaniga, M, Baroni, S, Riva, F, Cicchiello, F, Capici, S, Cogliati, V, Maggioni, C, Cordani, N, Cerrito, M, Malandrin, S, Pepe F. F., Cazzaniga M. E., Baroni S., Riva F., Cicchiello F., Capici S., Cogliati V., Maggioni C., Cordani N., Cerrito M. G., and Malandrin S.
- Abstract
Tregs are able of suppressing tumor-specific effector cells, such as lymphocytes CD8+, CD4+ and Natural Killer cells. Different drugs, especially different schedules of administration, like metronomic chemotherapy (mCHT), seem to be able to increase anticancer immunity, by acting on downregulation of Tregs. Most of the data available regarding the immunomodulating effect of mCHT have been obtained with Cyclophosphamide (CTX). Aim of the present study was to explore the effects of mVRL and mCAPE administration, alone or in combination, on T cells. Observation of 13 metastatic breast cancer patients lasted controlling for 56 days, where Treg frequencies and function, spontaneous anti-tumor T-cell responses were monitored, as well as the clinical outcome. No depletion in Treg absolute numbers, or percentage of T lymphocytes, was observed. Only in 5 patients, a modest and transient depletion of Tregs was observed during the first 14 days of treatment. To better describe the effect on Tregs, we subsequently looked at the variations in Memory, Naïve and Activated Treg subpopulations: we observed a trend in reduction for memory Treg (Treg MEM) and an increase for Treg Naïve (Treg NAIVE) and Treg Activated (Treg ACT) components. We finally analyzed the average trend of Treg in the Treg depleted patients and non-depleted ones, without fiding any significant differences. The trend of the Treg MEM appeared different, showing a reduction during the first 14 days, followed by an increase at the levels before treatment at Day 56 in the group of depleted patients and a progressive substantial reduction in the group of non-depleted patients along the entire course of treatment. Opposed to the data known, treatment with mVRL w/o mCAPE did not show any effect on Tregs.
- Published
- 2022
9. Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells
- Author
-
Cordani, N, Mologni, L, Piazza, R, Cogliati, V, Pepe, F, Capici, S, DI BELLA, C, Jaconi, M, Cerrito, M, Villa, M, Tettamanti, P, Cavaletti, G, Lavitrano, M, Cazzaniga, M, Nicoletta Cordani, Luca Mologni, Rocco Piazza, Viola Cogliati, Francesca Pepe, Serena Capici, Camillo Di Bella, Marta Jaconi, Maria Grazia Cerrito, Matteo Villa, Pietro Tettamanti, Guido Cavaletti, Marialuisa Lavitrano, Marina Elena Cazzaniga, Cordani, N, Mologni, L, Piazza, R, Cogliati, V, Pepe, F, Capici, S, DI BELLA, C, Jaconi, M, Cerrito, M, Villa, M, Tettamanti, P, Cavaletti, G, Lavitrano, M, Cazzaniga, M, Nicoletta Cordani, Luca Mologni, Rocco Piazza, Viola Cogliati, Francesca Pepe, Serena Capici, Camillo Di Bella, Marta Jaconi, Maria Grazia Cerrito, Matteo Villa, Pietro Tettamanti, Guido Cavaletti, Marialuisa Lavitrano, and Marina Elena Cazzaniga
- Abstract
Background Cyclin-Dependent Kinase (CDK) 4/6 inhibitors have significantly improved progression-free survival of Hormone Receptor positive (HR+), Human Epidermal Growth Factor Receptor type 2 negative (HER2-) luminal breast cancers (LBC). Several studies demonstrated that the addition of CDK4/6 inhibitors to endocrine therapy results in a significant prolongation of progression-free survival in patients with endocrine-sensitive or endocrine-resistant LBCs. However, the percentage of patients unresponsive or refractory to these therapies is as high as 40%, and no reliable and reproducible biomarkers able to select a priori responder or resistant patients have been validated till now. The main cause of resistance is the selection of mutant clones in the target oncoprotein. Other mechanisms, like oncogene amplification/overexpression or mutations in other pathways, have been described in several models. Here, we focused on palbociclib, a selective inhibitor of CDK4/6. Methods: We generated and characterized human luminal breast cancer MCF-7 and T47D derived cell lines, able to survive and proliferate at different palbociclib concentrations, which also shows cross-resistance to abemaciclib. The resistant MCF7 cell line was characterized by RNA sequencing. Results: To confirm resistance, we performed cell viability assays in MCF-7 and T47D palbociclib sensitive cells (MCF-7pS and T47pS) versus MCF-7 and T47D palbociclib resistant cells (MCF-7pR5), showing a 10-fold increase of IC50 in MCF-7pR5 compared to parental MCF-7pS cells (16.7 vs 1.8 µM) and a 3-fold increase of IC50 in T47DpR5 vs parental T47DpS. We also confirmed a significant cross resistance using abemaciclib in MCF-7pR5 with an IC50 equal to 6.8 vs 0.35 µM and in T47DpR with an IC50 of 10.72 vs 0.5 µM. RNA sequencing, qRT-qPCR and Western blot results demonstrated a dramatic downregulation of the CDK4 inhibitor CDKN2B in both cell lines and we found upregulation of an miR-31, a putative regulator of CDKN2B. T
- Published
- 2023
10. A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19
- Author
-
Aurisicchio, L, Brambilla, N, Cazzaniga, M, Bonfanti, P, Milleri, S, Ascierto, P, Capici, S, Vitalini, C, Girolami, F, Giacovelli, G, Caselli, G, Visintin, M, Fanti, F, Ghirri, M, Conforti, A, Compagnone, M, Lione, L, Salvatori, E, Pinto, E, Muzi, A, Marra, E, Palombo, F, Roscilli, G, Manenti, A, Montomoli, E, Cadossi, M, Rovati, L, Aurisicchio, Luigi, Brambilla, Nadia, Cazzaniga, Marina E, Bonfanti, Paolo, Milleri, Stefano, Ascierto, Paolo A, Capici, Serena, Vitalini, Cristina, Girolami, Federica, Giacovelli, Giampaolo, Caselli, Gianfranco, Visintin, Michela, Fanti, Francesca, Ghirri, Matteo, Conforti, Antonella, Compagnone, Mirco, Lione, Lucia, Salvatori, Erika, Pinto, Eleonora, Muzi, Alessia, Marra, Emanuele, Palombo, Fabio, Roscilli, Giuseppe, Manenti, Alessandro, Montomoli, Emanuele, Cadossi, Matteo, Rovati, Lucio C, Aurisicchio, L, Brambilla, N, Cazzaniga, M, Bonfanti, P, Milleri, S, Ascierto, P, Capici, S, Vitalini, C, Girolami, F, Giacovelli, G, Caselli, G, Visintin, M, Fanti, F, Ghirri, M, Conforti, A, Compagnone, M, Lione, L, Salvatori, E, Pinto, E, Muzi, A, Marra, E, Palombo, F, Roscilli, G, Manenti, A, Montomoli, E, Cadossi, M, Rovati, L, Aurisicchio, Luigi, Brambilla, Nadia, Cazzaniga, Marina E, Bonfanti, Paolo, Milleri, Stefano, Ascierto, Paolo A, Capici, Serena, Vitalini, Cristina, Girolami, Federica, Giacovelli, Giampaolo, Caselli, Gianfranco, Visintin, Michela, Fanti, Francesca, Ghirri, Matteo, Conforti, Antonella, Compagnone, Mirco, Lione, Lucia, Salvatori, Erika, Pinto, Eleonora, Muzi, Alessia, Marra, Emanuele, Palombo, Fabio, Roscilli, Giuseppe, Manenti, Alessandro, Montomoli, Emanuele, Cadossi, Matteo, and Rovati, Lucio C
- Abstract
The COVID-19 pandemic and the need for additional safe, effective, and affordable vaccines gave new impetus into development of vaccine genetic platforms. Here we report the findings from the phase 1, first-in-human, dose-escalation study of COVID-eVax, a DNA vaccine encoding the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. Sixty-eight healthy adults received two doses of 0.5, 1, or 2 mg 28 days apart, or a single 2-mg dose, via intramuscular injection followed by electroporation, and they were monitored for 6 months. All participants completed the primary safety and immunogenicity assessments after 8 weeks. COVID-eVax was well tolerated, with mainly mild to moderate solicited adverse events (tenderness, pain, bruising, headache, and malaise/fatigue), less frequent after the second dose, and it induced an immune response (binding antibodies and/or T cells) at all prime-boost doses tested in up to 90% of the volunteers at the highest dose. However, the vaccine did not induce neutralizing antibodies, while particularly relevant was the T cell-mediated immunity, with a robust Th1 response. This T cell-skewed immunological response adds significant information to the DNA vaccine platform and should be assessed in further studies for its protective capacity and potential usefulness also in other therapeutic areas, such as oncology.
- Published
- 2023
11. Metronomic chemotherapy
- Author
-
Cazzaniga, M, Cordani, N, Capici, S, Cogliati, V, Riva, F, Cerrito, M, Cazzaniga M. E., Cordani N., Capici S., Cogliati V., Riva F., Cerrito M. G., Cazzaniga, M, Cordani, N, Capici, S, Cogliati, V, Riva, F, Cerrito, M, Cazzaniga M. E., Cordani N., Capici S., Cogliati V., Riva F., and Cerrito M. G.
- Abstract
Metronomic chemotherapy treatment (mCHT) refers to the chronic administration of low doses chemotherapy that can sustain prolonged, and active plasma levels of drugs, producing favorable tolerability and it is a new promising therapeutic approach in solid and in hematologic tumors. mCHT has not only a direct effect on tumor cells, but also an action on cell microenvironment, by inhibiting tumor angiogenesis, or promoting immune response and for these reasons can be considered a multi‐target therapy itself. Here we review the state of the art of mCHT use in some classical tumour types, such as breast and no small cell lung cancer (NSCLC), see what is new regarding most recent data in different cancer types, such as glioblastoma (GBL) and acute myeloid leukemia (AML), and new drugs with potential metronomic administration. Finally, a look at the strategic use of mCHT in the context of health emergencies, or in low –and middle‐income countries (LMICs), where access to adequate healthcare is often not easy, is mandatory, as we always need to bear in in mind that equity in care must be a compulsory part of our medical work and research.
- Published
- 2021
12. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
- Author
-
Cazzaniga, M, Vallini, I, Montagna, E, Amoroso, D, Berardi, R, Butera, A, Cagossi, K, Cavanna, L, Ciccarese, M, Cinieri, S, Cretella, E, De Conciliis, E, Febbraro, A, Ferrau, F, Ferzi, A, Baldelli, A, Fontana, A, Gambaro, A, Garrone, O, Gebbia, V, Generali, D, Gianni, L, Giovanardi, F, Grassadonia, A, Leonardi, V, Marchetti, P, Sarti, S, Musolino, A, Nicolini, M, Putzu, C, Riccardi, F, Santini, D, Saracchini, S, Sarobba, M, Schintu, M, Scognamiglio, G, Spadaro, P, Taverniti, C, Toniolo, D, Tralongo, P, Turletti, A, Valenza, R, Valerio, M, Vici, P, Di Mauro, P, Cogliati, V, Capici, S, Clivio, L, Torri, V, Cazzaniga M. E., Vallini I., Montagna E., Amoroso D., Berardi R., Butera A., Cagossi K., Cavanna L., Ciccarese M., Cinieri S., Cretella E., De Conciliis E., Febbraro A., Ferrau F., Ferzi A., Baldelli A., Fontana A., Gambaro A. R., Garrone O., Gebbia V., Generali D., Gianni L., Giovanardi F., Grassadonia A., Leonardi V., Marchetti P., Sarti S., Musolino A., Nicolini M., Putzu C., Riccardi F., Santini D., Saracchini S., Sarobba M. G., Schintu M. G., Scognamiglio G., Spadaro P., Taverniti C., Toniolo D., Tralongo P., Turletti A., Valenza R., Valerio M. R., Vici P., Di Mauro P., Cogliati V., Capici S., Clivio L., Torri V., Cazzaniga, M, Vallini, I, Montagna, E, Amoroso, D, Berardi, R, Butera, A, Cagossi, K, Cavanna, L, Ciccarese, M, Cinieri, S, Cretella, E, De Conciliis, E, Febbraro, A, Ferrau, F, Ferzi, A, Baldelli, A, Fontana, A, Gambaro, A, Garrone, O, Gebbia, V, Generali, D, Gianni, L, Giovanardi, F, Grassadonia, A, Leonardi, V, Marchetti, P, Sarti, S, Musolino, A, Nicolini, M, Putzu, C, Riccardi, F, Santini, D, Saracchini, S, Sarobba, M, Schintu, M, Scognamiglio, G, Spadaro, P, Taverniti, C, Toniolo, D, Tralongo, P, Turletti, A, Valenza, R, Valerio, M, Vici, P, Di Mauro, P, Cogliati, V, Capici, S, Clivio, L, Torri, V, Cazzaniga M. E., Vallini I., Montagna E., Amoroso D., Berardi R., Butera A., Cagossi K., Cavanna L., Ciccarese M., Cinieri S., Cretella E., De Conciliis E., Febbraro A., Ferrau F., Ferzi A., Baldelli A., Fontana A., Gambaro A. R., Garrone O., Gebbia V., Generali D., Gianni L., Giovanardi F., Grassadonia A., Leonardi V., Marchetti P., Sarti S., Musolino A., Nicolini M., Putzu C., Riccardi F., Santini D., Saracchini S., Sarobba M. G., Schintu M. G., Scognamiglio G., Spadaro P., Taverniti C., Toniolo D., Tralongo P., Turletti A., Valenza R., Valerio M. R., Vici P., Di Mauro P., Cogliati V., Capici S., Clivio L., and Torri V.
- Abstract
Purpose: Triple-negative breast cancer (TNBC) represents a subtype of breast cancer which lacks the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2): TNBC accounts for approximately 20% of newly diagnosed breast cancers and is associated with younger age at diagnosis, greater recurrence risk and shorter survival time. Therapeutic options are very scarce. Aim of the present analysis is to provide further insights into the clinical activity of metronomic chemotherapy (mCHT), in a real-life setting. Methods: We used data included in the VICTOR-6 study for the present analysis. VICTOR-6 is an Italian multicentre retrospective cohort study, which collected data of metastatic breast cancer (MBC) patients who have received mCHT between 2011 and 2016. Amongst the 584 patients included in the study, 97 were triple negative. In 40.2% of the TNBC patients, mCHT was the first chemotherapy treatment, whereas 32.9% had received 2 or more lines of treatment for the metastatic disease. 45.4% out of 97 TNBC patients received a vinorelbine (VRL)-based regimen, which resulted in the most used type of mCHT, followed by cyclophosphamide (CTX)-based regimens (30.9%) and capecitabine (CAPE)-based combinations (22.7%). Results: Overall response rate (ORR) and disease control rate (DCR) were 17.5% and 64.9%, respectively. Median progression free survival (PFS) and overall survival (OS) were 6.0 months (95% CI: 4.9–7.2) and 12.1 months (95% CI: 9.6–16.7). Median PFS was 6.9 months for CAPE-based regimens (95% CI: 5.0–18.4), 6.1 months (95% CI: 4.0–8.9) for CTX-based and 5.3 months (95% CI: 4.1–9.5) for VRL-based ones. Median OS was 18.2 months (95% CI: 9.1-NE) for CAPE-based regimens and 11.8 months for VRL- (95% CI: 9.3–16.7 and CTX-based ones (95%CI: 8.7–52.8). Tumour response, PFS and OS decreased proportionally in later lines. Conclusion: This analysis represents the largest series of TNBC patients treated with mCHT in
- Published
- 2021
13. Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)
- Author
-
Perrone F., Perrone, F, Piccirillo, M, Ascierto, P, Salvarani, C, Parrella, R, Marata, A, Popoli, P, Ferraris, L, Marrocco-Trischitta, M, Ripamonti, D, Binda, F, Bonfanti, P, Squillace, N, Castelli, F, Muiesan, M, Lichtner, M, Calzetti, C, Salerno, N, Atripaldi, L, Cascella, M, Costantini, M, Dolci, G, Facciolongo, N, Fraganza, F, Massari, M, Montesarchio, V, Mussini, C, Negri, E, Botti, G, Cardone, C, Gargiulo, P, Gravina, A, Schettino, C, Arenare, L, Chiodini, P, Gallo, C, Vitale, M, Trojaniello, C, Palla, M, Bianchi, A, De Feo, G, Miscio, L, Chiodiniy, P, Froldi, M, Menicanti, L, Cuppone, M, Gobbo, G, Baldessari, C, Valenti, V, Castelvecchio, S, Poli, F, Giacomazzi, F, Piccinni, R, Annnunziata, M, Biondi, A, Bussolari, C, Mazzoleni, M, Giachi, A, Filtz, A, Manini, A, Poletti, E, Masserini, F, Conforti, F, Gaudiano, G, Favero, V, Moroni, A, Viva, T, Fancoli, F, Ferrari, D, Niro, D, Resta, M, Ballotta, A, Poli, M, Ranucci, M, Tebaldi, A, Gritti, G, Pasulo, L, Gaglio, L, Del Fabbro, R, Alborghetti, L, Giustinetti, G, Columpsi, P, Cazzaniga, M, Capici, S, Sala, L, Di Sciacca, R, Mosca, G, Pirozzi, M, Perrone F., Piccirillo M. C., Ascierto P. A., Salvarani C., Parrella R., Marata A. M., Popoli P., Ferraris L., Marrocco-Trischitta M. M., Ripamonti D., Binda F., Bonfanti P., Squillace N., Castelli F., Muiesan M. L., Lichtner M., Calzetti C., Salerno N. D., Atripaldi L., Cascella M., Costantini M., Dolci G., Facciolongo N. C., Fraganza F., Massari M., Montesarchio V., Mussini C., Negri E. A., Botti G., Cardone C., Gargiulo P., Gravina A., Schettino C., Arenare L., Chiodini P., Gallo C., Vitale M. G., Trojaniello C., Palla M., Bianchi A. A. M., De Feo G., Miscio L., Chiodiniy P., Froldi M., Menicanti L., Cuppone M. T., Gobbo G., Baldessari C., Valenti V., Castelvecchio S., Poli F., Giacomazzi F., Piccinni R., Annnunziata M. L., Biondi A., Bussolari C., Mazzoleni M., Giachi A., Filtz A., Manini A., Poletti E., Masserini F., Conforti F., Gaudiano G., Favero V., Moroni A., Viva T., Fancoli F., Ferrari D., Niro D., Resta M., Ballotta A., Poli M. D., Ranucci M., Tebaldi A., Gritti G., Pasulo L., Gaglio L., Del Fabbro R., Alborghetti L., Giustinetti G., Columpsi P., Cazzaniga M., Capici S., Sala L., Di Sciacca R., Mosca G., Pirozzi M. R., Perrone F., Perrone, F, Piccirillo, M, Ascierto, P, Salvarani, C, Parrella, R, Marata, A, Popoli, P, Ferraris, L, Marrocco-Trischitta, M, Ripamonti, D, Binda, F, Bonfanti, P, Squillace, N, Castelli, F, Muiesan, M, Lichtner, M, Calzetti, C, Salerno, N, Atripaldi, L, Cascella, M, Costantini, M, Dolci, G, Facciolongo, N, Fraganza, F, Massari, M, Montesarchio, V, Mussini, C, Negri, E, Botti, G, Cardone, C, Gargiulo, P, Gravina, A, Schettino, C, Arenare, L, Chiodini, P, Gallo, C, Vitale, M, Trojaniello, C, Palla, M, Bianchi, A, De Feo, G, Miscio, L, Chiodiniy, P, Froldi, M, Menicanti, L, Cuppone, M, Gobbo, G, Baldessari, C, Valenti, V, Castelvecchio, S, Poli, F, Giacomazzi, F, Piccinni, R, Annnunziata, M, Biondi, A, Bussolari, C, Mazzoleni, M, Giachi, A, Filtz, A, Manini, A, Poletti, E, Masserini, F, Conforti, F, Gaudiano, G, Favero, V, Moroni, A, Viva, T, Fancoli, F, Ferrari, D, Niro, D, Resta, M, Ballotta, A, Poli, M, Ranucci, M, Tebaldi, A, Gritti, G, Pasulo, L, Gaglio, L, Del Fabbro, R, Alborghetti, L, Giustinetti, G, Columpsi, P, Cazzaniga, M, Capici, S, Sala, L, Di Sciacca, R, Mosca, G, Pirozzi, M, Perrone F., Piccirillo M. C., Ascierto P. A., Salvarani C., Parrella R., Marata A. M., Popoli P., Ferraris L., Marrocco-Trischitta M. M., Ripamonti D., Binda F., Bonfanti P., Squillace N., Castelli F., Muiesan M. L., Lichtner M., Calzetti C., Salerno N. D., Atripaldi L., Cascella M., Costantini M., Dolci G., Facciolongo N. C., Fraganza F., Massari M., Montesarchio V., Mussini C., Negri E. A., Botti G., Cardone C., Gargiulo P., Gravina A., Schettino C., Arenare L., Chiodini P., Gallo C., Vitale M. G., Trojaniello C., Palla M., Bianchi A. A. M., De Feo G., Miscio L., Chiodiniy P., Froldi M., Menicanti L., Cuppone M. T., Gobbo G., Baldessari C., Valenti V., Castelvecchio S., Poli F., Giacomazzi F., Piccinni R., Annnunziata M. L., Biondi A., Bussolari C., Mazzoleni M., Giachi A., Filtz A., Manini A., Poletti E., Masserini F., Conforti F., Gaudiano G., Favero V., Moroni A., Viva T., Fancoli F., Ferrari D., Niro D., Resta M., Ballotta A., Poli M. D., Ranucci M., Tebaldi A., Gritti G., Pasulo L., Gaglio L., Del Fabbro R., Alborghetti L., Giustinetti G., Columpsi P., Cazzaniga M., Capici S., Sala L., Di Sciacca R., Mosca G., and Pirozzi M. R.
- Published
- 2021
14. The role for tocilizumab in covid-19 patients: Reflections on monza cohort data
- Author
-
Capici, S, Sala, L, Galimberti, S, Valsecchi, M, Squillace, N, Gustinetti, G, Cazzaniga, M, Bonfanti, P, Capici S., Sala L., Galimberti S., Valsecchi M. G., Squillace N., Gustinetti G., Cazzaniga M. E., Bonfanti P., Capici, S, Sala, L, Galimberti, S, Valsecchi, M, Squillace, N, Gustinetti, G, Cazzaniga, M, Bonfanti, P, Capici S., Sala L., Galimberti S., Valsecchi M. G., Squillace N., Gustinetti G., Cazzaniga M. E., and Bonfanti P.
- Abstract
The severe acute respiratory syndrome coronavirus 2 pandemic has dominated the global health scenario from the beginning of 2020 and still represents a major health emergency. Cytokine inhibitors as tocilizumab have been used to treat COVID-19 severe pneumonia with conflicting results. We performed a retrospective study whose results can contribute to the general overview regarding the role of these agents in severe COVID-19 pneumonia, suggesting an interesting, even not statistically significant evidence of the effectiveness of tocilizumab treatment in this disease and sow a seed of reflection about their use in future waves of pandemic. We compared two cohorts of patients treated with local standard of care and with tocilizumab in the experimental one. With a median follow-up of 92 days, deaths were 6 and 16 in the tocilizumab and the standard of care group, respectively. With a longer follow-up than previous studies, a trend in difference with regards to mortality of the groups was observed.
- Published
- 2021
15. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial
- Author
-
Perrone, F, Piccirillo, M, Ascierto, P, Salvarani, C, Parrella, R, Marata, A, Popoli, P, Ferraris, L, Marrocco-trischitta, M, Ripamonti, D, Binda, F, Bonfanti, P, Squillace, N, Castelli, F, Muiesan, M, Lichtner, M, Calzetti, C, Salerno, N, Atripaldi, L, Cascella, M, Costantini, M, Dolci, G, Facciolongo, N, Fraganza, F, Massari, M, Montesarchio, V, Mussini, C, Negri, E, Botti, G, Cardone, C, Gargiulo, P, Gravina, A, Schettino, C, Arenare, L, Chiodini, P, Gallo, C, Vitale, M, Trojaniello, C, Palla, M, Bianchi, A, De Feo, G, Miscio, L, Froldi, M, Menicanti, L, Cuppone, M, Gobbo, G, Baldessari, C, Valenti, V, Castelvecchio, S, Poli, F, Giacomazzi, F, Piccinni, R, Annnunziata, M, Biondi, A, Bussolari, C, Mazzoleni, M, Giachi, A, Filtz, A, Manini, A, Poletti, E, Masserini, F, Conforti, F, Gaudiano, G, Favero, V, Moroni, A, Viva, T, Fancoli, F, Ferrari, D, Niro, D, Resta, M, Ballotta, A, Poli, M, Ranucci, M, Tebaldi, A, Gritti, G, Pasulo, L, Gaglio, L, Del Fabbro, R, Alborghetti, L, Giustinetti, G, Columpsi, P, Cazzaniga, M, Capici, S, Sala, L, Di Sciacca, R, Mosca, G, Pirozzi, M, Franceschini, F, Roccaro, A, Salvetti, M, Paini, A, Corda, L, Ricci, C, Tomasoni, L, Nasta, P, Lorenzotti, S, Odolini, S, Foca, E, Roldan, E, Metra, M, Magrini, S, Borghetti, P, Latronico, N, Piva, S, Filippini, M, Tomasoni, G, Zuccala, F, Cattaneo, S, Scolari, F, Bossini, N, Gaggiotti, M, Properzi, M, Del Giudice, E, Marocco, R, Carraro, A, Del Borgo, C, Belvisi, V, Tieghi, T, De Masi, M, Zuccala, P, Fabietti, P, Vetica, A, Mercurio, V, Fondaco, L, Kertusha, B, Curtolo, A, Lubrano, R, Zotti, M, Puorto, A, Ciuffreda, M, Sarni, A, Monteforte, G, Romeo, D, Viola, E, Damiani, C, Barone, A, Mantovani, B, Di Sanzo, D, Gentili, V, Carletti, M, Aiuti, M, Gallo, A, Meliante, P, Martellucci, S, Riggio, O, Cardinale, V, Ridola, L, Bragazzi, M, Gioia, S, Valenzi, E, Graziosi, C, Bina, N, Fasolo, M, Ricci, S, Gioacchini, M, Lucci, A, Corso, L, Tornese, D, Nijhawan, P, Equitani, F, Cosentino, C, Palladino, M, Leonetti, F, Leto, G, Gnessi, C, Campagna, G, Cesareo, R, Marrocco, F, Straface, G, Mecozzi, A, Cerbo, L, Isgro, V, Parrocchia, S, Visconti, G, Casati, G, Ariani, A, Donghi, L, Tacconelli, E, Bertoldi, M, Cattaneo, P, Lambertenghi, L, Motta, L, Omega, L, Albano, G, Scarano, F, De Rosa, A, Buglione, A, Lavoretano, S, Gaglione, G, De Marco, M, Sangiovanni, V, Fusco, F, Viglietti, R, Manzillo, E, Rescigno, C, Pisapia, R, Plamieri, G, Maraolo, A, Calabria, G, Catalano, M, Fiorentino, G, Annunziata, A, Polistina, G, Imitazione, P, Mollica, M, Esposito, V, D'Abraccio, M, Punzi, R, Bianco, V, Sbreglia, C, Del Vecchio, R, Bordonali, A, Franco, A, Salsi, P, Fontana, M, Virzi, G, Ornella, C, Molteni, A, Gennarini, S, Gnudi, U, Ricci, M, Titolo, G, Mensi, G, Vuotto, P, Gasperini, B, Mancini, M, Pasquini, Z, Spanu, P, Clementi, S, Pierini, S, Bokor, D, Gori, D, Ciofetti, M, Caimi, M, Bettazzi, L, Allevi, E, Furiani, S, Capitanio, C, Mastropasqua, B, Fara, C, Pulitano, G, Matsuno, J, Porta, F, Dolfini, V, Beyene, N, Bezzi, M, Novali, M, Viale, P, Tedeschi, S, Pascale, R, Bruno, R, Di Filippo, A, Sachs, M, Oggionni, T, Di Stefano, M, Mengoli, C, Facchini, C, Daniele, D, Frausini, G, Mucci, L, Tedesco, S, Girolimetti, R, Manfredini, E, Di Carlo, A, Espinosa, E, Dennetta, D, Ticinesi, A, Meschi, T, Nouvenne, A, Claudio, N, Vitale, F, Saracco, M, Codeluppi, M, Fronti, E, Ferrante, P, Nespola, G, Francisci, D, Tosti, A, Carbonelli, C, Greco, A, Tinti, M, Stellini, R, Appiani, C, Reghenzi, P, Poletti, V, Ravaglia, C, Tacconi, D, Malcontenti, C, Sainaghi, P, Landi, R, Vassia, V, Rizzi, E, Bellan, M, Rossati, A, Castello, L, Mastroianni, C, Russo, G, Fabio, T, Serino, F, Brollo, L, Momesso, E, Turati, M, Monforte, A, Marchetti, G, Boni, F, Teopompi, E, Trenti, C, Boracchia, L, Minelli, E, Ghidoni, G, Matei, A, Caruso, A, Arcoleo, G, Camarda, G, Catalano, F, Spatafora, M, Bettega, D, Andreoni, M, Teti, E, Sarmati, L, Di Lorenzo, A, Celeste, M, Baratto, F, Monticelli, J, Criveller, P, Andrea, A, Anselmo, R, Castellano, M, Cappelli, C, Corvini, F, Zanini, B, Crippa, M, Ronconi, M, Costa, R, Casella, S, Brentana, L, Bernardi, L, Frascati, A, Panese, S, Presotto, F, Michieletto, L, Bernardi, C, Fusar, M, Agnoletti, V, Farina, M, Russo, Lavorini, F, Ginanni, R, Palmieri, F, Mosti, S, Amaglio, A, Cattaneo, A, Cirri, S, Montisci, A, Gallazzi, C, Cosseta, D, Baronio, B, Rampa, L, Maggi, P, Messina, V, Berlendis, M, Sabatti, M, Palumbo, M, Mazzone, A, Faggioli, P, Bussini, L, Fornaro, G, Volpato, F, Imperiale, D, Manno, E, Ferreri, E, Martelli, D, Verhovez, A, Giorgis, S, Faccio, L, Quadri, R, Negro, C, Converso, M, Bosco, F, Amadasi, S, Prandini, P, Cocchi, S, Manfrin, V, Del Punta, V, Mazzola, G, Sportato, G, Romagnoli, M, Cristini, F, Facondini, F, Perin, T, Boschi, A, Meschiari, M, Guaraldi, G, Modica, S, Moneta, S, Boccalatte, D, Marchetti, V, Ebbreo, G, Dale, M, Tura, P, Rizzoni, D, Boari, G, Bonetti, S, Marini, E, Daniele, I, Grossi, P, Delfrate, N, Bernhart, O, Spizzo, G, Mahlknecht, K, Volkl, T, Di Pietro, M, Trezzi, M, Monacci, C, Peris, A, Bonizzoli, M, Cavanna, L, Moroni, C, Stroppa, E, Savio, M, Gatti, F, Bartolaminelli, C, Petrosillo, N, Donno, D, Taglietti, F, Topino, S, Chinello, P, Galati, V, D'Offizi, G, Taibi, C, Cimolato, B, Moroni, F, Palagano, N, Pelagatti, L, Cristiana, S, Landini, G, Amitrano, M, Raimondo, M, Mangiacapra, S, Romano, A, Atteno, M, Blanc, P, Suardi, L, Pallotto, C, Casinelli, K, Uccella, I, Harari, S, Caminati, A, Lipani, F, Di Perri, G, Calcagno, A, Calleri, G, Montrucchio, C, Caputo, A, Cozzio, S, Donne, L, Bassetti, M, Malgorzata, M, Nicolini, L, Russo, C, Sepulcri, C, Beltramini, S, Mina, F, Puoti, M, Gandino, A, Langer, T, D'Amico, F, Rocchetti, C, Cettolo, F, Gabriele, F, Bocchi, P, Cioni, G, Cappi, C, Corcione, S, De Rosa, F, Scabini, S, Canta, F, Pinna, S, Pensa, A, Rocco, M, Cirasa, M, Spinicci, M, Mencarini, J, Zammarchi, L, Giovanni, C, Sciole, K, Bassi, F, Bianchi, M, Frigerio, S, Spaziani, S, Nucera, A, Rizzardini, G, Cossu, M, Antivalle, M, Carpinteri, G, Macheda, S, Labate, D, Bottiroli, M, Erne, E, Cristina, Z, Di Biase, V, Malberti, F, Montani, G, Poisa, P, Bettini, D, Cauda, R, Ciccullo, A, Riccardi, N, Angheben, A, Turrini, M, Clerici, R, Gardellini, A, Liparulo, L, Rossini, T, Ucciferri, C, Cipollone, F, Vecchiet, J, Nico, A, Marra, L, Leone, A, Sdanganelli, A, Palmiotti, G, D'Alagni, G, Santantonio, T, Caputo, S, Bottalico, I, Ponticiello, A, Di Perna, F, Bernardi, E, Beltrame, A, Bravi, S, David, M, Bernardi, P, Galante, D, Uccelli, M, Prestini, K, Drera, M, Zini, E, Peregrinelli, A, Blanzuoli, L, Benedetti, V, Calvi, R, Scaglione, N, Nallino, G, Bonazzi, M, Crespi, T, Masolin, T, Regazzetti, A, Cerri, M, Maffezzini, E, Piazza, M, Papetti, C, Filippi, C, Roveda, E, Cipolla, G, Scozzafava, M, Crepaldi, M, Henchi, S, Vanoni, N, Repossi, A, Vezzoli, M, Scorletti, E, Perugini, O, Pasini, S, Pacetti, V, Ferrari, L, de Paduanis, G, Del Duca, S, Dell'Ara, F, Brocchieri, A, Minoja, G, Storti, E, Pitagora, L, Costa, I, Delfanti, F, Orlandi, M, Ruggeri, R, Ruggieri, L, Livigni, S, Silengo, D, Ageno, W, Pedrini, L, Artiol, S, Morbidoni, L, De Donno, G, Ravagnani, V, Inglese, F, Scotton, P, Costantini, P, Delucchi, M, Clini, E, Ansuini, A, Marco, B, Giuseppe, L, Vincenzo, B, Rastelli, G, Doria, A, Vianello, A, Cattelan, A, Bindoli, S, Felicietti, M, Canetta, C, Scartabellati, A, Accordino, S, Ferrara, M, Cocco, L, Cirillo, F, Pace, E, De Caro, M, Alberico, M, Benigni, G, Damiano, T, Fusco, P, Iuorio, A, Torretta, G, Racagni, M, Muttini, S, Sala, G, Ghiringhelli, P, Chiumiento, F, Baccari, L, Luca, B, Bocchi, F, Benatti, F, Catellani, J, Coppola, M, Papi, A, Bosco, E, Lazzeri, C, Cesira, N, Puttini, C, Carli, T, Croci, L, Corridi, M, Arlotti, M, Guerrini, G, Cola, L, Romanelli, M, Bonifazi, M, Gasparini, S, Mei, F, Cerutti, E, Lacedonia, D, Santoro, A, Guidelli, G, Greco, S, Castellan, A, Infantino, G, Camici, L, Frigieri, F, Pavoni, V, Migliori, L, Rossetti, B, Montagnini, F, Mauro, I, Genovese, E, Capuozzo, A, Vitiello, L, Sirignano, E, Gnesin, P, Servillo, G, Marinelli, A, Pasero, D, Casadio, L, Babudieri, S, Madeddu, G, De Vito, A, Ranghitta, M, Passalacqua, R, Antonio, F, Gentile, I, Buonomo, A, Scotto, R, Zappulo, E, Dell'Aquila, G, Bianchetti, A, Guerini, F, Vallone, A, Oppedisano, P, Pusterla, L, Giglio, O, Sartori, E, Zanardini, C, Gatti, P, Vincenzo, V, Piconi, S, Molteni, C, Dognini, G, Cosimo, F, Guarneri, L, Pulvirenti, F, Mondino, V, Traballi, G, Iemoli, E, Grisolia, A, Giorgi, R, Nucera, G, Raffaelli, V, Marino, P, Negro, E, Serati, L, Silvia, T, Iacobello, C, Strano, G, Boglione, L, Catania, A, Gipponi, P, Di Cato, L, Panaccione, A, Vitale, G, Crippa, I, Giacomini, M, Basile, A, Andrea, B, Tundo, P, Buzzigoli, S, Palmiero, G, Magnaca, A, Silva, M, Crespi, S, Pasquino, B, Consales, G, Bragantini, D, Mastroianni, F, Righetti, G, Scarafino, A, Bitetto, M, Franzetti, F, Piga, S, Delmonte, V, Carbonara, S, Losappio, R, Dejaco, C, Del Bono, V, Gilioli, F, Barzan, D, De Struppi, S, Carlotto, A, Guadagnin, M, Girardis, M, Bertellini, E, Dentali, F, Foresta, G, Baratta, A, Viviani, R, Agrati, A, Perego, G, Montineri, A, Manuele, R, Bonfante, S, Aquilini, D, Prozzo, A, Santopuoli, D, Di Rosa, Z, Alborghetti, A, Peci, P, Bakhtadze, N, Pandini, C, Ashofarir, N, Casella, G, Spagnolli, W, Urru, S, Marchesoni, I, Caminiti, G, Argilloni, E, Danieli, E, Ghirardi, G, Antonioli, C, Lipari, A, Zavarise, P, Kokaly, F, Polati, E, Gottin, L, Lucernoni, P, De Conti, F, Marcon, E, Pontali, E, Vacca, E, Saffioti, C, Zunino, A, Pognuz, E, Berlot, G, Saltori, M, Tedesco, A, Agostini, C, Di Rosolini, M, Marino, F, Bellinzona, G, Grassi, W, Di Carlo, M, Scimonello, G, Nonini, S, Mondino, M, Mantovani, L, Tenti, E, Tropea, C, Di Stefano, D, Guelfi, P, Dagna, L, Morgana, G, Montemurro, L, Girelli, D, Crisafulli, E, Maroccia, A, Cemuschi, A, Bernasconi, M, Zummo, U, Barbato, V, Bevilacqua, S, Buonfanti, G, Canzanella, G, De Matteis, G, Florio, M, Martino, M, Ribecco, M, Romano, F, Savio, A, Sparavigna, L, Curvietto, M, Citarella, M, Nava, V, Maggioni, P, Magni, M, Iommelli, C, Bianco, A, Corsini, R, Valli, L, Ruggieri, M, Mancini, A, Melica, T, Ferrari, A, Cicognini, D, Delliponti, M, Zuccarini, A, Ciani, S, Raffaeli, D, Donati, L, Cannizzo, S, Lui, S, Santini, L, Roncaglia, E, Mighali, P, Eisendle, F, Cerino, G, Citterio, C, Di Nunzio, C, Lamonica, S, Resimini, S, Sarteschi, G, Pavei, C, Battistini, N, Gazzola, E, Miceli, M, Pontiggia, S, Lonati, V, Giannandrea, G, Sortino, C, Ravani, S, Uggeri, C, Jocolle, G, Bare, C, Baroni, I, De Candia, D, Fiorini, B, Chierico, K, Romeo, F, Bottega, R, Boccasile, L, Corsaro, A, Spadoni, C, Ria, E, Chiari, S, Ercolino, G, Dell'Uomo, V, Viri, S, Minato, M, Gazzola, L, Dorina, B, Gianelli, D, Maspero, S, Farinazzo, M, Zanini, P, Sangiovanni, A, Del Giudice, A, Dragonetti, M, Bordignon, S, Machiavelli, A, Chiodelli, G, Spatarella, M, Zenoni, D, Beretta, F, Santilli, G, Badagliacca, R, Angileri, M, Giannelli, L, Campomori, A, Maimone, P, Fadda, A, Faoro, S, Pisterna, A, Cacopardo, B, Marino, A, Pampaloni, A, Celesia, B, Cinnella, G, Labella, D, Caporusso, R, Danzi, M, Fiscon, M, Malena, M, Fendt, D, Nardi, S, Stobbione, P, Savi, M, De Monte, A, Scala, A, Liberato, N, Luchi, S, Vincenti, A, Cabrini, L, Pinelli, G, Brugioni, L, Potenza, D, Numis, F, Porta, G, D'Amico, M, Iengo, B, Angarano, G, Saracino, A, Blasi, L, De Negri, P, Angelici, S, Farina, A, Martino, G, Bitti, G, Tedeschi, A, De Ponti, S, Agostinone, A, Parruti, G, Consorte, A, Frattari, A, Filippelli, A, Pagliano, P, Masullo, A, Sellitto, C, Reta, M, Rossi, N, Raumer, L, Andreassi, S, Brancaleoni, P, Carai, A, Salerno, A, Marinangeli, F, Mariani, R, Ciccone, A, Meschini, C, Santoboni, G, Angrisani, C, Micarelli, D, Tarquini, G, Fregoni, V, Volta, C, Cherubini, A, Del Prete, M, Ciarrochi, E, Tasca, F, Ballarin, A, Bianchin, A, Flocco, R, Cuzzone, V, Carpinteri, M, Gallotti, P, Torre, F, Zannetti, P, Crapis, M, Venturini, S, Barattini, M, Gori, G, Mastroianni, A, De Stefano, G, Gilio, M, Rapisarda, G, Gulisano, L, Granata, M, Saglimbene, S, Montalto, M, Grasso, I, De Luca, S, Magro, G, Messina, F, Scapino, B, Abrate, P, Francisco, C, Pesce, L, Navarra, M, Agosti, M, Pagani, S, Piluso, M, Ricioppo, A, Tognella, S, Rovere, P, Vincenzi, M, Ghirardi, L, Generali, D, Ingrosso, M, Desiderio, E, Molaro, R, Vitiello, S, Lancione, L, Paone, T, Meli, A, Mainardi, S, Rastellino, V, Ursillo, A, Grigoli, P, Bovetto, E, Stefanetto, I, Mazzola, F, Daniele, A, Bisio, C, Delnero, P, Morando, G, Nava, A, Francesco, L, Fiammengo, F, Regis, M, Roccatello, D, Sabato, E, Liccardi, M, Bretto, C, Lutri, L, Castenetto, E, Roberti, G, Guidi, M, Bini, F, Zappa, M, Trequattrini, T, Rivitti, R, Vigliarolo, R, Succu, A, Lilli, M, Serao, M, Giogre, G, Ruggieri, A, Flores, K, Vairo, G, Satira, R, Lingua, A, Spina, R, Nicastri, E, Maffongelli, G, Barreca, F, Scollet, S, Franchi, F, Fabbri, C, Minuz, P, Dalbeni, A, Zanatta, P, Gelormini, D, Mandelli, A, Galderisi, F, Zoia, E, Marchi, M, Neves, N, Carbone, G, Di Caterino, E, Petrone, A, Usai, C, Bandiera, F, Monti, R, Hofer, A, Castiglione, G, Angeletti, C, Tarsia, P, Veronese, L, Artoni, P, Larussa, D, Fumagalli, R, Brioschi, P, Cerutti, A, Pasquino, P, Gilberto, F, Cantadori, L, Coppola, N, Spolveri, S, Pollastri, C, Fico, L, Principi, T, Pierantozzi, S, Fontana, C, Lubrano, G, Martinelli, L, Navalesi, P, Serra, E, Cogi, E, Manzi, A, Furino, E, Dasseni, N, Gentilini, C, Benatti, E, Pignatti, A, Aiello, G, Milia, M, Covesnon, M, Brianti, A, Francesco, C, Ilaria, B, Pagnozzi, F, Mietta, S, Rossi, A, Maroni, L, Borroni, V, Bellintani, C, Sgarabotto, C, Bizzotto, G, Bucci, L, Spagnuolo, G, Agostini, M, Caria, F, Testa, F, De Palma, R, Murdaca, G, Zanolini, G, Sala, N, Righini, E, Pontremoli, R, Aondio, G, Riccardi, F, De Cristoforo, M, De Michele, F, Storti, A, Perra, R, Deidda, S, Enrica, C, Valastro, F, Pierfranceschi, M, De Gennaro, F, Nardecchia, A, Castellini, M, Buetto, G, Ippoliti, G, Sicheri, D, Bottoli, M, De Arroyabe, B, Versaci, A, Pallotti, G, Civita, M, Grio, M, Liuzzi, N, Molino, P, Pastorelli, M, Ricchiardi, A, Varbella, F, Zeme, A, Sighieri, C, Portale, G, Olivetti, A, Pagnoni, C, Moschini, G, Boni, S, Guerra, A, Scudellari, R, Vella, S, Inchiostro, S, Piazza, O, Guarino, S, Aldegheri, G, Napoli, G, Morettini, A, Caldini, E, Menicacci, L, Pieralli, F, Torrini, M, Poggesi, L, Visetti, E, Mangano, C, Visconti, S, Maietta, P, Banfi, E, Cartella, S, Venturi, B, Nuceri, A, Chiesa, E, Pacentra, E, Panzolato, G, Giannotti, M, Bianchi, C, Pietrangelo, A, Para, O, Rutili, M, Russo, R, Lanfranco, M, Scalabrino, E, Tafuri, A, Chiarello, T, Perfetti, E, Cancanelli, L, Otero, M, Pannella, G, Bellucci, F, Ferrero, G, Vico, C, Stillante, M, D'Andrea, G, Amoroso, F, Arcidiacono, A, Bella, A, Belsito, A, Berte, Y, Carubia, G, Caruso, M, Casella, O, Chiereleson, F, Costa, C, De Franco, D, Germana, G, Messina, A, Musumeci, D, Noto, C, Valenti, M, Sorrentino, C, Panico, R, Schettino, G, Piccoli, J, Pepe, A, Ottaviano, M, Marrazzo, G, Raponi, G, Diberardino, S, Bausi, S, Marini, S, Giubellino, E, Innocenti, G, Gugliemi, G, Maccari, D, Baciu, I, Perrone F., Piccirillo M. C., Ascierto P. A., Salvarani C., Parrella R., Marata A. M., Popoli P., Ferraris L., Marrocco-trischitta M. M., Ripamonti D., Binda F., Bonfanti P., Squillace N., Castelli F., Muiesan M. L., Lichtner M., Calzetti C., Salerno N. D., Atripaldi L., Cascella M., Costantini M., Dolci G., Facciolongo N. C., Fraganza F., Massari M., Montesarchio V., Mussini C., Negri E. A., Botti G., Cardone C., Gargiulo P., Gravina A., Schettino C., Arenare L., Chiodini P., Gallo C., Vitale M. G., Trojaniello C., Palla M., Bianchi A. A. M., De Feo G., Miscio L., Froldi M., Menicanti L., Cuppone M. T., Gobbo G., Baldessari C., Valenti V., Castelvecchio S., Poli F., Giacomazzi F., Piccinni R., Annnunziata M. L., Biondi A., Bussolari C., Mazzoleni M., Giachi A., Filtz A., Manini A., Poletti E., Masserini F., Conforti F., Gaudiano G., Favero V., Moroni A., Viva T., Fancoli F., Ferrari D., Niro D., Resta M., Ballotta A., Poli M. D., Ranucci M., Tebaldi A., Gritti G., Pasulo L., Gaglio L., Del Fabbro R., Alborghetti L., Giustinetti G., Columpsi P., Cazzaniga M., Capici S., Sala L., Di Sciacca R., Mosca G., Pirozzi M. R., Franceschini F., Roccaro A., Salvetti M., Paini A., Corda L., Ricci C., Tomasoni L., Nasta P., Lorenzotti S., Odolini S., Foca E., Roldan E. Q., Metra M., Magrini S., Borghetti P., Latronico N., Piva S., Filippini M., Tomasoni G., Zuccala F., Cattaneo S., Scolari F., Bossini N., Gaggiotti M., Properzi M., Del Giudice E., Marocco R., Carraro A., Del Borgo C., Belvisi V., Tieghi T., De Masi M., Zuccala P., Fabietti P., Vetica A., Mercurio V. S., Fondaco L., Kertusha B., Curtolo A., Lubrano R., Zotti M. G., Puorto A., Ciuffreda M., Sarni A., Monteforte G., Romeo D., Viola E., Damiani C., Barone A., Mantovani B., Di Sanzo D., Gentili V., Carletti M., Aiuti M., Gallo A., Meliante P. G., Martellucci S., Riggio O., Cardinale V., Ridola L., Bragazzi M. C., Gioia S., Valenzi E., Graziosi C., Bina N., Fasolo M., Ricci S., Gioacchini M. T., Lucci A., Corso L., Tornese D., Nijhawan P., Equitani F., Cosentino C., Palladino M., Leonetti F., Leto G., Gnessi C., Campagna G., Cesareo R., Marrocco F., Straface G., Mecozzi A., Cerbo L., Isgro V., Parrocchia S., Visconti G., Casati G., Ariani A., Donghi L., Tacconelli E., Bertoldi M., Cattaneo P., Lambertenghi L., Motta L., Omega L., Albano G., Scarano F., De Rosa A., Buglione A., Lavoretano S., Gaglione G., De Marco M., Sangiovanni V., Fusco F. M., Viglietti R., Manzillo E., Rescigno C., Pisapia R., Plamieri G., Maraolo A., Calabria G., Catalano M., Fiorentino G., Annunziata A., Polistina G., Imitazione P., Mollica M., Esposito V., D'abraccio M., Punzi R., Bianco V., Sbreglia C., Del Vecchio R. F., Bordonali A., Franco A., Salsi P., Fontana M., Virzi G., Ornella C., Molteni A., Gennarini S., Gnudi U., Ricci M. A., Titolo G., Mensi G., Vuotto P., Gasperini B., Mancini M., Pasquini Z., Spanu P., Clementi S., Pierini S., Bokor D., Gori D., Ciofetti M., Caimi M., Bettazzi L., Allevi E., Furiani S., Capitanio C., Mastropasqua B., Fara C., Pulitano G., Matsuno J. S., Porta F. D., Dolfini V., Beyene N. B., Bezzi M., Novali M., Viale P., Tedeschi S., Pascale R., Bruno R., Di Filippo A., Sachs M., Oggionni T., Di Stefano M., Mengoli C., Facchini C., Daniele D. N., Frausini G., Mucci L., Tedesco S., Girolimetti R., Manfredini E., Di Carlo A. M., Espinosa E., Dennetta D., Ticinesi A., Meschi T., Nouvenne A., Claudio N., Vitale F., Saracco M., Codeluppi M., Fronti E., Ferrante P., Nespola G. A., Francisci D., Tosti A., Carbonelli C. M., Greco A., Tinti M. G., Stellini R., Appiani C., Reghenzi P., Poletti V., Ravaglia C., Tacconi D., Malcontenti C., Sainaghi P. P., Landi R., Vassia V., Rizzi E., Bellan M., Rossati A., Castello L., Mastroianni C. M., Russo G., Fabio T., Serino F. S., Brollo L., Momesso E., Turati M. L., Monforte A. D., Marchetti G., Boni F., Teopompi E., Trenti C., Boracchia L., Minelli E., Ghidoni G., Matei A., Caruso A., Arcoleo G., Camarda G., Catalano F., Spatafora M., Bettega D., Andreoni M., Teti E., Sarmati L., Di Lorenzo A., Celeste M., Baratto F., Monticelli J., Criveller P., Andrea A., Anselmo Riccio, Castellano M., Cappelli C., Corvini F., Zanini B., Crippa M., Ronconi M., Costa R., Casella S., Brentana L., Bernardi L., Frascati A., Panese S., Presotto F., Michieletto L., Bernardi C., Fusar M., Agnoletti V., Farina M., Lavorini F., Ginanni R., Palmieri F., Mosti S., Amaglio A., Cattaneo A., Cirri S., Montisci A., Gallazzi C., Cosseta D., Baronio B., Rampa L., Maggi P., Messina V., Berlendis M., Sabatti M. C., Palumbo M., Mazzone A., Faggioli P., Bussini L., Fornaro G., Volpato F., Imperiale D., Manno E., Ferreri E., Martelli D., Verhovez A., Giorgis S., Faccio L., Quadri R. D., Negro C., Converso M., Bosco F., Amadasi S., Prandini P., Cocchi S., Manfrin V., Del Punta V., Mazzola G., Sportato G., Romagnoli M., Cristini F., Facondini F., Perin T., Boschi A., Meschiari M., Guaraldi G., Modica S., Moneta S., Boccalatte D., Marchetti V., Ebbreo G., Dale M., Tura P., Rizzoni D., Boari G. E. M., Bonetti S., Marini E., Daniele I., Grossi P. A., Delfrate N. W., Bernhart O., Spizzo G., Mahlknecht K., Volkl T., Di Pietro M. A., Trezzi M., Monacci C., Peris A., Bonizzoli M., Cavanna L., Moroni C., Stroppa E. M., Savio M. C., Gatti F., Bartolaminelli C., Petrosillo N., Donno D. R., Taglietti F., Topino S., Chinello P., Galati V., D'offizi G., Taibi C., Cimolato B., Moroni F., Palagano N., Pelagatti L., Cristiana S., Landini G., Amitrano M., Raimondo M., Mangiacapra S., Romano A., Atteno M., Blanc P., Suardi L. R., Pallotto C., Casinelli K., Uccella I., Harari S., Caminati A., Lipani F., Di Perri G., Calcagno A., Calleri G., Montrucchio C., Caputo A. M., Cozzio S., Donne L. D., Bassetti M., Malgorzata M., Nicolini L. A., Russo C., Sepulcri C., Beltramini S., Mina F., Puoti M., Gandino A., Langer T., D'amico F., Rocchetti C., Cettolo F., Gabriele F., Bocchi P., Cioni G., Cappi C., Corcione S., De Rosa F. G., Scabini S., Canta F., Pinna S. M., Pensa A., Rocco M., Cirasa M. T., Spinicci M., Mencarini J., Zammarchi L., Giovanni C., Sciole K., Bassi F., Bianchi M., Frigerio S., Spaziani S., Nucera A., Rizzardini G., Cossu M. V., Antivalle M., Carpinteri G., Macheda S., Labate D., Bottiroli M., Erne E. M., Cristina Z., Di Biase V., Malberti F., Montani G., Poisa P., Bettini D., Cauda R., Ciccullo A., Riccardi N., Angheben A., Turrini M., Clerici R., Gardellini A., Liparulo L., Rossini T., Ucciferri C., Cipollone F., Vecchiet J., Nico A., Marra L., Leone A., Sdanganelli A., Palmiotti G. A., D'alagni G., Santantonio T. A., Caputo S. L., Bottalico I., Ponticiello A., Di Perna F., Bernardi E., Beltrame A., Bravi S., David M., Bernardi P., Galante D., Uccelli M. C., Prestini K., Drera M., Zini E., Peregrinelli A., Blanzuoli L., Benedetti V., Calvi R., Scaglione N., Nallino G., Bonazzi M., Crespi T., Masolin T., Regazzetti A., Cerri M. C., Maffezzini E., Piazza M., Papetti C., Filippi C. D., Roveda E., Cipolla G., Scozzafava M., Crepaldi M., Henchi S., Vanoni N., Repossi A., Vezzoli M., Scorletti E., Perugini O., Pasini S. M., Pacetti V., Ferrari L., de Paduanis G. A., Del Duca S., Dell'ara F., Brocchieri A., Minoja G., Storti E., Pitagora L., Costa I., Delfanti F., Orlandi M., Ruggeri R., Ruggieri L., Livigni S., Silengo D., Ageno W., Pedrini L., Artiol S., Morbidoni L., De Donno G., Ravagnani V., Inglese F., Scotton P. G., Costantini P., Delucchi M., Clini E., Ansuini A., Marco B., Giuseppe L., Vincenzo B., Rastelli G., Doria A., Vianello A., Cattelan A. M., Bindoli S., Felicietti M., Canetta C., Scartabellati A., Accordino S., Ferrara M., Cocco L., Cirillo F., Pace E., De Caro M., Alberico M., Benigni G., Damiano T., Fusco P., Iuorio A., Torretta G., Racagni M., Muttini S., Sala G., Ghiringhelli P., Chiumiento F., Baccari L., Luca B., Bocchi F., Benatti F., Catellani J., Coppola M., Papi A., Bosco E., Lazzeri C., Cesira N., Puttini C., Carli T., Croci L., Corridi M., Arlotti M., Guerrini G., Cola L., Romanelli M., Bonifazi M., Gasparini S., Mei F., Cerutti E., Lacedonia D., Santoro A., Guidelli G. M., Greco S., Castellan A., Infantino G., Camici L., Frigieri F. C., Pavoni V., Migliori L., Rossetti B., Montagnini F., Mauro I., Genovese E., Capuozzo A., Vitiello L., Sirignano E., Gnesin P., Servillo G., Marinelli A., Pasero D., Casadio L., Babudieri S., Madeddu G., De Vito A., Ranghitta M., Passalacqua R., Antonio F., Gentile I., Buonomo A. R., Scotto R., Zappulo E., Dell'aquila G., Bianchetti A., Guerini F., Vallone A., Oppedisano P., Pusterla L., Giglio O., Sartori E., Zanardini C., Gatti P., Vincenzo V., Piconi S., Molteni C., Dognini G., Cosimo F., Guarneri L., Pulvirenti F., Mondino V., Traballi G., Iemoli E., Grisolia A., Giorgi R., Nucera G., Raffaelli V., Marino P., Negro E., Serati L., Silvia T., Iacobello C., Strano G., Boglione L., Catania A., Gipponi P., Di Cato L., Panaccione A., Vitale G., Crippa I. A., Giacomini M., Basile A., Andrea B., Tundo P., Buzzigoli S., Palmiero G., Magnaca A., Silva M., Ricci M., Crespi S., Pasquino B., Consales G., Bragantini D., Mastroianni F., Righetti G., Scarafino A., Bitetto M., Franzetti F., Piga S., Delmonte V., Carbonara S., Losappio R., Dejaco C., Mastroianni C., Del Bono V., Gilioli F., Barzan D., De Struppi S., Carlotto A., Guadagnin M. L., Girardis M., Bertellini E., Dentali F., Foresta G., Baratta A., Viviani R., Agrati A. M., Perego G. B., Montineri A., Manuele R., Bonfante S., Aquilini D., Prozzo A., Santopuoli D., Di Rosa Z., Alborghetti A., Peci P., Bakhtadze N., Pandini C. S., Ashofarir N., Casella G., Spagnolli W., Urru S., Marchesoni I., Caminiti G., Argilloni E., Danieli E., Ghirardi G., Antonioli C. M., Lipari A., Zavarise P., Kokaly F., Polati E., Gottin L., Lucernoni P., De Conti F., Marcon E., Pontali E., Vacca E. B., Saffioti C., Zunino A., Pognuz E. R., Berlot G., Saltori M., Tedesco A., Agostini C., Di Rosolini M. A., Marino F., Bellinzona G., Grassi W., Di Carlo M., Scimonello G., Nonini S., Mondino M., Mantovani L. F., Tenti E., Tropea C. M. G., Di Stefano D. E., Guelfi P., Dagna L., Morgana G., Montemurro L., Girelli D., Crisafulli E., Maroccia A., Cemuschi A. M., Bernasconi M., Zummo U., Barbato V., Bevilacqua S., Buonfanti G., Canzanella G., De Matteis G., Florio M., Martino M., Ribecco M. T., Romano F., Savio A., Sparavigna L., Curvietto M., Citarella M., Nava V., Maggioni P., Magni M., Iommelli C., Bianco A., Corsini R., Valli L., Ruggieri M. P., Mancini A., Melica T., Ferrari A., Cicognini D., Delliponti M., Zuccarini A., Ciani S., Raffaeli D., Donati L., Cannizzo S., Lui S., Santini L., Roncaglia E., Mighali P., Eisendle F., Cerino G., Citterio C., Di Nunzio C., Lamonica S., Resimini S., Sarteschi G., Pavei C., Battistini N., Gazzola E., Miceli M., Pontiggia S., Lonati V., Giannandrea G., Sortino C., Ravani S., Uggeri C., Jocolle G., Bare C., Baroni I., De Candia D., Fiorini B., Chierico K., Romeo F., Bottega R., Boccasile L., Corsaro A., Spadoni C., Ria E., Chiari S., Ercolino G., Dell'uomo V., Viri S., Minato M., Gazzola L., Dorina B., Gianelli D., Maspero S., Farinazzo M., Zanini P., Sangiovanni A., Del Giudice A., Dragonetti M. M., Bordignon S., Machiavelli A. M., Chiodelli G., Spatarella M., Zenoni D., Beretta F. N., Santilli G., Badagliacca R., Angileri M., Giannelli L., Campomori A., Maimone P., Fadda A., Faoro S., Pisterna A., Cacopardo B., Marino A., Pampaloni A., Celesia B. M., Cinnella G., Labella D., Caporusso R. R., Danzi M., Fiscon M., Malena M., Fendt D., Nardi S., Stobbione P., Savi M. L., De Monte A., Scala A., Liberato N. L., Luchi S., Vincenti A., Cabrini L., Pinelli G., Brugioni L., Potenza D., Numis F. G., Porta G., D'amico M., Iengo B., Angarano G., Saracino A., Blasi L., De Negri P., Angelici S., Farina A., Martino G. P., Bitti G., Tedeschi A., De Ponti S., Agostinone A., Parruti G., Consorte A., Frattari A., Filippelli A., Pagliano P., Masullo A., Sellitto C., Reta M., Rossi N., Raumer L., Andreassi S., Brancaleoni P., Carai A., Salerno A. M., Marinangeli F., Mariani R., Ciccone A., Meschini C., Santoboni G., Angrisani C., Micarelli D., Tarquini G., Fregoni V., Volta C. A., Cherubini A., Del Prete M. S., Ciarrochi E., Tasca F., Ballarin A., Bianchin A., Flocco R., Cuzzone V., Carpinteri M., Gallotti P., Torre F., Zannetti P., Crapis M., Venturini S., Barattini M., Gori G., Mastroianni A., De Stefano G., Gilio M., Rapisarda G., Gulisano L., Granata M. L., Saglimbene S., Montalto M. T., Grasso I., De Luca S., Magro G., Messina F., Scapino B., Abrate P., Francisco C., Pesce L., Navarra M., Agosti M., Pagani S., Piluso M., Ricioppo A., Tognella S., Rovere P., Vincenzi M., Ghirardi L., Generali D., Ingrosso M., Desiderio E., Molaro R., Vitiello S., Lancione L., Paone T. C., Meli A., Mainardi S., Rastellino V., Ursillo A., Grigoli P. D., Bovetto E., Stefanetto I. M., Mazzola F., Daniele A., Bisio C., Delnero P., Morando G., Nava A., Francesco L., Fiammengo F., Regis M., Roccatello D., Sabato E., Liccardi M. M., Bretto C., Lutri L., Castenetto E., Roberti G., Guidi M. F., Bini F., Zappa M. C., Trequattrini T., Rivitti R., Vigliarolo R., Succu A., Lilli M., Serao M., Giogre G., Ruggieri A., Flores K., Vairo G., Satira R., Lingua A., Spina R., Nicastri E., Maffongelli G., Barreca F., Scollet S., Franchi F., Fabbri C., Minuz P., Dalbeni A., Zanatta P., Gelormini D., Mandelli A., Galderisi F., Zoia E., Marchi M. R., Neves N. D. A., Carbone G., Di Caterino E., Petrone A., Usai C. A., Bandiera F., Monti R., Hofer A., Castiglione G., Angeletti C., Tarsia P., Veronese L., Artoni P. D., Larussa D., Fumagalli R., Brioschi P., Cerutti A., Pasquino P., Gilberto F., Cantadori L., Tomasoni L. R., Coppola N., Spolveri S., Pollastri C., Fico L., Principi T., Pierantozzi S., Fontana C. C., Lubrano G., Martinelli L., Navalesi P., Serra E., Cogi E., Manzi A., Furino E., Dasseni N., Gentilini C., Benatti E., Pignatti A., Aiello G., Milia M., Covesnon M. G., Brianti A., Francesco C., Ilaria B., Pagnozzi F., Mietta S., Rossi A., Maroni L., Borroni V., Bellintani C., Sgarabotto C., Bizzotto G., Bucci L., Spagnuolo G., Agostini M., Caria F. C., Testa F., De Palma R., Murdaca G., Zanolini G., Sala N., Righini E., Pontremoli R., Aondio G., Riccardi F., De Cristoforo M. G., De Michele F., Storti A., Perra R., Deidda S., Enrica C., Valastro F., Pierfranceschi M. G., De Gennaro F., Nardecchia A. L., Castellini M., Buetto G., Ippoliti G., Sicheri D., Bottoli M. G., De Arroyabe B. M. L., Versaci A., Pallotti G., Civita M., Grio M., Liuzzi N., Molino P., Pastorelli M., Ricchiardi A., Varbella F., Zeme A. D., Sighieri C., Portale G., Olivetti A., Pagnoni C., Moschini G., Boni S., Guerra A., Scudellari R., Vella S., Inchiostro S., Piazza O., Guarino S., Aldegheri G., Napoli G., Morettini A., Caldini E., Menicacci L., Pieralli F., Torrini M., Poggesi L., Visetti E. M., Mangano C., Visconti S., Maietta P., Banfi E., Cartella S., Venturi B., Nuceri A., Chiesa E., Pacentra E., Panzolato G., Giannotti M., Bianchi C., Pietrangelo A., Para O., Rutili M. S., Russo R., Lanfranco M., Scalabrino E., Tafuri A., Chiarello T., Perfetti E., Cancanelli L., Otero M., Pannella G., Bellucci F., Ferrero G., Vico C., Stillante M. S., D'andrea G., Amoroso F., Arcidiacono A., Bella A. M., Belsito A., Berte Y., Carubia G., Caruso M. G., Casella O., Chiereleson F., Costa C., De Franco D., Germana G., Messina A., Musumeci D., Noto C., Valenti M., Sorrentino C., Panico R., Schettino G., Piccoli J., Pepe A., De Rosa F., Ottaviano M., Marrazzo G., Raponi G., Diberardino S., Bausi S., Marini S. F., Giubellino E., Innocenti G., Gugliemi G., Maccari D., Baciu I., Perrone, F, Piccirillo, M, Ascierto, P, Salvarani, C, Parrella, R, Marata, A, Popoli, P, Ferraris, L, Marrocco-trischitta, M, Ripamonti, D, Binda, F, Bonfanti, P, Squillace, N, Castelli, F, Muiesan, M, Lichtner, M, Calzetti, C, Salerno, N, Atripaldi, L, Cascella, M, Costantini, M, Dolci, G, Facciolongo, N, Fraganza, F, Massari, M, Montesarchio, V, Mussini, C, Negri, E, Botti, G, Cardone, C, Gargiulo, P, Gravina, A, Schettino, C, Arenare, L, Chiodini, P, Gallo, C, Vitale, M, Trojaniello, C, Palla, M, Bianchi, A, De Feo, G, Miscio, L, Froldi, M, Menicanti, L, Cuppone, M, Gobbo, G, Baldessari, C, Valenti, V, Castelvecchio, S, Poli, F, Giacomazzi, F, Piccinni, R, Annnunziata, M, Biondi, A, Bussolari, C, Mazzoleni, M, Giachi, A, Filtz, A, Manini, A, Poletti, E, Masserini, F, Conforti, F, Gaudiano, G, Favero, V, Moroni, A, Viva, T, Fancoli, F, Ferrari, D, Niro, D, Resta, M, Ballotta, A, Poli, M, Ranucci, M, Tebaldi, A, Gritti, G, Pasulo, L, Gaglio, L, Del Fabbro, R, Alborghetti, L, Giustinetti, G, Columpsi, P, Cazzaniga, M, Capici, S, Sala, L, Di Sciacca, R, Mosca, G, Pirozzi, M, Franceschini, F, Roccaro, A, Salvetti, M, Paini, A, Corda, L, Ricci, C, Tomasoni, L, Nasta, P, Lorenzotti, S, Odolini, S, Foca, E, Roldan, E, Metra, M, Magrini, S, Borghetti, P, Latronico, N, Piva, S, Filippini, M, Tomasoni, G, Zuccala, F, Cattaneo, S, Scolari, F, Bossini, N, Gaggiotti, M, Properzi, M, Del Giudice, E, Marocco, R, Carraro, A, Del Borgo, C, Belvisi, V, Tieghi, T, De Masi, M, Zuccala, P, Fabietti, P, Vetica, A, Mercurio, V, Fondaco, L, Kertusha, B, Curtolo, A, Lubrano, R, Zotti, M, Puorto, A, Ciuffreda, M, Sarni, A, Monteforte, G, Romeo, D, Viola, E, Damiani, C, Barone, A, Mantovani, B, Di Sanzo, D, Gentili, V, Carletti, M, Aiuti, M, Gallo, A, Meliante, P, Martellucci, S, Riggio, O, Cardinale, V, Ridola, L, Bragazzi, M, Gioia, S, Valenzi, E, Graziosi, C, Bina, N, Fasolo, M, Ricci, S, Gioacchini, M, Lucci, A, Corso, L, Tornese, D, Nijhawan, P, Equitani, F, Cosentino, C, Palladino, M, Leonetti, F, Leto, G, Gnessi, C, Campagna, G, Cesareo, R, Marrocco, F, Straface, G, Mecozzi, A, Cerbo, L, Isgro, V, Parrocchia, S, Visconti, G, Casati, G, Ariani, A, Donghi, L, Tacconelli, E, Bertoldi, M, Cattaneo, P, Lambertenghi, L, Motta, L, Omega, L, Albano, G, Scarano, F, De Rosa, A, Buglione, A, Lavoretano, S, Gaglione, G, De Marco, M, Sangiovanni, V, Fusco, F, Viglietti, R, Manzillo, E, Rescigno, C, Pisapia, R, Plamieri, G, Maraolo, A, Calabria, G, Catalano, M, Fiorentino, G, Annunziata, A, Polistina, G, Imitazione, P, Mollica, M, Esposito, V, D'Abraccio, M, Punzi, R, Bianco, V, Sbreglia, C, Del Vecchio, R, Bordonali, A, Franco, A, Salsi, P, Fontana, M, Virzi, G, Ornella, C, Molteni, A, Gennarini, S, Gnudi, U, Ricci, M, Titolo, G, Mensi, G, Vuotto, P, Gasperini, B, Mancini, M, Pasquini, Z, Spanu, P, Clementi, S, Pierini, S, Bokor, D, Gori, D, Ciofetti, M, Caimi, M, Bettazzi, L, Allevi, E, Furiani, S, Capitanio, C, Mastropasqua, B, Fara, C, Pulitano, G, Matsuno, J, Porta, F, Dolfini, V, Beyene, N, Bezzi, M, Novali, M, Viale, P, Tedeschi, S, Pascale, R, Bruno, R, Di Filippo, A, Sachs, M, Oggionni, T, Di Stefano, M, Mengoli, C, Facchini, C, Daniele, D, Frausini, G, Mucci, L, Tedesco, S, Girolimetti, R, Manfredini, E, Di Carlo, A, Espinosa, E, Dennetta, D, Ticinesi, A, Meschi, T, Nouvenne, A, Claudio, N, Vitale, F, Saracco, M, Codeluppi, M, Fronti, E, Ferrante, P, Nespola, G, Francisci, D, Tosti, A, Carbonelli, C, Greco, A, Tinti, M, Stellini, R, Appiani, C, Reghenzi, P, Poletti, V, Ravaglia, C, Tacconi, D, Malcontenti, C, Sainaghi, P, Landi, R, Vassia, V, Rizzi, E, Bellan, M, Rossati, A, Castello, L, Mastroianni, C, Russo, G, Fabio, T, Serino, F, Brollo, L, Momesso, E, Turati, M, Monforte, A, Marchetti, G, Boni, F, Teopompi, E, Trenti, C, Boracchia, L, Minelli, E, Ghidoni, G, Matei, A, Caruso, A, Arcoleo, G, Camarda, G, Catalano, F, Spatafora, M, Bettega, D, Andreoni, M, Teti, E, Sarmati, L, Di Lorenzo, A, Celeste, M, Baratto, F, Monticelli, J, Criveller, P, Andrea, A, Anselmo, R, Castellano, M, Cappelli, C, Corvini, F, Zanini, B, Crippa, M, Ronconi, M, Costa, R, Casella, S, Brentana, L, Bernardi, L, Frascati, A, Panese, S, Presotto, F, Michieletto, L, Bernardi, C, Fusar, M, Agnoletti, V, Farina, M, Russo, Lavorini, F, Ginanni, R, Palmieri, F, Mosti, S, Amaglio, A, Cattaneo, A, Cirri, S, Montisci, A, Gallazzi, C, Cosseta, D, Baronio, B, Rampa, L, Maggi, P, Messina, V, Berlendis, M, Sabatti, M, Palumbo, M, Mazzone, A, Faggioli, P, Bussini, L, Fornaro, G, Volpato, F, Imperiale, D, Manno, E, Ferreri, E, Martelli, D, Verhovez, A, Giorgis, S, Faccio, L, Quadri, R, Negro, C, Converso, M, Bosco, F, Amadasi, S, Prandini, P, Cocchi, S, Manfrin, V, Del Punta, V, Mazzola, G, Sportato, G, Romagnoli, M, Cristini, F, Facondini, F, Perin, T, Boschi, A, Meschiari, M, Guaraldi, G, Modica, S, Moneta, S, Boccalatte, D, Marchetti, V, Ebbreo, G, Dale, M, Tura, P, Rizzoni, D, Boari, G, Bonetti, S, Marini, E, Daniele, I, Grossi, P, Delfrate, N, Bernhart, O, Spizzo, G, Mahlknecht, K, Volkl, T, Di Pietro, M, Trezzi, M, Monacci, C, Peris, A, Bonizzoli, M, Cavanna, L, Moroni, C, Stroppa, E, Savio, M, Gatti, F, Bartolaminelli, C, Petrosillo, N, Donno, D, Taglietti, F, Topino, S, Chinello, P, Galati, V, D'Offizi, G, Taibi, C, Cimolato, B, Moroni, F, Palagano, N, Pelagatti, L, Cristiana, S, Landini, G, Amitrano, M, Raimondo, M, Mangiacapra, S, Romano, A, Atteno, M, Blanc, P, Suardi, L, Pallotto, C, Casinelli, K, Uccella, I, Harari, S, Caminati, A, Lipani, F, Di Perri, G, Calcagno, A, Calleri, G, Montrucchio, C, Caputo, A, Cozzio, S, Donne, L, Bassetti, M, Malgorzata, M, Nicolini, L, Russo, C, Sepulcri, C, Beltramini, S, Mina, F, Puoti, M, Gandino, A, Langer, T, D'Amico, F, Rocchetti, C, Cettolo, F, Gabriele, F, Bocchi, P, Cioni, G, Cappi, C, Corcione, S, De Rosa, F, Scabini, S, Canta, F, Pinna, S, Pensa, A, Rocco, M, Cirasa, M, Spinicci, M, Mencarini, J, Zammarchi, L, Giovanni, C, Sciole, K, Bassi, F, Bianchi, M, Frigerio, S, Spaziani, S, Nucera, A, Rizzardini, G, Cossu, M, Antivalle, M, Carpinteri, G, Macheda, S, Labate, D, Bottiroli, M, Erne, E, Cristina, Z, Di Biase, V, Malberti, F, Montani, G, Poisa, P, Bettini, D, Cauda, R, Ciccullo, A, Riccardi, N, Angheben, A, Turrini, M, Clerici, R, Gardellini, A, Liparulo, L, Rossini, T, Ucciferri, C, Cipollone, F, Vecchiet, J, Nico, A, Marra, L, Leone, A, Sdanganelli, A, Palmiotti, G, D'Alagni, G, Santantonio, T, Caputo, S, Bottalico, I, Ponticiello, A, Di Perna, F, Bernardi, E, Beltrame, A, Bravi, S, David, M, Bernardi, P, Galante, D, Uccelli, M, Prestini, K, Drera, M, Zini, E, Peregrinelli, A, Blanzuoli, L, Benedetti, V, Calvi, R, Scaglione, N, Nallino, G, Bonazzi, M, Crespi, T, Masolin, T, Regazzetti, A, Cerri, M, Maffezzini, E, Piazza, M, Papetti, C, Filippi, C, Roveda, E, Cipolla, G, Scozzafava, M, Crepaldi, M, Henchi, S, Vanoni, N, Repossi, A, Vezzoli, M, Scorletti, E, Perugini, O, Pasini, S, Pacetti, V, Ferrari, L, de Paduanis, G, Del Duca, S, Dell'Ara, F, Brocchieri, A, Minoja, G, Storti, E, Pitagora, L, Costa, I, Delfanti, F, Orlandi, M, Ruggeri, R, Ruggieri, L, Livigni, S, Silengo, D, Ageno, W, Pedrini, L, Artiol, S, Morbidoni, L, De Donno, G, Ravagnani, V, Inglese, F, Scotton, P, Costantini, P, Delucchi, M, Clini, E, Ansuini, A, Marco, B, Giuseppe, L, Vincenzo, B, Rastelli, G, Doria, A, Vianello, A, Cattelan, A, Bindoli, S, Felicietti, M, Canetta, C, Scartabellati, A, Accordino, S, Ferrara, M, Cocco, L, Cirillo, F, Pace, E, De Caro, M, Alberico, M, Benigni, G, Damiano, T, Fusco, P, Iuorio, A, Torretta, G, Racagni, M, Muttini, S, Sala, G, Ghiringhelli, P, Chiumiento, F, Baccari, L, Luca, B, Bocchi, F, Benatti, F, Catellani, J, Coppola, M, Papi, A, Bosco, E, Lazzeri, C, Cesira, N, Puttini, C, Carli, T, Croci, L, Corridi, M, Arlotti, M, Guerrini, G, Cola, L, Romanelli, M, Bonifazi, M, Gasparini, S, Mei, F, Cerutti, E, Lacedonia, D, Santoro, A, Guidelli, G, Greco, S, Castellan, A, Infantino, G, Camici, L, Frigieri, F, Pavoni, V, Migliori, L, Rossetti, B, Montagnini, F, Mauro, I, Genovese, E, Capuozzo, A, Vitiello, L, Sirignano, E, Gnesin, P, Servillo, G, Marinelli, A, Pasero, D, Casadio, L, Babudieri, S, Madeddu, G, De Vito, A, Ranghitta, M, Passalacqua, R, Antonio, F, Gentile, I, Buonomo, A, Scotto, R, Zappulo, E, Dell'Aquila, G, Bianchetti, A, Guerini, F, Vallone, A, Oppedisano, P, Pusterla, L, Giglio, O, Sartori, E, Zanardini, C, Gatti, P, Vincenzo, V, Piconi, S, Molteni, C, Dognini, G, Cosimo, F, Guarneri, L, Pulvirenti, F, Mondino, V, Traballi, G, Iemoli, E, Grisolia, A, Giorgi, R, Nucera, G, Raffaelli, V, Marino, P, Negro, E, Serati, L, Silvia, T, Iacobello, C, Strano, G, Boglione, L, Catania, A, Gipponi, P, Di Cato, L, Panaccione, A, Vitale, G, Crippa, I, Giacomini, M, Basile, A, Andrea, B, Tundo, P, Buzzigoli, S, Palmiero, G, Magnaca, A, Silva, M, Crespi, S, Pasquino, B, Consales, G, Bragantini, D, Mastroianni, F, Righetti, G, Scarafino, A, Bitetto, M, Franzetti, F, Piga, S, Delmonte, V, Carbonara, S, Losappio, R, Dejaco, C, Del Bono, V, Gilioli, F, Barzan, D, De Struppi, S, Carlotto, A, Guadagnin, M, Girardis, M, Bertellini, E, Dentali, F, Foresta, G, Baratta, A, Viviani, R, Agrati, A, Perego, G, Montineri, A, Manuele, R, Bonfante, S, Aquilini, D, Prozzo, A, Santopuoli, D, Di Rosa, Z, Alborghetti, A, Peci, P, Bakhtadze, N, Pandini, C, Ashofarir, N, Casella, G, Spagnolli, W, Urru, S, Marchesoni, I, Caminiti, G, Argilloni, E, Danieli, E, Ghirardi, G, Antonioli, C, Lipari, A, Zavarise, P, Kokaly, F, Polati, E, Gottin, L, Lucernoni, P, De Conti, F, Marcon, E, Pontali, E, Vacca, E, Saffioti, C, Zunino, A, Pognuz, E, Berlot, G, Saltori, M, Tedesco, A, Agostini, C, Di Rosolini, M, Marino, F, Bellinzona, G, Grassi, W, Di Carlo, M, Scimonello, G, Nonini, S, Mondino, M, Mantovani, L, Tenti, E, Tropea, C, Di Stefano, D, Guelfi, P, Dagna, L, Morgana, G, Montemurro, L, Girelli, D, Crisafulli, E, Maroccia, A, Cemuschi, A, Bernasconi, M, Zummo, U, Barbato, V, Bevilacqua, S, Buonfanti, G, Canzanella, G, De Matteis, G, Florio, M, Martino, M, Ribecco, M, Romano, F, Savio, A, Sparavigna, L, Curvietto, M, Citarella, M, Nava, V, Maggioni, P, Magni, M, Iommelli, C, Bianco, A, Corsini, R, Valli, L, Ruggieri, M, Mancini, A, Melica, T, Ferrari, A, Cicognini, D, Delliponti, M, Zuccarini, A, Ciani, S, Raffaeli, D, Donati, L, Cannizzo, S, Lui, S, Santini, L, Roncaglia, E, Mighali, P, Eisendle, F, Cerino, G, Citterio, C, Di Nunzio, C, Lamonica, S, Resimini, S, Sarteschi, G, Pavei, C, Battistini, N, Gazzola, E, Miceli, M, Pontiggia, S, Lonati, V, Giannandrea, G, Sortino, C, Ravani, S, Uggeri, C, Jocolle, G, Bare, C, Baroni, I, De Candia, D, Fiorini, B, Chierico, K, Romeo, F, Bottega, R, Boccasile, L, Corsaro, A, Spadoni, C, Ria, E, Chiari, S, Ercolino, G, Dell'Uomo, V, Viri, S, Minato, M, Gazzola, L, Dorina, B, Gianelli, D, Maspero, S, Farinazzo, M, Zanini, P, Sangiovanni, A, Del Giudice, A, Dragonetti, M, Bordignon, S, Machiavelli, A, Chiodelli, G, Spatarella, M, Zenoni, D, Beretta, F, Santilli, G, Badagliacca, R, Angileri, M, Giannelli, L, Campomori, A, Maimone, P, Fadda, A, Faoro, S, Pisterna, A, Cacopardo, B, Marino, A, Pampaloni, A, Celesia, B, Cinnella, G, Labella, D, Caporusso, R, Danzi, M, Fiscon, M, Malena, M, Fendt, D, Nardi, S, Stobbione, P, Savi, M, De Monte, A, Scala, A, Liberato, N, Luchi, S, Vincenti, A, Cabrini, L, Pinelli, G, Brugioni, L, Potenza, D, Numis, F, Porta, G, D'Amico, M, Iengo, B, Angarano, G, Saracino, A, Blasi, L, De Negri, P, Angelici, S, Farina, A, Martino, G, Bitti, G, Tedeschi, A, De Ponti, S, Agostinone, A, Parruti, G, Consorte, A, Frattari, A, Filippelli, A, Pagliano, P, Masullo, A, Sellitto, C, Reta, M, Rossi, N, Raumer, L, Andreassi, S, Brancaleoni, P, Carai, A, Salerno, A, Marinangeli, F, Mariani, R, Ciccone, A, Meschini, C, Santoboni, G, Angrisani, C, Micarelli, D, Tarquini, G, Fregoni, V, Volta, C, Cherubini, A, Del Prete, M, Ciarrochi, E, Tasca, F, Ballarin, A, Bianchin, A, Flocco, R, Cuzzone, V, Carpinteri, M, Gallotti, P, Torre, F, Zannetti, P, Crapis, M, Venturini, S, Barattini, M, Gori, G, Mastroianni, A, De Stefano, G, Gilio, M, Rapisarda, G, Gulisano, L, Granata, M, Saglimbene, S, Montalto, M, Grasso, I, De Luca, S, Magro, G, Messina, F, Scapino, B, Abrate, P, Francisco, C, Pesce, L, Navarra, M, Agosti, M, Pagani, S, Piluso, M, Ricioppo, A, Tognella, S, Rovere, P, Vincenzi, M, Ghirardi, L, Generali, D, Ingrosso, M, Desiderio, E, Molaro, R, Vitiello, S, Lancione, L, Paone, T, Meli, A, Mainardi, S, Rastellino, V, Ursillo, A, Grigoli, P, Bovetto, E, Stefanetto, I, Mazzola, F, Daniele, A, Bisio, C, Delnero, P, Morando, G, Nava, A, Francesco, L, Fiammengo, F, Regis, M, Roccatello, D, Sabato, E, Liccardi, M, Bretto, C, Lutri, L, Castenetto, E, Roberti, G, Guidi, M, Bini, F, Zappa, M, Trequattrini, T, Rivitti, R, Vigliarolo, R, Succu, A, Lilli, M, Serao, M, Giogre, G, Ruggieri, A, Flores, K, Vairo, G, Satira, R, Lingua, A, Spina, R, Nicastri, E, Maffongelli, G, Barreca, F, Scollet, S, Franchi, F, Fabbri, C, Minuz, P, Dalbeni, A, Zanatta, P, Gelormini, D, Mandelli, A, Galderisi, F, Zoia, E, Marchi, M, Neves, N, Carbone, G, Di Caterino, E, Petrone, A, Usai, C, Bandiera, F, Monti, R, Hofer, A, Castiglione, G, Angeletti, C, Tarsia, P, Veronese, L, Artoni, P, Larussa, D, Fumagalli, R, Brioschi, P, Cerutti, A, Pasquino, P, Gilberto, F, Cantadori, L, Coppola, N, Spolveri, S, Pollastri, C, Fico, L, Principi, T, Pierantozzi, S, Fontana, C, Lubrano, G, Martinelli, L, Navalesi, P, Serra, E, Cogi, E, Manzi, A, Furino, E, Dasseni, N, Gentilini, C, Benatti, E, Pignatti, A, Aiello, G, Milia, M, Covesnon, M, Brianti, A, Francesco, C, Ilaria, B, Pagnozzi, F, Mietta, S, Rossi, A, Maroni, L, Borroni, V, Bellintani, C, Sgarabotto, C, Bizzotto, G, Bucci, L, Spagnuolo, G, Agostini, M, Caria, F, Testa, F, De Palma, R, Murdaca, G, Zanolini, G, Sala, N, Righini, E, Pontremoli, R, Aondio, G, Riccardi, F, De Cristoforo, M, De Michele, F, Storti, A, Perra, R, Deidda, S, Enrica, C, Valastro, F, Pierfranceschi, M, De Gennaro, F, Nardecchia, A, Castellini, M, Buetto, G, Ippoliti, G, Sicheri, D, Bottoli, M, De Arroyabe, B, Versaci, A, Pallotti, G, Civita, M, Grio, M, Liuzzi, N, Molino, P, Pastorelli, M, Ricchiardi, A, Varbella, F, Zeme, A, Sighieri, C, Portale, G, Olivetti, A, Pagnoni, C, Moschini, G, Boni, S, Guerra, A, Scudellari, R, Vella, S, Inchiostro, S, Piazza, O, Guarino, S, Aldegheri, G, Napoli, G, Morettini, A, Caldini, E, Menicacci, L, Pieralli, F, Torrini, M, Poggesi, L, Visetti, E, Mangano, C, Visconti, S, Maietta, P, Banfi, E, Cartella, S, Venturi, B, Nuceri, A, Chiesa, E, Pacentra, E, Panzolato, G, Giannotti, M, Bianchi, C, Pietrangelo, A, Para, O, Rutili, M, Russo, R, Lanfranco, M, Scalabrino, E, Tafuri, A, Chiarello, T, Perfetti, E, Cancanelli, L, Otero, M, Pannella, G, Bellucci, F, Ferrero, G, Vico, C, Stillante, M, D'Andrea, G, Amoroso, F, Arcidiacono, A, Bella, A, Belsito, A, Berte, Y, Carubia, G, Caruso, M, Casella, O, Chiereleson, F, Costa, C, De Franco, D, Germana, G, Messina, A, Musumeci, D, Noto, C, Valenti, M, Sorrentino, C, Panico, R, Schettino, G, Piccoli, J, Pepe, A, Ottaviano, M, Marrazzo, G, Raponi, G, Diberardino, S, Bausi, S, Marini, S, Giubellino, E, Innocenti, G, Gugliemi, G, Maccari, D, Baciu, I, Perrone F., Piccirillo M. C., Ascierto P. A., Salvarani C., Parrella R., Marata A. M., Popoli P., Ferraris L., Marrocco-trischitta M. M., Ripamonti D., Binda F., Bonfanti P., Squillace N., Castelli F., Muiesan M. L., Lichtner M., Calzetti C., Salerno N. D., Atripaldi L., Cascella M., Costantini M., Dolci G., Facciolongo N. C., Fraganza F., Massari M., Montesarchio V., Mussini C., Negri E. A., Botti G., Cardone C., Gargiulo P., Gravina A., Schettino C., Arenare L., Chiodini P., Gallo C., Vitale M. G., Trojaniello C., Palla M., Bianchi A. A. M., De Feo G., Miscio L., Froldi M., Menicanti L., Cuppone M. T., Gobbo G., Baldessari C., Valenti V., Castelvecchio S., Poli F., Giacomazzi F., Piccinni R., Annnunziata M. L., Biondi A., Bussolari C., Mazzoleni M., Giachi A., Filtz A., Manini A., Poletti E., Masserini F., Conforti F., Gaudiano G., Favero V., Moroni A., Viva T., Fancoli F., Ferrari D., Niro D., Resta M., Ballotta A., Poli M. D., Ranucci M., Tebaldi A., Gritti G., Pasulo L., Gaglio L., Del Fabbro R., Alborghetti L., Giustinetti G., Columpsi P., Cazzaniga M., Capici S., Sala L., Di Sciacca R., Mosca G., Pirozzi M. R., Franceschini F., Roccaro A., Salvetti M., Paini A., Corda L., Ricci C., Tomasoni L., Nasta P., Lorenzotti S., Odolini S., Foca E., Roldan E. Q., Metra M., Magrini S., Borghetti P., Latronico N., Piva S., Filippini M., Tomasoni G., Zuccala F., Cattaneo S., Scolari F., Bossini N., Gaggiotti M., Properzi M., Del Giudice E., Marocco R., Carraro A., Del Borgo C., Belvisi V., Tieghi T., De Masi M., Zuccala P., Fabietti P., Vetica A., Mercurio V. S., Fondaco L., Kertusha B., Curtolo A., Lubrano R., Zotti M. G., Puorto A., Ciuffreda M., Sarni A., Monteforte G., Romeo D., Viola E., Damiani C., Barone A., Mantovani B., Di Sanzo D., Gentili V., Carletti M., Aiuti M., Gallo A., Meliante P. G., Martellucci S., Riggio O., Cardinale V., Ridola L., Bragazzi M. C., Gioia S., Valenzi E., Graziosi C., Bina N., Fasolo M., Ricci S., Gioacchini M. T., Lucci A., Corso L., Tornese D., Nijhawan P., Equitani F., Cosentino C., Palladino M., Leonetti F., Leto G., Gnessi C., Campagna G., Cesareo R., Marrocco F., Straface G., Mecozzi A., Cerbo L., Isgro V., Parrocchia S., Visconti G., Casati G., Ariani A., Donghi L., Tacconelli E., Bertoldi M., Cattaneo P., Lambertenghi L., Motta L., Omega L., Albano G., Scarano F., De Rosa A., Buglione A., Lavoretano S., Gaglione G., De Marco M., Sangiovanni V., Fusco F. M., Viglietti R., Manzillo E., Rescigno C., Pisapia R., Plamieri G., Maraolo A., Calabria G., Catalano M., Fiorentino G., Annunziata A., Polistina G., Imitazione P., Mollica M., Esposito V., D'abraccio M., Punzi R., Bianco V., Sbreglia C., Del Vecchio R. F., Bordonali A., Franco A., Salsi P., Fontana M., Virzi G., Ornella C., Molteni A., Gennarini S., Gnudi U., Ricci M. A., Titolo G., Mensi G., Vuotto P., Gasperini B., Mancini M., Pasquini Z., Spanu P., Clementi S., Pierini S., Bokor D., Gori D., Ciofetti M., Caimi M., Bettazzi L., Allevi E., Furiani S., Capitanio C., Mastropasqua B., Fara C., Pulitano G., Matsuno J. S., Porta F. D., Dolfini V., Beyene N. B., Bezzi M., Novali M., Viale P., Tedeschi S., Pascale R., Bruno R., Di Filippo A., Sachs M., Oggionni T., Di Stefano M., Mengoli C., Facchini C., Daniele D. N., Frausini G., Mucci L., Tedesco S., Girolimetti R., Manfredini E., Di Carlo A. M., Espinosa E., Dennetta D., Ticinesi A., Meschi T., Nouvenne A., Claudio N., Vitale F., Saracco M., Codeluppi M., Fronti E., Ferrante P., Nespola G. A., Francisci D., Tosti A., Carbonelli C. M., Greco A., Tinti M. G., Stellini R., Appiani C., Reghenzi P., Poletti V., Ravaglia C., Tacconi D., Malcontenti C., Sainaghi P. P., Landi R., Vassia V., Rizzi E., Bellan M., Rossati A., Castello L., Mastroianni C. M., Russo G., Fabio T., Serino F. S., Brollo L., Momesso E., Turati M. L., Monforte A. D., Marchetti G., Boni F., Teopompi E., Trenti C., Boracchia L., Minelli E., Ghidoni G., Matei A., Caruso A., Arcoleo G., Camarda G., Catalano F., Spatafora M., Bettega D., Andreoni M., Teti E., Sarmati L., Di Lorenzo A., Celeste M., Baratto F., Monticelli J., Criveller P., Andrea A., Anselmo Riccio, Castellano M., Cappelli C., Corvini F., Zanini B., Crippa M., Ronconi M., Costa R., Casella S., Brentana L., Bernardi L., Frascati A., Panese S., Presotto F., Michieletto L., Bernardi C., Fusar M., Agnoletti V., Farina M., Lavorini F., Ginanni R., Palmieri F., Mosti S., Amaglio A., Cattaneo A., Cirri S., Montisci A., Gallazzi C., Cosseta D., Baronio B., Rampa L., Maggi P., Messina V., Berlendis M., Sabatti M. C., Palumbo M., Mazzone A., Faggioli P., Bussini L., Fornaro G., Volpato F., Imperiale D., Manno E., Ferreri E., Martelli D., Verhovez A., Giorgis S., Faccio L., Quadri R. D., Negro C., Converso M., Bosco F., Amadasi S., Prandini P., Cocchi S., Manfrin V., Del Punta V., Mazzola G., Sportato G., Romagnoli M., Cristini F., Facondini F., Perin T., Boschi A., Meschiari M., Guaraldi G., Modica S., Moneta S., Boccalatte D., Marchetti V., Ebbreo G., Dale M., Tura P., Rizzoni D., Boari G. E. M., Bonetti S., Marini E., Daniele I., Grossi P. A., Delfrate N. W., Bernhart O., Spizzo G., Mahlknecht K., Volkl T., Di Pietro M. A., Trezzi M., Monacci C., Peris A., Bonizzoli M., Cavanna L., Moroni C., Stroppa E. M., Savio M. C., Gatti F., Bartolaminelli C., Petrosillo N., Donno D. R., Taglietti F., Topino S., Chinello P., Galati V., D'offizi G., Taibi C., Cimolato B., Moroni F., Palagano N., Pelagatti L., Cristiana S., Landini G., Amitrano M., Raimondo M., Mangiacapra S., Romano A., Atteno M., Blanc P., Suardi L. R., Pallotto C., Casinelli K., Uccella I., Harari S., Caminati A., Lipani F., Di Perri G., Calcagno A., Calleri G., Montrucchio C., Caputo A. M., Cozzio S., Donne L. D., Bassetti M., Malgorzata M., Nicolini L. A., Russo C., Sepulcri C., Beltramini S., Mina F., Puoti M., Gandino A., Langer T., D'amico F., Rocchetti C., Cettolo F., Gabriele F., Bocchi P., Cioni G., Cappi C., Corcione S., De Rosa F. G., Scabini S., Canta F., Pinna S. M., Pensa A., Rocco M., Cirasa M. T., Spinicci M., Mencarini J., Zammarchi L., Giovanni C., Sciole K., Bassi F., Bianchi M., Frigerio S., Spaziani S., Nucera A., Rizzardini G., Cossu M. V., Antivalle M., Carpinteri G., Macheda S., Labate D., Bottiroli M., Erne E. M., Cristina Z., Di Biase V., Malberti F., Montani G., Poisa P., Bettini D., Cauda R., Ciccullo A., Riccardi N., Angheben A., Turrini M., Clerici R., Gardellini A., Liparulo L., Rossini T., Ucciferri C., Cipollone F., Vecchiet J., Nico A., Marra L., Leone A., Sdanganelli A., Palmiotti G. A., D'alagni G., Santantonio T. A., Caputo S. L., Bottalico I., Ponticiello A., Di Perna F., Bernardi E., Beltrame A., Bravi S., David M., Bernardi P., Galante D., Uccelli M. C., Prestini K., Drera M., Zini E., Peregrinelli A., Blanzuoli L., Benedetti V., Calvi R., Scaglione N., Nallino G., Bonazzi M., Crespi T., Masolin T., Regazzetti A., Cerri M. C., Maffezzini E., Piazza M., Papetti C., Filippi C. D., Roveda E., Cipolla G., Scozzafava M., Crepaldi M., Henchi S., Vanoni N., Repossi A., Vezzoli M., Scorletti E., Perugini O., Pasini S. M., Pacetti V., Ferrari L., de Paduanis G. A., Del Duca S., Dell'ara F., Brocchieri A., Minoja G., Storti E., Pitagora L., Costa I., Delfanti F., Orlandi M., Ruggeri R., Ruggieri L., Livigni S., Silengo D., Ageno W., Pedrini L., Artiol S., Morbidoni L., De Donno G., Ravagnani V., Inglese F., Scotton P. G., Costantini P., Delucchi M., Clini E., Ansuini A., Marco B., Giuseppe L., Vincenzo B., Rastelli G., Doria A., Vianello A., Cattelan A. M., Bindoli S., Felicietti M., Canetta C., Scartabellati A., Accordino S., Ferrara M., Cocco L., Cirillo F., Pace E., De Caro M., Alberico M., Benigni G., Damiano T., Fusco P., Iuorio A., Torretta G., Racagni M., Muttini S., Sala G., Ghiringhelli P., Chiumiento F., Baccari L., Luca B., Bocchi F., Benatti F., Catellani J., Coppola M., Papi A., Bosco E., Lazzeri C., Cesira N., Puttini C., Carli T., Croci L., Corridi M., Arlotti M., Guerrini G., Cola L., Romanelli M., Bonifazi M., Gasparini S., Mei F., Cerutti E., Lacedonia D., Santoro A., Guidelli G. M., Greco S., Castellan A., Infantino G., Camici L., Frigieri F. C., Pavoni V., Migliori L., Rossetti B., Montagnini F., Mauro I., Genovese E., Capuozzo A., Vitiello L., Sirignano E., Gnesin P., Servillo G., Marinelli A., Pasero D., Casadio L., Babudieri S., Madeddu G., De Vito A., Ranghitta M., Passalacqua R., Antonio F., Gentile I., Buonomo A. R., Scotto R., Zappulo E., Dell'aquila G., Bianchetti A., Guerini F., Vallone A., Oppedisano P., Pusterla L., Giglio O., Sartori E., Zanardini C., Gatti P., Vincenzo V., Piconi S., Molteni C., Dognini G., Cosimo F., Guarneri L., Pulvirenti F., Mondino V., Traballi G., Iemoli E., Grisolia A., Giorgi R., Nucera G., Raffaelli V., Marino P., Negro E., Serati L., Silvia T., Iacobello C., Strano G., Boglione L., Catania A., Gipponi P., Di Cato L., Panaccione A., Vitale G., Crippa I. A., Giacomini M., Basile A., Andrea B., Tundo P., Buzzigoli S., Palmiero G., Magnaca A., Silva M., Ricci M., Crespi S., Pasquino B., Consales G., Bragantini D., Mastroianni F., Righetti G., Scarafino A., Bitetto M., Franzetti F., Piga S., Delmonte V., Carbonara S., Losappio R., Dejaco C., Mastroianni C., Del Bono V., Gilioli F., Barzan D., De Struppi S., Carlotto A., Guadagnin M. L., Girardis M., Bertellini E., Dentali F., Foresta G., Baratta A., Viviani R., Agrati A. M., Perego G. B., Montineri A., Manuele R., Bonfante S., Aquilini D., Prozzo A., Santopuoli D., Di Rosa Z., Alborghetti A., Peci P., Bakhtadze N., Pandini C. S., Ashofarir N., Casella G., Spagnolli W., Urru S., Marchesoni I., Caminiti G., Argilloni E., Danieli E., Ghirardi G., Antonioli C. M., Lipari A., Zavarise P., Kokaly F., Polati E., Gottin L., Lucernoni P., De Conti F., Marcon E., Pontali E., Vacca E. B., Saffioti C., Zunino A., Pognuz E. R., Berlot G., Saltori M., Tedesco A., Agostini C., Di Rosolini M. A., Marino F., Bellinzona G., Grassi W., Di Carlo M., Scimonello G., Nonini S., Mondino M., Mantovani L. F., Tenti E., Tropea C. M. G., Di Stefano D. E., Guelfi P., Dagna L., Morgana G., Montemurro L., Girelli D., Crisafulli E., Maroccia A., Cemuschi A. M., Bernasconi M., Zummo U., Barbato V., Bevilacqua S., Buonfanti G., Canzanella G., De Matteis G., Florio M., Martino M., Ribecco M. T., Romano F., Savio A., Sparavigna L., Curvietto M., Citarella M., Nava V., Maggioni P., Magni M., Iommelli C., Bianco A., Corsini R., Valli L., Ruggieri M. P., Mancini A., Melica T., Ferrari A., Cicognini D., Delliponti M., Zuccarini A., Ciani S., Raffaeli D., Donati L., Cannizzo S., Lui S., Santini L., Roncaglia E., Mighali P., Eisendle F., Cerino G., Citterio C., Di Nunzio C., Lamonica S., Resimini S., Sarteschi G., Pavei C., Battistini N., Gazzola E., Miceli M., Pontiggia S., Lonati V., Giannandrea G., Sortino C., Ravani S., Uggeri C., Jocolle G., Bare C., Baroni I., De Candia D., Fiorini B., Chierico K., Romeo F., Bottega R., Boccasile L., Corsaro A., Spadoni C., Ria E., Chiari S., Ercolino G., Dell'uomo V., Viri S., Minato M., Gazzola L., Dorina B., Gianelli D., Maspero S., Farinazzo M., Zanini P., Sangiovanni A., Del Giudice A., Dragonetti M. M., Bordignon S., Machiavelli A. M., Chiodelli G., Spatarella M., Zenoni D., Beretta F. N., Santilli G., Badagliacca R., Angileri M., Giannelli L., Campomori A., Maimone P., Fadda A., Faoro S., Pisterna A., Cacopardo B., Marino A., Pampaloni A., Celesia B. M., Cinnella G., Labella D., Caporusso R. R., Danzi M., Fiscon M., Malena M., Fendt D., Nardi S., Stobbione P., Savi M. L., De Monte A., Scala A., Liberato N. L., Luchi S., Vincenti A., Cabrini L., Pinelli G., Brugioni L., Potenza D., Numis F. G., Porta G., D'amico M., Iengo B., Angarano G., Saracino A., Blasi L., De Negri P., Angelici S., Farina A., Martino G. P., Bitti G., Tedeschi A., De Ponti S., Agostinone A., Parruti G., Consorte A., Frattari A., Filippelli A., Pagliano P., Masullo A., Sellitto C., Reta M., Rossi N., Raumer L., Andreassi S., Brancaleoni P., Carai A., Salerno A. M., Marinangeli F., Mariani R., Ciccone A., Meschini C., Santoboni G., Angrisani C., Micarelli D., Tarquini G., Fregoni V., Volta C. A., Cherubini A., Del Prete M. S., Ciarrochi E., Tasca F., Ballarin A., Bianchin A., Flocco R., Cuzzone V., Carpinteri M., Gallotti P., Torre F., Zannetti P., Crapis M., Venturini S., Barattini M., Gori G., Mastroianni A., De Stefano G., Gilio M., Rapisarda G., Gulisano L., Granata M. L., Saglimbene S., Montalto M. T., Grasso I., De Luca S., Magro G., Messina F., Scapino B., Abrate P., Francisco C., Pesce L., Navarra M., Agosti M., Pagani S., Piluso M., Ricioppo A., Tognella S., Rovere P., Vincenzi M., Ghirardi L., Generali D., Ingrosso M., Desiderio E., Molaro R., Vitiello S., Lancione L., Paone T. C., Meli A., Mainardi S., Rastellino V., Ursillo A., Grigoli P. D., Bovetto E., Stefanetto I. M., Mazzola F., Daniele A., Bisio C., Delnero P., Morando G., Nava A., Francesco L., Fiammengo F., Regis M., Roccatello D., Sabato E., Liccardi M. M., Bretto C., Lutri L., Castenetto E., Roberti G., Guidi M. F., Bini F., Zappa M. C., Trequattrini T., Rivitti R., Vigliarolo R., Succu A., Lilli M., Serao M., Giogre G., Ruggieri A., Flores K., Vairo G., Satira R., Lingua A., Spina R., Nicastri E., Maffongelli G., Barreca F., Scollet S., Franchi F., Fabbri C., Minuz P., Dalbeni A., Zanatta P., Gelormini D., Mandelli A., Galderisi F., Zoia E., Marchi M. R., Neves N. D. A., Carbone G., Di Caterino E., Petrone A., Usai C. A., Bandiera F., Monti R., Hofer A., Castiglione G., Angeletti C., Tarsia P., Veronese L., Artoni P. D., Larussa D., Fumagalli R., Brioschi P., Cerutti A., Pasquino P., Gilberto F., Cantadori L., Tomasoni L. R., Coppola N., Spolveri S., Pollastri C., Fico L., Principi T., Pierantozzi S., Fontana C. C., Lubrano G., Martinelli L., Navalesi P., Serra E., Cogi E., Manzi A., Furino E., Dasseni N., Gentilini C., Benatti E., Pignatti A., Aiello G., Milia M., Covesnon M. G., Brianti A., Francesco C., Ilaria B., Pagnozzi F., Mietta S., Rossi A., Maroni L., Borroni V., Bellintani C., Sgarabotto C., Bizzotto G., Bucci L., Spagnuolo G., Agostini M., Caria F. C., Testa F., De Palma R., Murdaca G., Zanolini G., Sala N., Righini E., Pontremoli R., Aondio G., Riccardi F., De Cristoforo M. G., De Michele F., Storti A., Perra R., Deidda S., Enrica C., Valastro F., Pierfranceschi M. G., De Gennaro F., Nardecchia A. L., Castellini M., Buetto G., Ippoliti G., Sicheri D., Bottoli M. G., De Arroyabe B. M. L., Versaci A., Pallotti G., Civita M., Grio M., Liuzzi N., Molino P., Pastorelli M., Ricchiardi A., Varbella F., Zeme A. D., Sighieri C., Portale G., Olivetti A., Pagnoni C., Moschini G., Boni S., Guerra A., Scudellari R., Vella S., Inchiostro S., Piazza O., Guarino S., Aldegheri G., Napoli G., Morettini A., Caldini E., Menicacci L., Pieralli F., Torrini M., Poggesi L., Visetti E. M., Mangano C., Visconti S., Maietta P., Banfi E., Cartella S., Venturi B., Nuceri A., Chiesa E., Pacentra E., Panzolato G., Giannotti M., Bianchi C., Pietrangelo A., Para O., Rutili M. S., Russo R., Lanfranco M., Scalabrino E., Tafuri A., Chiarello T., Perfetti E., Cancanelli L., Otero M., Pannella G., Bellucci F., Ferrero G., Vico C., Stillante M. S., D'andrea G., Amoroso F., Arcidiacono A., Bella A. M., Belsito A., Berte Y., Carubia G., Caruso M. G., Casella O., Chiereleson F., Costa C., De Franco D., Germana G., Messina A., Musumeci D., Noto C., Valenti M., Sorrentino C., Panico R., Schettino G., Piccoli J., Pepe A., De Rosa F., Ottaviano M., Marrazzo G., Raponi G., Diberardino S., Bausi S., Marini S. F., Giubellino E., Innocenti G., Gugliemi G., Maccari D., and Baciu I.
- Abstract
Background: Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients. Methods: A multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study the effect of tocilizumab on lethality rates at 14 and 30 days (co-primary endpoints, a priori expected rates being 20 and 35%, respectively). A further prospective cohort of patients, consecutively enrolled after the first cohort was accomplished, was used as a secondary validation dataset. The two cohorts were evaluated jointly in an exploratory multivariable logistic regression model to assess prognostic variables on survival. Results: In the primary intention-to-treat (ITT) phase 2 population, 180/301 (59.8%) subjects received tocilizumab, and 67 deaths were observed overall. Lethality rates were equal to 18.4% (97.5% CI: 13.6-24.0, P = 0.52) and 22.4% (97.5% CI: 17.2-28.3, P < 0.001) at 14 and 30 days, respectively. Lethality rates were lower in the validation dataset, that included 920 patients. No signal of specific drug toxicity was reported. In the exploratory multivariable logistic regression analysis, older age and lower PaO2/FiO2 ratio negatively affected survival, while the concurrent use of steroids was associated with greater survival. A statistically significant interaction was found between tocilizumab and respiratory support, suggesting that tocilizumab might be more effective in patients not requiring mechanical respiratory support at baseline. Conclusions: Tocilizumab reduced lethality rate at 30 days compared with null hypothesis, without significant toxicity. Possibly, this effect could be limited to patients not requiring mechanical respiratory support at baseline. Registration EudraCT (2020-001110-38); clinicaltrials.gov (NCT04317092).
- Published
- 2020
16. Prevenzione del rischio di disturbo muscoloscheletrico in lavoratori videoterminalisti affetti da Malattia di Parkinson. Studio ergonomico e riabilitativo
- Author
-
Gentili, S, Schirinzi, T, Capici, S, Mancini, S, Stefani, A, Pisani, A, and Magrini, A
- Subjects
Settore MED/44 ,Settore MED/34 - Published
- 2022
17. Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything
- Author
-
Capici, S, Ammoni, L, Meli, N, Cogliati, V, Pepe, F, Piazza, F, Cazzaniga, M, Capici, Serena, Ammoni, Luca Carlofrancesco, Meli, Nicole, Cogliati, Viola, Pepe, Francesca Fulvia, Piazza, Francesca, Cazzaniga, Marina Elena, Capici, S, Ammoni, L, Meli, N, Cogliati, V, Pepe, F, Piazza, F, Cazzaniga, M, Capici, Serena, Ammoni, Luca Carlofrancesco, Meli, Nicole, Cogliati, Viola, Pepe, Francesca Fulvia, Piazza, Francesca, and Cazzaniga, Marina Elena
- Abstract
Triple-negative breast cancer—defined by the absence of oestrogen/progesterone receptors and human epidermal growth factor receptor 2 expression—is a complex and heterogeneous type of tumour characterised by poor prognosis, aggressive behaviour and lack of effective therapeutic strategies. The identification of new biomarkers and molecular signatures is leading to development of new therapeutic strategies including immunotherapy, targeted therapy and antibody-drug conjugates (ADCs). Against a background where chemotherapy has always been considered the standard of care, evolution towards a precision medicine approach could improve TNBC clinical practice in a complex scenario, with many therapeutic options and new drugs. The aim of this review was to focus on emerging therapeutic targets and their related specific therapy, discussing available and emerging drugs, underlining differences in approval by American and European regulatory authorities and showing the future perspective in the large number of ongoing clinical trials.
- Published
- 2022
18. Why not? Motivations for entering a volunteer register for clinical trials during the COVID-19 pandemic
- Author
-
Russo, S, Bani, M, Terraneo, M, Quaglia, V, Nuvolati, G, Cavaliere, R, Capici, S, Cazzaniga, M, Strepparava, M, Russo, Selena, Bani, Marco, Terraneo, Marco, Quaglia, Valeria, Nuvolati, Giampaolo, Cavaliere, Rebecca, Capici, Serena, Cazzaniga, Marina Elena, Strepparava, Maria Grazia, Russo, S, Bani, M, Terraneo, M, Quaglia, V, Nuvolati, G, Cavaliere, R, Capici, S, Cazzaniga, M, Strepparava, M, Russo, Selena, Bani, Marco, Terraneo, Marco, Quaglia, Valeria, Nuvolati, Giampaolo, Cavaliere, Rebecca, Capici, Serena, Cazzaniga, Marina Elena, and Strepparava, Maria Grazia
- Abstract
Backgrounds: Healthy volunteers play a key role in clinical trials and it is crucial to develop recruitment strategies that capitalise on their motivations and maximise their participation. The COVID-19 pandemic has shown the importance of finding motivated healthy volunteers for the development of new vaccines. Public registers represent a promising way to promote the participation of healthy volunteers in the research field, but their adoption is still limited. The current study aimed to explore the motivations of healthy volunteers to enrol in an Italian public register for clinical trials during the COVID-19 pandemic and their attitude toward participating in a phase 1 COVID-19 vaccine clinical trial. The impacts of different enrolling interview modalities (in person, by phone, by mail) on motivation, understanding of information and trust in researchers were also investigated. Methods: An online survey investigating experience with COVID-19, motivations to enrol, trust in researchers, political and healthcare authorities and pharmacological companies was presented to people applying as healthy volunteers in the public register for clinical trials at Phase 1 Unit Research Centre of ASST Monza, Italy, and considering to participate in a COVID-19 vaccine clinical trial. Data were collected in June 2021. Results: Altruistic motivations were the main driver for enrolling in the public register, while self-interested motivations were secondary. No gender differences were found. As for enrolling modalities, no differences emerged between in-person and interviews for motivation to enrol, understanding of information and trust in researchers. Email modality led to significantly lower volunteers’ satisfaction and understanding of information but similar trust in research. Conclusions: This study supports the validity of different interview modalities (in person and by phone) for the enrolment of healthy volunteers for clinical trials and highlights the positive role of p
- Published
- 2022
19. Social capital and willingness to participate in COVID-19 vaccine trials: an Italian case-control study
- Author
-
Terraneo, M, Quaglia, V, Nuvolati, G, Bani, M, Russo, S, Strepparava, M, Capici, S, Cavaliere, R, Cazzaniga, M, Terraneo, Marco, Quaglia, Valeria, Nuvolati, Giampaolo, Bani, Marco, Russo, Selena, Strepparava, Maria Grazia, Capici, Serena, Cavaliere, Rebecca, Cazzaniga, Marina Elena, Terraneo, M, Quaglia, V, Nuvolati, G, Bani, M, Russo, S, Strepparava, M, Capici, S, Cavaliere, R, Cazzaniga, M, Terraneo, Marco, Quaglia, Valeria, Nuvolati, Giampaolo, Bani, Marco, Russo, Selena, Strepparava, Maria Grazia, Capici, Serena, Cavaliere, Rebecca, and Cazzaniga, Marina Elena
- Abstract
Background: What leads healthy people to enter in a volunteer register for clinical trials? This study aimed to investigate the relationship between the decision to volunteer in clinical trials for a COVID-19 vaccine and social capital, in a sample of healthy volunteers in Italy. Since social capital is characterized by trust, reciprocity, and social and political participation, we claim that it is key in leading individuals to actively take action to protect public health, and to take a risk for the (potential) benefit not only of themselves but for the entire community. Methods: This study was conducted through the administration of a questionnaire to healthy volunteers registered for a phase 1 clinical trial for a COVID-19 vaccine in the Unit Research Centre of ASST-Monza, in September 2020. The primary purpose of a phase 1 study is to evaluate the safety of a new drug candidate before it proceeds to further clinical studies. To approximate a case–control study, we randomly matched the 318 respondents to healthy volunteers (cases) with 318 people randomly selected by Round 9 of the European Social Survey (controls), using three variables, which we considered to be associated with the decision to volunteer: gender, age, and education level. To execute this matching procedure, we used the “ccmatch” module in STATA. Results: The findings highlight the positive impact of social capital in the choice of healthy individuals to volunteer in COVID-19 vaccine clinical trials. Controlling for possible confounding factors, some exemplary results show that people with a high level of general trust have a greater likelihood of volunteering compared to people with low trust (OR = 2.75, CI = 1.58–4.77); we also found that it is more probable that volunteers are people who have actively taken action to improve things compared with people who have not (for individuals who did three or more actions: OR = 7.54, CI = 4.10–13.86). People who reported voting (OR = 3.91, CI = 1.70–8.99
- Published
- 2022
20. Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows
- Author
-
Cazzaniga, M, Capici, S, Cordani, N, Cogliati, V, Fulvia Pepe, F, Riva, F, Cerrito, M, Marina Elena Cazzaniga, Serena Capici, Nicoletta Cordani, Viola Cogliati, Francesca Fulvia Pepe, Francesca Riva, Maria Grazia Cerrito, Cazzaniga, M, Capici, S, Cordani, N, Cogliati, V, Fulvia Pepe, F, Riva, F, Cerrito, M, Marina Elena Cazzaniga, Serena Capici, Nicoletta Cordani, Viola Cogliati, Francesca Fulvia Pepe, Francesca Riva, and Maria Grazia Cerrito
- Abstract
Metronomic chemotherapy (mCHT), defined as continuous administration of low-dose chemotherapeutic agents with no or short regular treatment-free intervals, was first introduced to the clinic in international guidelines in 2017, and, since then, has become one of the available strategies for the treatment of advanced breast cancer (ABC). Despite recent successes, many unsolved practical and theoretical issues remain to be addressed. The present review aims to identify the “lights and shadows” of mCHT in preclinical and clinical settings. In the preclinical setting, several findings indicate that one of the most noticeable effects of mCHT is on the tumor microenvironment, which, over the last twenty years, has been demonstrated to be pivotal in supporting tumor cell survival and proliferation. On the other hand, the direct effects on tumor cells have been less well-defined. In addition, critical items to be addressed are the lack of definition of an optimal biological dose (OBD), the method of administration of metronomic schedules, and the recognition and validation of predictive biomarkers. In the clinical context—where mCHT has mainly been used in a metastatic setting—low toxicity is the most well-recognised light of mCHT, whereas the type of study design, the absence of randomised trials and uncertainty in terms of doses and drugs remain among the shadows. In conclusion, growing evidence indicates that mCHT is a suitable treatment option for selected metastatic breast cancer (MBC) patients. Moreover, given its multimodal mechanisms of action, its addition to immunological and targeted therapies might represent a promising new approach to the treatment of MBC. More preclinical data are needed in this regard, which can only be obtained through support for translational research as the key link between basic science and patient care.
- Published
- 2022
21. Additional file 1 of Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study
- Author
-
Pepe, F. F., Cazzaniga, M. E., Baroni, S., Riva, F., Cicchiello, F., Capici, S., Cogliati, V., Maggioni, C., Cordani, N., Cerrito, M. G., and Malandrin, S.
- Abstract
Additional file 1.
- Published
- 2022
- Full Text
- View/download PDF
22. Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)
- Author
-
Perrone, F., Piccirillo, M. C., Ascierto, P. A., Salvarani, C., Parrella, R., Marata, A. M., Popoli, P., Ferraris, L., Marrocco-Trischitta, M. M., Ripamonti, D., Binda, F., Bonfanti, P., Squillace, N., Castelli, F., Muiesan, M. L., Lichtner, M., Calzetti, C., Salerno, N. D., Atripaldi, L., Cascella, M., Costantini, M., Dolci, G., Facciolongo, N. C., Fraganza, F., Massari, M., Montesarchio, V., Mussini, C., Negri, E. A., Botti, G., Cardone, C., Gargiulo, P., Gravina, A., Schettino, C., Arenare, L., Chiodini, P., Gallo, C., Vitale, M. G., Trojaniello, C., Palla, M., Bianchi, A. A. M., De Feo, G., Miscio, L., Chiodiniy, P., Froldi, M., Menicanti, L., Cuppone, M. T., Gobbo, G., Baldessari, C., Valenti, V., Castelvecchio, S., Poli, F., Giacomazzi, F., Piccinni, R., Annnunziata, M. L., Biondi, A., Bussolari, C., Mazzoleni, M., Giachi, A., Filtz, A., Manini, A., Poletti, E., Masserini, F., Conforti, F., Gaudiano, G., Favero, V., Moroni, A., Viva, T., Fancoli, F., Ferrari, D., Niro, D., Resta, M., Ballotta, A., Poli, M. D., Ranucci, M., Tebaldi, A., Gritti, G., Pasulo, L., Gaglio, L., Del Fabbro, R., Alborghetti, L., Giustinetti, G., Columpsi, P., Cazzaniga, M., Capici, S., Sala, L., Di Sciacca, R., Mosca, G., Pirozzi, M. R., Franceschini, F., Roccaro, A., Salvetti, M., Paini, A., Corda, L., Ricci, C., Tomasoni, L., Nasta, P., Lorenzotti, S., Odolini, S., Foca, E., Roldan, E. Q., Metra, M., Magrini, S., Borghetti, P., Latronico, N., Piva, S., Filippini, M., Tomasi, G., Zuccala, F., Cattaneo, S., Scolari, F., Bossini, N., Gaggiotti, M., Properzi, M., Del Borgo, C., Marocco, R., Belvisi, V., Tieghi, T., De Masi, M., Zuccala, P., Fabietti, P., Vetica, A., Mercurio, V. S., Carraro, A., Fondaco, L., Kertusha, B., Curtolo, A., Del Giudice, E., Lubrano, R., Zotti, M. G., Puorto, A., Ciuffreda, M., Sarni, A., Monteforte, G., Romeo, D., Viola, E., Damiani, C., Barone, A., Mantovani, B., Di Sanzo, D., Gentili, V., Carletti, M., Aiuti, M., Gallo, A., Meliante, P. G., Martellucci, S., Riggio, O., Cardinale, V., Ridola, L., Bragazzi, M. C., Gioia, S., Valenzi, E., Graziosi, C., Bina, N., Fasolo, M., Ricci, S., Gioacchini, M. T., Lucci, A., Corso, L., Tornese, D., Nijhawan, P., Equitani, F., Cosentino, C., Palladino, M., Leonetti, F., Leto, G., Gnessi, C., Campagna, G., Cesareo, R., Marrocco, F., Straface, G., Mecozzi, A., Cerbo, L., Isgro, V., Parrocchia, S., Visconti, G., Casati, G., Ariani, A., Donghi, L., Tacconelli, E., Bertoldi, M., Cattaneo, P., Lambertenghi, L., Motta, L., Omega, L., Albano, G., Scarano, F., De Rosa, A., Buglione, A., Lavoretano, S., Gaglione, G., De Marco, M., Sangiovanni, V., Fusco, F. M., Viglietti, R., Manzillo, E., Rescigno, C., Pisapia, R., Plamieri, G., Maraolo, A., Calabria, G., Catalano, M., Fiorentino, G., Annunziata, A., Polistina, G., Imitazione, P., Mollica, M., Esposito, V., D'Abraccio, M., Punzi, R., Bianco, V., Sbreglia, C., Del Vecchio, R. F., Bordonali, A., Franco, A., Salsi, P., Fontana, M., Virzi, G., Calderone, O., Molteni, A., Gennarini, S., Gnudi, U., Ricci, M. A., Titolo, G., Mensi, G., Vuotto, P., Gasperini, B., Mancini, M., Pasquini, Z., Spanu, P., Clementi, S., Pierini, S., Bokor, D., Gori, D., Ciofetti, M., Caimi, M., Bettazzi, L., Allevi, E., Furiani, S., Capitanio, C., Mastropasqua, B., Fara, C., Pulitano, G., Matsuno, J. S., Porta, F. D., Dolfini, V., Beyene, N. B., Bezzi, M., Novali, M., Viale, P., Tedeschi, S., Pascale, R., Bruno, R., Di Filippo, A., Sachs, M., Oggionni, T., Di Stefano, M., Mengoli, C., Facchini, C., De Nardo, D., Frausini, G., Mucci, L., Tedesco, S., Girolimetti, R., Manfredini, E., Di Carlo, A. M., Espinosa, E., Dennetta, D., Ticinesi, A., Meschi, T., Nouvenne, A., Norbiato, C., Vitale, F., Saracco, M., Codeluppi, M., Fronti, E., Ferrante, P., Nespola, G. A., Francisci, D., Tosti, A., Carbonelli, C. M., Greco, A., Tinti, M. G., Stellini, R., Appiani, C., Reghenzi, P., Poletti, V., Ravaglia, C., Tacconi, D., Malcontenti, C., Sainaghi, P. P., Landi, R., Vassia, V., Rizzi, E., Bellan, M., Rossati, A., Castello, L., Mastroianni, C. M., Russo, G., Toffoletto, F., Serino, F. S., Brollo, L., Momesso, E., Turati, M. L., Monforte, A. D., Marchetti, G., Boni, F., Teopompi, E., Trenti, C., Boracchia, L., Minelli, E., Ghidoni, G., Matei, A., Caruso, A., Arcoleo, G., Camarda, G., Catalano, F., Spatafora, M., Bettega, D., Andreoni, M., Teti, E., Sarmati, L., Di Lorenzo, A., Celeste, M., Baratto, F., Monticelli, J., Criveller, P., Antonini, A., Anselmo, Riccio, Castellano, M., Cappelli, C., Corvini, F., Zanini, B., Crippa, M., Ronconi, M., Costa, R., Casella, S., Brentana, L., Bernardi, L., Frascati, A., Panese, S., Presotto, F., Michieletto, L., Bernardi, C., Fusar, M., Agnoletti, V., Farina, M., Russo, Lavorini, F., Ginanni, R., Palmieri, F., Mosti, S., Amaglio, A., Cattaneo, A., Cirri, S., Montisci, A., Gallazzi, C., Cosseta, D., Baronio, B., Rampa, L., Maggi, P., Messina, V., Sabatti, M. C., Palumbo, M., Mazzone, A., Faggioli, P., Bussini, L., Fornaro, G., Volpato, F., Imperiale, D., Manno, E., Ferreri, E., Martelli, D., Verhovez, A., Giorgis, S., Faccio, L., Delli Quadri, R., Negro, C., Converso, M., Bosco, F., Amadosi, S., Prandini, P., Cocchi, S., Manfrin, V., Del Punta, V., Mazzola, G., Sportato, G., Romagnoli, M., Cristini, F., Facondini, F., Perin, T., Boschi, A., Meschiari, M., Guaraldi, G., Modica, S., Moneta, S., Boccalatte, D., Marchetti, V., Amadasi, S., Ebbreo, G., Dale, M., Tura, P., Rizzoni, D., Boari, G. E. M., Bonetti, S., Marini, E., Daniele, I., Grossi, P. A., Delfrate, N. W., Bernhart, O., Spizzo, G., Mahlknecht, K., Volkl, T., Di Pietro, M. A., Trezzi, M., Monacci, C., Peris, A., Bonizzoli, M., Cavanna, L., Moroni, C., Stroppa, E. M., Savio, M. C., Gatti, F., Bartolaminelli, C., Petrosillo, N., Donno, D. R., Taglietti, F., Topino, S., Chinello, P., Galati, V., D'Offizi, G., Taibi, C., Cimolato, B., Moroni, F., Palagano, N., Pelagatti, L., Seravalle, C., Landini, G., Amitrano, M., Raimondo, M., Mangiacapra, S., Romano, A., Atteno, M., Blanc, P., Suardi, L. R., Pallotto, C., Casinelli, K., Uccella, I., Harari, S., Caminati, A., Lipani, F., Di Perri, G., Calcagno, A., Calleri, G., Montrucchio, C., Caputo, A. M., Cozzio, S., Delle Donne, L., Bassetti, M., Malgorzata, M., Nicolini, L. A., Russo, C., Sepulcri, C., Beltramini, S., Mina, F., Puoti, M., Gandino, A., Langer, T., D'Amico, F., Berlendis, M., Rocchetti, C., Cettolo, F., Fausini, G., Bocchi, P., Cioni, G., Cappi, C., Corcione, S., De Rosa, F. G., Scabini, S., Canta, F., Mornese Pinna, S., Pensa, A., Rocco, M., Cirasa, M. T., Spinicci, M., Mencarini, J., Zammarchi, L., Cenderello, G., Sciole, K., Bassi, F., Bianchi, M., Frigerio, S., Spaziani, S., Nucera, A., Rizzardini, G., Cossu, M. V., Antivalle, M., Carpinteri, G., Macheda, S., Labate, D., Bottiroli, M., Erne, E. M., Cristina, Z., Di Biase, V., Malberti, F., Montani, G., Poisa, P., Bettini, D., Cauda, R., Ciccullo, A., Riccardi, N., Angheben, A., Turrini, M., Clerici, R., Gardellini, A., Liparulo, L., Rossini, T., Ucciferri, C., Cipollone, F., Vecchiet, J., Nico, A., Marra, L., Leone, A., Sdanganelli, A., Palmiotti, G. A., D'Alagni, G., Santantonio, T. A., Lo Caputo, S., Bottalico, I., Ponticiello, A., Di Perna, F., Bernardi, E., Beltrame, A., Bravi, S., David, M., Bernardi, P., Galante, D., Uccelli, M. C., Prestini, K., Drera, M., Zini, E., Peregrinelli, A., Blanzuoli, L., Benedetti, V., Calvi, R., Scaglione, N., Nallino, G., Bonazzi, M., Crespi, T., Masolin, T., Regazzetti, A., Cerri, M. C., Maffezzini, E., Piazza, M., Papetti, C., De Filippi, C., Roveda, E., Cipolla, G., Scozzafava, M., Crepaldi, M., Henchi, S., Vanoni, N., Repossi, A., Vezzoli, M., Scorletti, E., Perugini, O., Pasini, S. M., Pacetti, V., Ferrari, L., de Paduanis, G. A., del Duca, S., Dell'Ara, F., Brocchieri, A., Minoja, G., Storti, E., Pitagora, L., Costa, I., Delfanti, F., Orlandi, M., Ruggeri, R., Ruggieri, L., Livigni, S., Silengo, D., Ageno, W., Pedrini, L., Artiol, S., Morbidoni, L., De Donno, G., Ravagnani, V., Inglese, F., Scotton, P. G., Costantini, P., Delucchi, M., Clini, E., Ansuini, A., Baiocchi, M., Lain, G., Vincenzo, B., Rastelli, G., Doria, A., Vianello, A., Cattelan, A. M., Bindoli, S., Felicietti, M., Canetta, C., Scartabellati, A., Accordino, S., Ferrara, M., Cocco, L., Cirillo, F., Pace, E., De Caro, M., Alberico, M., Benigni, G., Damiano, T., Fusco, P., Iuorio, A., Torretta, G., Racagni, M., Muttini, S., Sala, G., Ghiringhelli, P., Chiumiento, F., Baccari, L., Bocchi, F., Benatti, F., Catellani, J., Coppola, M., Papi, A., Bosco, E., Lazzeri, C., Cesira, N., Puttini, C., Carli, T., Croci, L., Corridi, M., Arlotti, M., Guerrini, G., Cola, L., Romanelli, M., Bonifazi, M., Gasparini, S., Mei, F., Cerutti, E., Lacedonia, D., Santoro, A., Guidelli, G. M., Greco, S., Castellan, A., Infantino, G., Camici, L., Covani Frigieri, F. C., Pavoni, V., Migliori, L., Rossetti, B., Montagnini, F., Mauro, I., Genovese, E., Capuozzo, A., Vitiello, L., Sirignano, E., Gnesin, P., Servillo, G., Marinelli, A., Pasero, D., Babudieri, S., Madeddu, G., De Vito, A., Casadio, L., Ranghitta, M., Passalacqua, R., Fioravanti, A., Gentile, I., Buonomo, A. R., Scotto, R., Zappulo, E., Dell'Aquila, G., Bianchetti, A., Guerini, F., Vallone, A., Oppedisano, P., Pusterla, L., Giglio, O., Sartori, E., Zanardini, C., Gatti, P., Valiani, V., Piconi, S., Molteni, C., Dognini, G., Cosimo, F., Guarneri, L., Pulvirenti, F., Mondino, V., Traballi, G., Iemoli, E., Grisolia, A., Giorgi, R., Nucera, G., Raffaelli, V., Marino, P., Negro, E., Serati, L., Tamanini, S., Iacobello, C., Strano, G., Boglione, L., Catania, A., Gipponi, P., Di Cato, L., Panaccione, A., Vitale, G., Crippa, I. A., Giacomini, M., Basile, A., Bellone, A., Tundo, P., Buzzigoli, S., Palmiero, G., Magnaca, A., Silva, M., Ricci, M., Crespi, S., Pasquino, B., Consales, G., Bragantini, D., Mastroianni, F., Righetti, G., Scarafino, A., Bitetto, M., Franzetti, F., Piga, S., Delmonte, V., Carbonara, S., Losappio, R., Dejaco, C., Mastroianni, C., Del Bono, V., Gilioli, F., Barzan, D., De Struppi, S., Carlotto, A., Guadagnin, M. L., Girardis, M., Bertellini, E., Dentali, F., Foresta, G., Baratta, A., Viviani, R., Agrati, A. M., Perego, G. B., Montineri, A., Manuele, R., Bonfante, S., Aquilini, D., Prozzo, A., Santopuoli, D., Di Rosa, Z., Alborghetti, A., Peci, P., Bakhtadze, N., Pandini, C. S., Ashofarir, N., Casella, G., Spagnolli, W., Urru, S., Marchesoni, I., Caminiti, G., Argilloni, E., Danieli, E., Ghirardi, G., Antonioli, C. M., Lipari, A., Zavarise, P., Kokaly, F., Polati, E., Gottin, L., Lucernoni, P., De Conti, F., Marcon, E., Pontali, E., Vacca, E. B., Saffioti, C., Zunino, A., Pognuz, E. R., Berlot, G., Saltori, M., Tedesco, A., Agostini, C., Di Rosolini, M. A., Marino, F., Bellinzona, G., Grassi, W., Di Carlo, M., Scimonello, G., Nonini, S., Mondino, M., Mantovani, L. F., Tenti, E., Tropea, C. M. G., Di Stefano, D. E., Guelfi, P., Dagna, L., Morgana, G., Montemurro, L., Girelli, D., Crisafulli, E., Maroccia, A., Cemuschi, A. M., Bernasconi, M., Zummo, U., Barbato, V., Bevilacqua, S., Buonfanti, G., Canzanella, G., De Matteis, G., Florio, M., Martino, M., Ribecco, M. T., Romano, F., Savio, A., Sparavigna, L., Curvietto, M., Citarella, M., Nava, V., Maggioni, P., Magni, M., Iommelli, C., Bianco, A., Corsini, R., Valli, L., Ruggieri, M. P., Melica, T., Ferrari, A., Cicognini, D., Delliponti, M., Zuccarini, A., Ciani, S., Raffaeli, D., Donati, L., Cannizzo, S., Lui, S., Santini, L., Roncaglia, E., Mighali, P., Eisendle, F., Cerino, G., Citterio, C., Di Nunzio, C., Mancini, A., Lamonica, S., Resimini, S., Sarteschi, G., Pavei, C., Battistini, N., Gazzola, O. E., Miceli, M., Pontiggia, S., Lonati, V., Giannandrea, G., Sortino, C., Ravani, S., Uggeri, C., Jocolle, G., Bare, C., Baroni, I., De Candia, D., Fiorini, B., Chierico, K., Romeo, F., Bottega, R., Boccasile, L., Corsaro, A., Spadoni, C., Chiari, S., Ercolino, G., Dell'Uomo, V., Viri, S., Minato, M., Gazzola, L., Dorina, B., Gianelli, D., Maspero, S., Farinazzo, M., Zanini, P., Sangiovanni, A., Del Giudice, A., Dragonetti, M. M., Bordignon, S., Machiavelli, A. M., Chiodelli, G., Spatarella, M., Zenoni, D., Beretta, F. N., Santilli, G., Badagliacca, R., Angileri, M., Giannelli, L., Campomori, A., Maimone, P., Fadda, A., Faoro, S., Pisterna, A., Cacopardo, B., Marino, A., Pampaloni, A., Celesia, B. M., Cinnella, G., Labella, D., Caporusso, R. R., Danzi, M., Fiscon, M., Malena, M., Fendt, D., Nardi, S., Stobbione, P., Savi, M. L., De Monte, A., Scala, A., Liberato, N. L., Luchi, S., Vincenti, A., Cabrini, L., Pinelli, G., Brugioni, L., Potenza, D., Numis, F. G., Porta, G., D'Amico, M., Iengo, B., Angarano, G., Saracino, A., Blasi, L., De Negri, P., Angelici, S., Farina, A., Martino, G. P., Bitti, G., Tedeschi, A., De Ponti, S., Agostinone, A., Parruti, G., Consorte, A., Frattari, A., Filippelli, A., Pagliano, P., Masullo, A., Sellitto, C., Reta, M., Rossi, N., Raumer, L., Andreassi, S., Brancaleoni, P., Carai, A., Salerno, A. M., Marinangeli, F., Mariani, R., Ciccone, A., Meschini, C., Santoboni, G., Angrisani, C., Micarelli, D., Tarquini, G., Fregoni, V., Volta, C. A., Cherubini, A., Del Prete, M. S., Ciarrochi, E., Tasca, F., Ballarin, A., Bianchin, A., Flocco, R., Cuzzone, V., Carpinteri, M., Gallotti, P., Torre, F., Zannetti, P., Crapis, M., Venturini, S., Barattini, M., Gori, G., Mastroianni, A., De Stefano, G., Gilio, M., Rapisarda, G., Gulisano, L., Granata, M. L., Saglimbene, S., Montalto, M. T., Grasso, I., De Luca, S., Magro, G., Messina, F., Scapino, B., Abrate, P., Francisco, C., Pesce, L., Navarra, M., Agosti, M., Pagani, S., Piluso, M., Ricioppo, A., Tognella, S., Rovere, P., Vincenzi, M., Ghirardi, L., Generali, D., Ingrosso, M., Desiderio, E., Molaro, R., Vitiello, S., Lancione, L., Paone, T. C., Meli, A., Mainardi, S., Rastellino, V., Ursillo, A., di Grigoli, P., Bovetto, E., Stefanetto, I. M., Mazzola, F., Daniele, A., Bisio, C., Delnero, P., Morando, G., Nava, A., Francesco, L., Fiammengo, F., Regis, M., Roccatello, D., Sabato, E., Liccardi, M. M., Bretto, C., Lutri, L., Castenetto, E., Roberti, G., Guidi, M. F., Bini, F., Zappa, M. C., Trequattrini, T., Rivitti, R., Vigliarolo, R., Succu, A., Lilli, M., Serao, M., Giogre, G., Ruggieri, A., Flores, K., Vairo, G., Satira, R., Lingua, A., Spina, R., Nicastri, E., Maffongelli, G., Barreca, F., Scollet, S., Franchi, F., Fabbri, C., Minuz, P., Dalbeni, A., Zanatta, P., Gelormini, D., Mandelli, A., Galderisi, F., Zoia, E., Marchi, M. R., De Almeida Neves, N., Carbone, G., Di Caterino, E., Petrone, A., Usai, C. A., Bandiera, F., Monti, R., Hofer, A., Castiglione, G., Angeletti, C., Tarsia, P., Veronese, L., Artoni, P. D., Larussa, D., Fumagalli, R., Brioschi, P., Cerutti, A., Pasquino, P., Gilberto, F., Cantadori, L., Tomasoni, G., Tomasoni, L. R., Coppola, N., Spolveri, S., Pollastri, C., Fico, L., Principi, T., Pierantozzi, S., Fontana, C., Lubrano, G., Martinelli, L., Navalesi, P., Serra, E., Cogi, E., Manzi, A., Furino, E., Dasseni, N., Gentilini, C., Benatti, E., Pignatti, A., Aiello, G., Milia, M., Covesnon, M. G., Brianti, A., Francesco, C., Ilaria, B., Pagnozzi, F., Mietta, S., Rossi, A., Maroni, L., Borroni, V., Bellintani, C., Sgarabotto, C., Bizzotto, G., Bucci, L., Spagnuolo, G., Agostini, M., Caria, F. C., Testa, F., De Palma, R., Murdaca, G., Zanolini, G., Sala, N., Righini, E., Pontremoli, R., Aondio, G., Riccardi, F., De Cristoforo, M. G., De Michele, F., Storti, A., Perra, R., Deidda, S., Enrica, C., Valastro, F., Pierfranceschi, M. G., De Gennaro, F., Nardecchia, A. L., Castellini, M., Buetto, G., Ippoliti, G., Sicheri, D., Bottoli, M. G., De Arroyabe, B. M. L., Versaci, A., Di Cura Villa Giada Pallotti, C., Civita, M., Grio, M., Liuzzi, N., Molino, P., Pastorelli, M., Ricchiardi, A., Varbella, F., Zeme, A. D., Sighieri, C., Portale, G., Olivetti, A., Pagnoni, C., Moschini, G., Boni, S., Guerra, A., Scudellari, R., Vella, S., Inchiostro, S., Piazza, O., Guarino, S., Aldegheri, G., Napoli, G., Morettini, A., Caldini, E., Menicacci, L., Pieralli, F., Torrini, M., Poggesi, L., Visetti, E. M., Mangano, C., Visconti, S., Maietta, P., Banfi, E., Cartella, S., Venturi, B., Nuceri, A., Chiesa, E., Pacentra, E., Panzolato, G., Giannotti, M., Bianchi, C., Pietrangelo, A., Para, O., Rutili, M. S., Russo, R., Lanfranco, M., Scalabrino, E., Tafuri, A., Perfetti, E., Chiarello, T., Cancanelli, L., Otero, M., Pannella, G., Bellucci, F., Ferrero, G., Vico, C., Stillante, M. S., D'Andrea, G., Amoroso, F., Arcidiacono, A., Bella, A. M., Belsito, A., Berte, Y., Carubia, G., Caruso, M. G., Casella, O., Chiereleson, F., Costa, C., De Franco, D., Germana, G., Messina, A., Musumeci, D., Noto, C., Valenti, M., Sorrentino, C., Panico, R., Schettino, G., Piccoli, J., Pepe, A., De Rosa, F., Ottaviano, M., Marrazzo, G., Raponi, G., Diberardino, S., Bausi, S., Marini, S. F., Giubellino, E., Innocenti, G., Gugliemi, G., Maccari, D., and Baciu, I.
- Subjects
tocilizumab ,covid 19 ,pneumonia - Published
- 2021
23. Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study
- Author
-
Zeppellini, A, Galimberti, S, Leone, B, Pacifico, C, Riva, F, Cicchiello, F, Capici, S, Maggioni, C, Sala, L, Cazzaniga, M, Zeppellini, Annalisa, Galimberti, Stefania, Leone, Biagio Eugenio, Pacifico, Claudia, Riva, Francesca, Cicchiello, Federica, Capici, Serena, Maggioni, Claudia, Sala, Luca, Cazzaniga, Marina Elena, Zeppellini, A, Galimberti, S, Leone, B, Pacifico, C, Riva, F, Cicchiello, F, Capici, S, Maggioni, C, Sala, L, Cazzaniga, M, Zeppellini, Annalisa, Galimberti, Stefania, Leone, Biagio Eugenio, Pacifico, Claudia, Riva, Francesca, Cicchiello, Federica, Capici, Serena, Maggioni, Claudia, Sala, Luca, and Cazzaniga, Marina Elena
- Abstract
BACKGROUND: Tumor microenvironment (TME) is a dynamic setting and changes in TILs and their subpopulations are potential candidates to influence the metastatic process. Aim of this pilot study is to describe the changes occurring between primary breast cancers and their paired metastases in terms of TILs composition. To assess if these changes influence the process of metastasis development, we used a control group of patients.METHODS: We retrospectively identified 18 Luminal patients, for whom primary and metastatic tissue were available (cases) and 18 paired-matched patients (controls), not relapsed after at least 9years of follow-up, and we quantified TILs and their composition (i.e. T CD8+ and CD4+/FOXP3+). The presence of TILs was defined as ≥10%.RESULTS: Our results showed that the microenvironment composition of relapsed patients was poor of TILs (median=5%, I-III quartiles=0.6-5%), CD8+ (2.5%, 0-5%) and CD4+/FOXP3+(0%, 0-0.6%) in the primary tumor. Comparable results were observed in their related metastases (TILs 3.8%, 0.6-5%; CD8+0%, 0-1.3%; CD4+/FOXP3+0%,0-1.9%). On the contrary, the microenvironment in the control group was richer of TILs (5%, 5-17.5%) in comparison to cases, both in primary tumor (p=0.035) and related metastases (p=0.018). Although CD8+ in controls were similar to cases at primary tumor (p=0.6498), but not at metastasis (p=0.0223), they expressed only one part on the TILs subpopulations (p=0.0060), while TILs in the cases at primary tumor were almost completely CD8+ (p=0.5034).CONCLUSIONS: These findings suggest that the lack of activation of immune system in the primary tumor might influence the multifactor process of cancer progression.
- Published
- 2021
24. Therapy of Sars-Coronavirus-2 pneumonia: is there an optimal IL-6 cut-off for successful tocilizumab treatment?
- Author
-
Squillace, N, Pozzi, M, Gustinetti, G, Ricci, E, Capici, S, Columpsi, P, Sala, L, Bonfanti, P, Squillace, Nicola, Pozzi, Maria Rosa, Gustinetti, Giulia, Ricci, Elena, Capici, Serena, Columpsi, Paola, Sala, Luca, Bonfanti, Paolo, Squillace, N, Pozzi, M, Gustinetti, G, Ricci, E, Capici, S, Columpsi, P, Sala, L, Bonfanti, P, Squillace, Nicola, Pozzi, Maria Rosa, Gustinetti, Giulia, Ricci, Elena, Capici, Serena, Columpsi, Paola, Sala, Luca, and Bonfanti, Paolo
- Published
- 2021
25. 417P New insights into second-line (2L) choices after CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive (HR+)/ human epidermal growth factor 2-negative (HER2-) metastatic breast cancer (MBC) patients (pts): Preliminary results of the HERMIONE-13 study
- Author
-
Cogliati, V., Rossi, E., Turla, A., Ambroggi, M., Berardi, R., Borella, F., Coltelli, L., De Giorgi, U.F.F., Ferro, A., Garrone, O., Giordano, M., Landucci, E., Mazzotta, M., Moretti, G., Palumbo, R., Vici, P., Zustovich, F., Riva, F., Capici, S., and Cazzaniga, M.E.
- Published
- 2023
- Full Text
- View/download PDF
26. Efficacy and safety of vinorelbine-capecitabine oral metronomic combinaton in elderly metastatc breast cancer patents: VICTOR-1 study
- Author
-
Cazzaniga, M, Torri, V, Riva, F, Porcu, L, Cicchiello, F, Capici, S, Cortinovis, D, Digiacomo, N, Bidoli, P, Cazzaniga ME, Torri V, Riva F, Porcu L, Cicchiello F, Capici S, Cortinovis D, Digiacomo N, Bidoli P, Cazzaniga, M, Torri, V, Riva, F, Porcu, L, Cicchiello, F, Capici, S, Cortinovis, D, Digiacomo, N, Bidoli, P, Cazzaniga ME, Torri V, Riva F, Porcu L, Cicchiello F, Capici S, Cortinovis D, Digiacomo N, and Bidoli P
- Abstract
Purpose: Elderly patents with metastatc breast cancer are expected to derive similar benefits from chemotherapy as younger patents, but are more likely to experience therapy-related toxicity. Data from the VICTOR-1 study showed that metronomic therapy with vinorelbine and capecitabine was effectve and well tolerated in patents with metastatc breast cancer. This analysis determined the efficacy and safety of the metronomic combinaton of oral vinorelbine and capecitabine in a subgroup of VICTOR-1 study patents aged ≥70 years. Methods: Eighteen of the 32 patents enrolled in VICTOR-1 were aged ≥70 years. Objectve response and clinical benefit rates were calculated and toxicity was determined using the NCI-CTCAE criteria. Results: All patents had at least 1 comorbidity (4 had 2 comorbidites), and 77.7% were taking concomitant medicaton. Eight patents (44%) had received ≥1 chemotherapy regimens for metastatc disease and most (78%) had ≥2 metastatc sites. Grade 1-2 adverse events occurred in 45.8% of cycles, whereas the incidence of grade 3 and grade 4 events was very low (1.5% and 0.7%, respectvely). Median tme to progression was 10.5 months (range 1-40). The objectve response rate was 33% and the clinical benefit rate was 67%. Conclusions: The all-oral metronomic combinaton of vinorelbine and capecitabine had an acceptable efficacy profile and appears to be beter tolerated than standard treatment schedules in elderly metastatc breast cancer patents (age ≥70 years).
- Published
- 2017
27. Idoneità lavorativa, ergonomia e aspetti medico-legali nella Malattia di Parkinson
- Author
-
Gentili, S, Capici, S, Di Lazzaro, G, Ebner, G, Livigni, L, Magrini, A, Marsella, Lt, Mencarelli, R, Mugnaini, S, Olivieri, E, Pierantozzi, M, Pietroiusti, A, Pisani, A, and Stefani, A
- Subjects
Settore MED/44 - Medicina del Lavoro - Published
- 2018
28. Targeted therapies and immunotherapy in non-small-cell lung cancer
- Author
-
Cortinovis, D, Abbate, M, Bidoli, P, Capici, S, Canova, S, Cortinovis D, Abbate M, Bidoli P, Capici S, Canova S, Cortinovis, D, Abbate, M, Bidoli, P, Capici, S, Canova, S, Cortinovis D, Abbate M, Bidoli P, Capici S, and Canova S
- Abstract
Non-small-cell lung cancer is still considered a difficult disease to manage because of its aggressiveness and resistance to common therapies. Chemotherapy remains the gold standard in nearly 80%of lung cancers, but clinical outcomes are discouraging, and the impact on median overall survival (OS) barely reaches 12 months. At the end of the last century, the discovery of oncogene-driven tumours completely changed the therapeutic landscape in lung cancers, harbouring specific gene mutations/translocations. Epidermal growth factors receptor (EGFR) common mutations first and anaplastic lymphoma kinase (ALK) translocations later led new insights in lung cancer biology knowledge. The use of specific tyrosine kinases inhibitors overturned the biological behaviour of EGFR mutation positive tumours and became a preclinical model to understand the heterogeneity of lung cancers and the mechanisms of drug resistance. In this review, we summarise the employment of targeted agents against the most representative biomolecular alterations and provide some criticisms of the therapeutic strategies.
- Published
- 2016
29. Predictive role of absolute lymphocyte count (alc) and neutrophil/lymphocyte ratio (nlr) in patients with metastatic non small cell lung cancer (nsclc) treated with nivolumab: results of a retrospective monocentric study
- Author
-
Canova, S., primary, Bidoli, P., additional, Lissoni, P., additional, Abbate, M.I., additional, Capici, S., additional, Casiraghi, S., additional, and Cortinovis, D., additional
- Published
- 2016
- Full Text
- View/download PDF
30. Subcutaneous Trastuzumab (scT) and metronomic oral Vinorelbine (mVRL) combination in HER2 + ve advanced breast cancer (ABC) patients (pts): a pilot evaluation of toxicity. Preliminary results of the VICTOR-4 study
- Author
-
Cicchiello, F., primary, Riva, F., additional, Cazzaniga, M.E., additional, Digiacomo, N., additional, Pelizzoni, D., additional, Longarini, R., additional, Capici, S., additional, and Bidoli, P., additional
- Published
- 2016
- Full Text
- View/download PDF
31. Targeted therapies and immunotherapy in non-small-cell lung cancer
- Author
-
Cortinovis, D, primary, Abbate, M, additional, Bidoli, P, additional, Capici, S, additional, and Canova, S, additional
- Published
- 2016
- Full Text
- View/download PDF
32. F44 - Subcutaneous Trastuzumab (scT) and metronomic oral Vinorelbine (mVRL) combination in HER2 + ve advanced breast cancer (ABC) patients (pts): a pilot evaluation of toxicity. Preliminary results of the VICTOR-4 study
- Author
-
Cicchiello, F., Riva, F., Cazzaniga, M.E., Digiacomo, N., Pelizzoni, D., Longarini, R., Capici, S., and Bidoli, P.
- Published
- 2016
- Full Text
- View/download PDF
33. A29 - Predictive role of absolute lymphocyte count (alc) and neutrophil/lymphocyte ratio (nlr) in patients with metastatic non small cell lung cancer (nsclc) treated with nivolumab: results of a retrospective monocentric study
- Author
-
Canova, S., Bidoli, P., Lissoni, P., Abbate, M.I., Capici, S., Casiraghi, S., and Cortinovis, D.
- Published
- 2016
- Full Text
- View/download PDF
34. RACHIALGIE: MECCANISMI DEL DOLORE LOMBARE, TRATTAMENTO CON MEZZI FISICI E TERAPIA INFILTRATIVA
- Author
-
Santilli, Valter, DI GIROLAMO, G., Finucci, S., Capici, S., and Paris, E.
- Published
- 1999
35. Quality of life in patients with Charcot–Marie–Tooth disease
- Author
-
Vinci, P., primary, Serrao, M., additional, Millul, A., additional, Deidda, A., additional, De Santis, F., additional, Capici, S., additional, Martini, D., additional, Pierelli, F., additional, and Santilli, V., additional
- Published
- 2005
- Full Text
- View/download PDF
36. Reprise du travail et qualité de vie des traumatisés crâniens graves: l'expérience d'une section d'observation et d'aide à l'insertion professionnelle
- Author
-
Dehail, P, primary, Rouleaud, S, additional, Le Chapelain, L, additional, Debelleix, X, additional, Petit, H, additional, Destaillats, JM, additional, Capici, S, additional, Joseph, PA, additional, Mazaux, JM, additional, and Barat, M, additional
- Published
- 1998
- Full Text
- View/download PDF
37. Why not? Motivations for entering a volunteer register for clinical trials during the COVID-19 pandemic
- Author
-
Selena Russo, Marco Bani, Marco Terraneo, Valeria Quaglia, Giampaolo Nuvolati, Rebecca Cavaliere, Serena Capici, Marina Elena Cazzaniga, Maria Grazia Strepparava, Russo, S, Bani, M, Terraneo, M, Quaglia, V, Nuvolati, G, Cavaliere, R, Capici, S, Cazzaniga, M, and Strepparava, M
- Subjects
Volunteers ,Pharmacology ,Clinical Trials as Topic ,Motivation ,Vaccines ,COVID-19 Vaccines ,COVID-19 ,General Medicine ,Trust ,Healthy volunteers register ,Clinical trial ,Humans ,Pharmacology (medical) ,Vaccine ,Pandemics ,Healthy volunteer - Abstract
Backgrounds Healthy volunteers play a key role in clinical trials and it is crucial to develop recruitment strategies that capitalise on their motivations and maximise their participation. The COVID-19 pandemic has shown the importance of finding motivated healthy volunteers for the development of new vaccines. Public registers represent a promising way to promote the participation of healthy volunteers in the research field, but their adoption is still limited. The current study aimed to explore the motivations of healthy volunteers to enrol in an Italian public register for clinical trials during the COVID-19 pandemic and their attitude toward participating in a phase 1 COVID-19 vaccine clinical trial. The impacts of different enrolling interview modalities (in person, by phone, by mail) on motivation, understanding of information and trust in researchers were also investigated. Methods An online survey investigating experience with COVID-19, motivations to enrol, trust in researchers, political and healthcare authorities and pharmacological companies was presented to people applying as healthy volunteers in the public register for clinical trials at Phase 1 Unit Research Centre of ASST Monza, Italy, and considering to participate in a COVID-19 vaccine clinical trial. Data were collected in June 2021. Results Altruistic motivations were the main driver for enrolling in the public register, while self-interested motivations were secondary. No gender differences were found. As for enrolling modalities, no differences emerged between in-person and interviews for motivation to enrol, understanding of information and trust in researchers. Email modality led to significantly lower volunteers’ satisfaction and understanding of information but similar trust in research. Conclusions This study supports the validity of different interview modalities (in person and by phone) for the enrolment of healthy volunteers for clinical trials and highlights the positive role of public registers for the recruitment procedures.
- Published
- 2022
- Full Text
- View/download PDF
38. Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells
- Author
-
Nicoletta Cordani, Luca Mologni, Rocco Piazza, Viola Cogliati, Francesca Pepe, Serena Capici, Camillo Di Bella, Marta Jaconi, Maria Grazia Cerrito, Matteo Villa, Pietro Tettamanti, Guido Cavaletti, Marialuisa Lavitrano, Marina Elena Cazzaniga, Cordani, N, Mologni, L, Piazza, R, Cogliati, V, Pepe, F, Capici, S, DI BELLA, C, Jaconi, M, Cerrito, M, Villa, M, Tettamanti, P, Cavaletti, G, Lavitrano, M, and Cazzaniga, M
- Subjects
CDKN2B expression, LBC, CDK4/6i - Abstract
Background Cyclin-Dependent Kinase (CDK) 4/6 inhibitors have significantly improved progression-free survival of Hormone Receptor positive (HR+), Human Epidermal Growth Factor Receptor type 2 negative (HER2-) luminal breast cancers (LBC). Several studies demonstrated that the addition of CDK4/6 inhibitors to endocrine therapy results in a significant prolongation of progression-free survival in patients with endocrine-sensitive or endocrine-resistant LBCs. However, the percentage of patients unresponsive or refractory to these therapies is as high as 40%, and no reliable and reproducible biomarkers able to select a priori responder or resistant patients have been validated till now. The main cause of resistance is the selection of mutant clones in the target oncoprotein. Other mechanisms, like oncogene amplification/overexpression or mutations in other pathways, have been described in several models. Here, we focused on palbociclib, a selective inhibitor of CDK4/6. Methods: We generated and characterized human luminal breast cancer MCF-7 and T47D derived cell lines, able to survive and proliferate at different palbociclib concentrations, which also shows cross-resistance to abemaciclib. The resistant MCF7 cell line was characterized by RNA sequencing. Results: To confirm resistance, we performed cell viability assays in MCF-7 and T47D palbociclib sensitive cells (MCF-7pS and T47pS) versus MCF-7 and T47D palbociclib resistant cells (MCF-7pR5), showing a 10-fold increase of IC50 in MCF-7pR5 compared to parental MCF-7pS cells (16.7 vs 1.8 µM) and a 3-fold increase of IC50 in T47DpR5 vs parental T47DpS. We also confirmed a significant cross resistance using abemaciclib in MCF-7pR5 with an IC50 equal to 6.8 vs 0.35 µM and in T47DpR with an IC50 of 10.72 vs 0.5 µM. RNA sequencing, qRT-qPCR and Western blot results demonstrated a dramatic downregulation of the CDK4 inhibitor CDKN2B in both cell lines and we found upregulation of an miR-31, a putative regulator of CDKN2B. This finding was further validated in a biopsy from a patient progressing on CDK4/6 inhibitor therapy. Conclusions: This study provides new relevant information regarding the mechanism of resistance to CDK4/6 inhibitors and suggests potential new markers to follow up patients during the treatment.
- Published
- 2023
39. Social capital and willingness to participate in COVID-19 vaccine trials: an Italian case-control study
- Author
-
Marco, Terraneo, Valeria, Quaglia, Giampaolo, Nuvolati, Marco, Bani, Selena, Russo, Maria Grazia, Strepparava, Serena, Capici, Rebecca, Cavaliere, Marina Elena, Cazzaniga, Terraneo, M, Quaglia, V, Nuvolati, G, Bani, M, Russo, S, Strepparava, M, Capici, S, Cavaliere, R, and Cazzaniga, M
- Subjects
COVID-19 Vaccines ,Italy ,Social capital ,Case-Control Studies ,Vaccine trials willingne ,Public Health, Environmental and Occupational Health ,Humans ,COVID-19 ,Trust ,Vaccine - Abstract
Background What leads healthy people to enter in a volunteer register for clinical trials? This study aimed to investigate the relationship between the decision to volunteer in clinical trials for a COVID-19 vaccine and social capital, in a sample of healthy volunteers in Italy. Since social capital is characterized by trust, reciprocity, and social and political participation, we claim that it is key in leading individuals to actively take action to protect public health, and to take a risk for the (potential) benefit not only of themselves but for the entire community. Methods This study was conducted through the administration of a questionnaire to healthy volunteers registered for a phase 1 clinical trial for a COVID-19 vaccine in the Unit Research Centre of ASST-Monza, in September 2020. The primary purpose of a phase 1 study is to evaluate the safety of a new drug candidate before it proceeds to further clinical studies. To approximate a case–control study, we randomly matched the 318 respondents to healthy volunteers (cases) with 318 people randomly selected by Round 9 of the European Social Survey (controls), using three variables, which we considered to be associated with the decision to volunteer: gender, age, and education level. To execute this matching procedure, we used the “ccmatch” module in STATA. Results The findings highlight the positive impact of social capital in the choice of healthy individuals to volunteer in COVID-19 vaccine clinical trials. Controlling for possible confounding factors, some exemplary results show that people with a high level of general trust have a greater likelihood of volunteering compared to people with low trust (OR = 2.75, CI = 1.58–4.77); we also found that it is more probable that volunteers are people who have actively taken action to improve things compared with people who have not (for individuals who did three or more actions: OR = 7.54, CI = 4.10–13.86). People who reported voting (OR = 3.91, CI = 1.70–8.99) and participating in social activities more than other people of their age (OR = 2.89, CI = 1.82–4.60) showed a higher probability to volunteer. Conclusions Together with the adoption of urgent health measures in response to COVID-19, government policymakers should also promote social capital initiatives to encourage individuals to actively engage in actions aimed at protecting collective health. Our findings make an empirical contribution to the research on vaccines and its intersection with social behaviour, and they provide useful insights for policymakers to manage current and future disease outbreaks and to enhance the enrolment in vaccine trials.
- Published
- 2022
- Full Text
- View/download PDF
40. The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data
- Author
-
Giulia Gustinetti, Marina Cazzaniga, Stefania Galimberti, Maria Grazia Valsecchi, Nicola Squillace, Paolo Bonfanti, Luca Sala, Serena Capici, Capici, S, Sala, L, Galimberti, S, Valsecchi, M, Squillace, N, Gustinetti, G, Cazzaniga, M, and Bonfanti, P
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,030106 microbiology ,Disease ,lcsh:Infectious and parasitic diseases ,03 medical and health sciences ,chemistry.chemical_compound ,tocilizumab ,0302 clinical medicine ,Tocilizumab ,Internal medicine ,Pandemic ,Global health ,Medicine ,pneumonia ,Pharmacology (medical) ,lcsh:RC109-216 ,030212 general & internal medicine ,Pharmacology ,business.industry ,Retrospective cohort study ,medicine.disease ,Pneumonia ,sars-cov-2 ,Infectious Diseases ,chemistry ,covid-19 ,Infection and Drug Resistance ,Cohort ,business ,Rapid Communication - Abstract
Serena Capici,1,* Luca Sala,1,* Stefania Galimberti,2 Maria Grazia Valsecchi,2 Nicola Squillace,3 Giulia Gustinetti,3 Marina Elena Cazzaniga,1,4 Paolo Bonfanti3,4 1Phase 1 Research Unit, ASST Monza, Monza, Italy; 2Bicocca Bioinformatics Biostatistics and Bioimaging B4 Center, School of Medicine and Surgery, University of Milano - Bicocca, Monza, Italy; 3Infectious Disease Unit, ASST Monza, Monza, Italy; 4School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy*These authors contributed equally to this workCorrespondence: Marina Elena CazzanigaPhase 1 Research Unit, ASST Monza, Monza, ItalyTel +390392339037Email marina.cazzaniga@asst-monza.itAbstract: The severe acute respiratory syndrome coronavirus 2 pandemic has dominated the global health scenario from the beginning of 2020 and still represents a major health emergency. Cytokine inhibitors as tocilizumab have been used to treat COVID-19 severe pneumonia with conflicting results. We performed a retrospective study whose results can contribute to the general overview regarding the role of these agents in severe COVID-19 pneumonia, suggesting an interesting, even not statistically significant evidence of the effectiveness of tocilizumab treatment in this disease and sow a seed of reflection about their use in future waves of pandemic. We compared two cohorts of patients treated with local standard of care and with tocilizumab in the experimental one. With a median follow-up of 92 days, deaths were 6 and 16 in the tocilizumab and the standard of care group, respectively. With a longer follow-up than previous studies, a trend in difference with regards to mortality of the groups was observed.Keywords: Sars-Cov-2, COVID-19, pneumonia, tocilizumab
- Published
- 2021
41. Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows
- Author
-
Marina Elena Cazzaniga, Serena Capici, Nicoletta Cordani, Viola Cogliati, Francesca Fulvia Pepe, Francesca Riva, Maria Grazia Cerrito, Cazzaniga, M, Capici, S, Cordani, N, Cogliati, V, Fulvia Pepe, F, Riva, F, and Cerrito, M
- Subjects
safety ,breast cancer ,metronomic chemotherapy ,General Medicine - Abstract
Metronomic chemotherapy (mCHT), defined as continuous administration of low-dose chemotherapeutic agents with no or short regular treatment-free intervals, was first introduced to the clinic in international guidelines in 2017, and, since then, has become one of the available strategies for the treatment of advanced breast cancer (ABC). Despite recent successes, many unsolved practical and theoretical issues remain to be addressed. The present review aims to identify the “lights and shadows” of mCHT in preclinical and clinical settings. In the preclinical setting, several findings indicate that one of the most noticeable effects of mCHT is on the tumor microenvironment, which, over the last twenty years, has been demonstrated to be pivotal in supporting tumor cell survival and proliferation. On the other hand, the direct effects on tumor cells have been less well-defined. In addition, critical items to be addressed are the lack of definition of an optimal biological dose (OBD), the method of administration of metronomic schedules, and the recognition and validation of predictive biomarkers. In the clinical context—where mCHT has mainly been used in a metastatic setting—low toxicity is the most well-recognised light of mCHT, whereas the type of study design, the absence of randomised trials and uncertainty in terms of doses and drugs remain among the shadows. In conclusion, growing evidence indicates that mCHT is a suitable treatment option for selected metastatic breast cancer (MBC) patients. Moreover, given its multimodal mechanisms of action, its addition to immunological and targeted therapies might represent a promising new approach to the treatment of MBC. More preclinical data are needed in this regard, which can only be obtained through support for translational research as the key link between basic science and patient care.
- Published
- 2022
- Full Text
- View/download PDF
42. Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything
- Author
-
Capici, Serena, Ammoni, Luca Carlofrancesco, Meli, Nicole, Cogliati, Viola, Pepe, Francesca Fulvia, Piazza, Francesca, Cazzaniga, Marina Elena, Capici, S, Ammoni, L, Meli, N, Cogliati, V, Pepe, F, Piazza, F, and Cazzaniga, M
- Subjects
Cancer Research ,Oncology ,androgen receptor ,PI3K/AKT/mTOR ,metronomic ,TNBC - Abstract
Triple-negative breast cancer—defined by the absence of oestrogen/progesterone receptors and human epidermal growth factor receptor 2 expression—is a complex and heterogeneous type of tumour characterised by poor prognosis, aggressive behaviour and lack of effective therapeutic strategies. The identification of new biomarkers and molecular signatures is leading to development of new therapeutic strategies including immunotherapy, targeted therapy and antibody-drug conjugates (ADCs). Against a background where chemotherapy has always been considered the standard of care, evolution towards a precision medicine approach could improve TNBC clinical practice in a complex scenario, with many therapeutic options and new drugs. The aim of this review was to focus on emerging therapeutic targets and their related specific therapy, discussing available and emerging drugs, underlining differences in approval by American and European regulatory authorities and showing the future perspective in the large number of ongoing clinical trials.
- Published
- 2022
- Full Text
- View/download PDF
43. Metronomic Chemotherapy
- Author
-
Maria Grazia Cerrito, Viola Cogliati, Marina Elena Cazzaniga, Serena Capici, Nicoletta Cordani, Francesca Riva, Cazzaniga, M, Cordani, N, Capici, S, Cogliati, V, Riva, F, and Cerrito, M
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Context (language use) ,Review ,03 medical and health sciences ,Therapeutic approach ,0302 clinical medicine ,Immune system ,Internal medicine ,metronomic chemotherapy ,medicine ,RC254-282 ,Chemotherapy ,clinical trials ,business.industry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Myeloid leukemia ,Cancer ,medicine.disease ,Metronomic Chemotherapy ,Clinical trial ,030104 developmental biology ,Tolerability ,030220 oncology & carcinogenesis ,MED/06 - ONCOLOGIA MEDICA ,business ,mechanism of action - Abstract
Simple Summary The present article reviews the state of the art of metronomic chemotherapy use to treat the principal types of cancers, namely breast, non-small cell lung cancer and colorectal ones, and of the most recent progresses in understanding the underlying mechanisms of action. Areas of novelty, in terms of new regimens, new types of cancer suitable for Metronomic chemotherapy (mCHT) and the overview of current ongoing trials, along with a critical review of them, are also provided. Abstract Metronomic chemotherapy treatment (mCHT) refers to the chronic administration of low doses chemotherapy that can sustain prolonged, and active plasma levels of drugs, producing favorable tolerability and it is a new promising therapeutic approach in solid and in hematologic tumors. mCHT has not only a direct effect on tumor cells, but also an action on cell microenvironment, by inhibiting tumor angiogenesis, or promoting immune response and for these reasons can be considered a multi-target therapy itself. Here we review the state of the art of mCHT use in some classical tumour types, such as breast and no small cell lung cancer (NSCLC), see what is new regarding most recent data in different cancer types, such as glioblastoma (GBL) and acute myeloid leukemia (AML), and new drugs with potential metronomic administration. Finally, a look at the strategic use of mCHT in the context of health emergencies, or in low –and middle-income countries (LMICs), where access to adequate healthcare is often not easy, is mandatory, as we always need to bear in in mind that equity in care must be a compulsory part of our medical work and research.
- Published
- 2021
44. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
- Author
-
Katia Cagossi, A. Ferzi, Domenico Amoroso, A. Baldelli, Luca Clivio, Mariangela Ciccarese, Viola Cogliati, Ornella Garrone, P. Spadaro, Daniele Santini, Vita Leonardi, Elisabetta Cretella, Luca Gianni, A. Gambaro, Alfredo Butera, A. Turletti, M.G. Sarobba, Giovanni Scognamiglio, Vittorio Gebbia, Cristiana Taverniti, F. Ferraù, D. Toniolo, Saverio Cinieri, C. Putzu, S. Capici, Antonino Musolino, Daniele Generali, Paolo Tralongo, Marina Elena Cazzaniga, Valter Torri, Antonino Grassadonia, Andrea Fontana, Emilia Montagna, E. de Conciliis, P. Di Mauro, Maria Rosaria Valerio, Rossana Berardi, Silvana Saracchini, Ferdinando Riccardi, Antonio Febbraro, I. Vallini, Patrizia Vici, Luigi Cavanna, M. G. Schintu, Roberto Valenza, F. Giovanardi, M. Nicolini, Samanta Sarti, Paolo Marchetti, Cazzaniga, M, Vallini, I, Montagna, E, Amoroso, D, Berardi, R, Butera, A, Cagossi, K, Cavanna, L, Ciccarese, M, Cinieri, S, Cretella, E, De Conciliis, E, Febbraro, A, Ferrau, F, Ferzi, A, Baldelli, A, Fontana, A, Gambaro, A, Garrone, O, Gebbia, V, Generali, D, Gianni, L, Giovanardi, F, Grassadonia, A, Leonardi, V, Marchetti, P, Sarti, S, Musolino, A, Nicolini, M, Putzu, C, Riccardi, F, Santini, D, Saracchini, S, Sarobba, M, Schintu, M, Scognamiglio, G, Spadaro, P, Taverniti, C, Toniolo, D, Tralongo, P, Turletti, A, Valenza, R, Valerio, M, Vici, P, Di Mauro, P, Cogliati, V, Capici, S, Clivio, L, Torri, V, Cazzaniga, M. E., Vallini, I., Montagna, E., Amoroso, D., Berardi, R., Butera, A., Cagossi, K., Cavanna, L., Ciccarese, M., Cinieri, S., Cretella, E., De Conciliis, E., Febbraro, A., Ferrau, F., Ferzi, A., Baldelli, A., Fontana, A., Gambaro, A. R., Garrone, O., Gebbia, V., Generali, D., Gianni, L., Giovanardi, F., Grassadonia, A., Leonardi, V., Marchetti, P., Sarti, S., Musolino, A., Nicolini, M., Putzu, C., Riccardi, F., Santini, D., Saracchini, S., Sarobba, M. G., Schintu, M. G., Scognamiglio, G., Spadaro, P., Taverniti, C., Toniolo, D., Tralongo, P., Turletti, A., Valenza, R., Valerio, M. R., Vici, P., Clivio, L., Torri, V., Cazzaniga, M E, Ferraù, F, Gambaro, A R, Sarobba, M G, Schintu, M G, and Valerio, M R
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Receptor, ErbB-2 ,Breast Neoplasms ,Triple Negative Breast Neoplasms ,Vinorelbine ,Capecitabine ,Cyclophosphamide ,Methotrexate ,Metronomic chemotherapy ,Triple-negative breast cancer ,Antineoplastic Combined Chemotherapy Protocols ,Female ,Humans ,Retrospective Studies ,ErbB-2 ,Breast cancer ,Retrospective Studie ,Internal medicine ,medicine ,Progression-free survival ,Antineoplastic Combined Chemotherapy Protocol ,business.industry ,medicine.disease ,Clinical Trial ,Metronomic Chemotherapy ,Metastatic breast cancer ,Regimen ,business ,Breast Neoplasm ,Human ,Receptor ,medicine.drug - Abstract
Purpose Triple-negative breast cancer (TNBC) represents a subtype of breast cancer which lacks the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2): TNBC accounts for approximately 20% of newly diagnosed breast cancers and is associated with younger age at diagnosis, greater recurrence risk and shorter survival time. Therapeutic options are very scarce. Aim of the present analysis is to provide further insights into the clinical activity of metronomic chemotherapy (mCHT), in a real-life setting. Methods We used data included in the VICTOR-6 study for the present analysis. VICTOR-6 is an Italian multicentre retrospective cohort study, which collected data of metastatic breast cancer (MBC) patients who have received mCHT between 2011 and 2016. Amongst the 584 patients included in the study, 97 were triple negative. In 40.2% of the TNBC patients, mCHT was the first chemotherapy treatment, whereas 32.9% had received 2 or more lines of treatment for the metastatic disease. 45.4% out of 97 TNBC patients received a vinorelbine (VRL)-based regimen, which resulted in the most used type of mCHT, followed by cyclophosphamide (CTX)-based regimens (30.9%) and capecitabine (CAPE)-based combinations (22.7%). Results Overall response rate (ORR) and disease control rate (DCR) were 17.5% and 64.9%, respectively. Median progression free survival (PFS) and overall survival (OS) were 6.0 months (95% CI: 4.9–7.2) and 12.1 months (95% CI: 9.6–16.7). Median PFS was 6.9 months for CAPE-based regimens (95% CI: 5.0–18.4), 6.1 months (95% CI: 4.0–8.9) for CTX-based and 5.3 months (95% CI: 4.1–9.5) for VRL-based ones. Median OS was 18.2 months (95% CI: 9.1-NE) for CAPE-based regimens and 11.8 months for VRL- (95% CI: 9.3–16.7 and CTX-based ones (95%CI: 8.7–52.8). Tumour response, PFS and OS decreased proportionally in later lines. Conclusion This analysis represents the largest series of TNBC patients treated with mCHT in a real-life setting and provides further insights into the advantages of using this strategy even in this poor prognosis subpopulation.
- Published
- 2021
45. How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
- Author
-
Viola Cogliati, Serena Capici, Francesca Fulvia Pepe, Pierluigi di Mauro, Francesca Riva, Federica Cicchiello, Claudia Maggioni, Nicoletta Cordani, Maria Grazia Cerrito, Marina Elena Cazzaniga, Cogliati, V, Capici, S, Pepe, F, Di Mauro, P, Riva, F, Cicchiello, F, Maggioni, C, Cordani, N, Cerrito, M, and Cazzaniga, M
- Subjects
Space and Planetary Science ,Treatment sequencing ,Therapy resistance ,Paleontology ,Metastatic breast cancer ,CDK4/6 inhibitor ,General Biochemistry, Genetics and Molecular Biology ,Ecology, Evolution, Behavior and Systematics - Abstract
CDK4/6 inhibitors in association with endocrine therapy represent the best therapeutic choice for either endocrine-sensitive or resistant hormone-receptor-positive advanced breast cancer patients. On the contrary, the optimal therapeutic strategy after the failure of CDK4/6 inhibitors-based treatment still remains an open question worldwide. In this review, we analyze the most studied mechanisms of resistance to CDK4/6 inhibitors treatment, as well as the most significant results of retrospective and prospective trials in the setting of progression after CDK4/6 inhibitors, to provide the reader a comprehensive overview from both a preclinical and especially a clinical perspective. In our opinion, an approach based on a deeper knowledge of resistance mechanisms to CDK4/6 inhibitors, but also on a careful analysis of what is done in clinical practice, can lead to a better definition of prospective randomized trials, to implement a personalized sequence approach, based on molecular analyses.
- Published
- 2022
- Full Text
- View/download PDF
46. Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study
- Author
-
Federica Cicchiello, Marina Elena Cazzaniga, Luca Sala, Annalisa Zeppellini, Biagio Eugenio Leone, Stefania Galimberti, Serena Capici, Francesca Riva, Claudia Maggioni, Claudia Pacifico, Zeppellini, A, Galimberti, S, Leone, B, Pacifico, C, Riva, F, Cicchiello, F, Capici, S, Maggioni, C, Sala, L, and Cazzaniga, M
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,Receptor, ErbB-2 ,T CD8 + ,Biopsy ,Pilot Projects ,Metastasis ,0302 clinical medicine ,Surgical oncology ,Tumor Microenvironment ,Breast ,Mastectomy ,Aged, 80 and over ,FOXP3 ,hemic and immune systems ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Prognosis ,Primary tumor ,Receptors, Estrogen ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Disease Progression ,Female ,Research Article ,medicine.medical_specialty ,Microenvironment ,chemical and pharmacologic phenomena ,Breast Neoplasms ,lcsh:RC254-282 ,Luminal ,03 medical and health sciences ,Breast cancer ,Lymphocytes, Tumor-Infiltrating ,Internal medicine ,Breast Cancer ,Genetics ,medicine ,Humans ,Aged ,Retrospective Studies ,Tumor microenvironment ,business.industry ,Cancer ,T CD4+ FOXP3+ ,medicine.disease ,030104 developmental biology ,Case-Control Studies ,Tumor infiltrating lymphocytes (TILs) ,Neoplasm Recurrence, Local ,business ,CD8 ,Follow-Up Studies - Abstract
Background Tumor microenvironment (TME) is a dynamic setting and changes in TILs and their subpopulations are potential candidates to influence the metastatic process. Aim of this pilot study is to describe the changes occurring between primary breast cancers and their paired metastases in terms of TILs composition. To assess if these changes influence the process of metastasis development, we used a control group of patients. Methods We retrospectively identified 18 Luminal patients, for whom primary and metastatic tissue were available (cases) and 18 paired-matched patients (controls), not relapsed after at least 9 years of follow-up, and we quantified TILs and their composition (i.e. T CD8+ and CD4+/FOXP3+). The presence of TILs was defined as ≥10%. Results Our results showed that the microenvironment composition of relapsed patients was poor of TILs (median = 5%, I-III quartiles = 0.6–5%), CD8+ (2.5%, 0–5%) and CD4+/FOXP3 + (0%, 0–0.6%) in the primary tumor. Comparable results were observed in their related metastases (TILs 3.8%, 0.6–5%; CD8+ 0%, 0–1.3%; CD4+/FOXP3+ 0%,0–1.9%). On the contrary, the microenvironment in the control group was richer of TILs (5%, 5–17.5%) in comparison to cases, both in primary tumor (p = 0.035) and related metastases (p = 0.018). Although CD8+ in controls were similar to cases at primary tumor (p = 0.6498), but not at metastasis (p = 0.0223), they expressed only one part on the TILs subpopulations (p = 0.0060), while TILs in the cases at primary tumor were almost completely CD8+ (p = 0.5034). Conclusions These findings suggest that the lack of activation of immune system in the primary tumor might influence the multifactor process of cancer progression.
- Published
- 2020
47. Therapy of Sars-Coronavirus-2 pneumonia: is there an optimal IL-6 cut-off for successful tocilizumab treatment?
- Author
-
Nicola Squillace, Elena Ricci, Luca Sala, Paolo Bonfanti, Paola Columpsi, Giulia Gustinetti, Maria Rosa Pozzi, Serena Capici, Squillace, N, Pozzi, M, Gustinetti, G, Ricci, E, Capici, S, Columpsi, P, Sala, L, and Bonfanti, P
- Subjects
Microbiology (medical) ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Antibodies, Monoclonal, Humanized ,chemistry.chemical_compound ,Tocilizumab ,Correspondence ,Medicine ,Humans ,Interleukin 6 ,biology ,business.industry ,Interleukin-6 ,SARS-CoV-2 ,COVID-19 ,Pneumonia ,medicine.disease ,COVID-19 Drug Treatment ,Infectious Diseases ,AcademicSubjects/MED00290 ,chemistry ,Immunology ,biology.protein ,business - Published
- 2020
48. Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study
- Author
-
Luca Porcu, Federica Cicchiello, Nunzio Digiacomo, Marina Elena Cazzaniga, Paolo Bidoli, Diego Cortinovis, Valter Torri, Serena Capici, Francesca Riva, Cazzaniga, M, Torri, V, Riva, F, Porcu, L, Cicchiello, F, Capici, S, Cortinovis, D, Digiacomo, N, and Bidoli, P
- Subjects
0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,MEDLINE ,Breast Neoplasms ,Vinorelbine ,Vinblastine ,Capecitabine ,03 medical and health sciences ,Breast cancer ,Elderly ,0302 clinical medicine ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Humans ,Aged ,Aged, 80 and over ,Chemotherapy ,business.industry ,Metronomic chemotherapy ,General Medicine ,medicine.disease ,Metastatic breast cancer ,Metronomic Chemotherapy ,Clinical trial ,030104 developmental biology ,030220 oncology & carcinogenesis ,Female ,metastatic breast cancer ,business ,medicine.drug - Abstract
Purpose Elderly patients with metastatic breast cancer are expected to derive similar benefits from chemotherapy as younger patients, but are more likely to experience therapy-related toxicity. Data from the VICTOR-1 study showed that metronomic therapy with vinorelbine and capecitabine was effective and well tolerated in patients with metastatic breast cancer. This analysis determined the efficacy and safety of the metronomic combination of oral vinorelbine and capecitabine in a subgroup of VICTOR-1 study patients aged ≥70 years. Methods Eighteen of the 32 patients enrolled in VICTOR-1 were aged ≥70 years. Objective response and clinical benefit rates were calculated and toxicity was determined using the NCI-CTCAE criteria. Results All patients had at least 1 comorbidity (4 had 2 comorbidities), and 77.7% were taking concomitant medication. Eight patients (44%) had received ≥1 chemotherapy regimens for metastatic disease and most (78%) had ≥2 metastatic sites. Grade 1-2 adverse events occurred in 45.8% of cycles, whereas the incidence of grade 3 and grade 4 events was very low (1.5% and 0.7%, respectively). Median time to progression was 10.5 months (range 1-40). The objective response rate was 33% and the clinical benefit rate was 67%. Conclusions The all-oral metronomic combination of vinorelbine and capecitabine had an acceptable efficacy profile and appears to be better tolerated than standard treatment schedules in elderly metastatic breast cancer patients (age ≥70 years).
- Published
- 2016
49. Targeted therapies and immunotherapy in non-small-cell lung cancer
- Author
-
D Cortinovis, S. Canova, M.I. Abbate, P. Bidoli, S. Capici, Cortinovis, D, Abbate, M, Bidoli, P, Capici, S, and Canova, S
- Subjects
0301 basic medicine ,Cancer Research ,targeted agents ,oncogene drivers ,medicine.medical_treatment ,Disease ,Drug resistance ,Review ,Gene mutation ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Anaplastic lymphoma kinase ,Oncogene driver ,Lung cancer ,non-small cell lung cancer ,Chemotherapy ,business.industry ,Immunotherapy ,medicine.disease ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Immunology ,Cancer research ,immunotherapy ,business ,Non-small-cell lung cancer ,Tyrosine kinase ,Targeted agent - Abstract
Non-small-cell lung cancer is still considered a difficult disease to manage because of its aggressiveness and resistance to common therapies. Chemotherapy remains the gold standard in nearly 80% of lung cancers, but clinical outcomes are discouraging, and the impact on median overall survival (OS) barely reaches 12 months. At the end of the last century, the discovery of oncogene-driven tumours completely changed the therapeutic landscape in lung cancers, harbouring specific gene mutations/translocations. Epidermal growth factors receptor (EGFR) common mutations first and anaplastic lymphoma kinase (ALK) translocations later led new insights in lung cancer biology knowledge. The use of specific tyrosine kinases inhibitors overturned the biological behaviour of EGFR mutation positive tumours and became a preclinical model to understand the heterogeneity of lung cancers and the mechanisms of drug resistance. In this review, we summarise the employment of targeted agents against the most representative biomolecular alterations and provide some criticisms of the therapeutic strategies.
- Published
- 2016
50. GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial.
- Author
-
Capone S, Fusco FM, Milleri S, Borrè S, Carbonara S, Lo Caputo S, Leone S, Gori G, Maggi P, Cascio A, Lichtner M, Cauda R, Dal Zoppo S, Cossu MV, Gori A, Roda S, Confalonieri P, Bonora S, Missale G, Codeluppi M, Mezzaroma I, Capici S, Pontali E, Libanore M, Diani A, Lanini S, Battella S, Contino AM, Piano Mortari E, Genova F, Parente G, Dragonetti R, Colloca S, Visani L, Iannacone C, Carsetti R, Folgori A, and Camerini R
- Subjects
- Humans, SARS-CoV-2, COVID-19 Vaccines, Immunity, Cellular, COVID-19 prevention & control, Vaccines
- Abstract
The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and heterologous immunization approaches implemented worldwide for booster doses call for diversified vaccine portfolios. GRAd-COV2 is a gorilla adenovirus-based COVID-19 vaccine candidate encoding prefusion-stabilized spike. The safety and immunogenicity of GRAd-COV2 is evaluated in a dose- and regimen-finding phase 2 trial (COVITAR study, ClinicalTrials.gov: NCT04791423) whereby 917 eligible participants are randomized to receive a single intramuscular GRAd-COV2 administration followed by placebo, or two vaccine injections, or two doses of placebo, spaced over 3 weeks. Here, we report that GRAd-COV2 is well tolerated and induces robust immune responses after a single immunization; a second administration increases binding and neutralizing antibody titers. Potent, variant of concern (VOC) cross-reactive spike-specific T cell response peaks after the first dose and is characterized by high frequencies of CD8s. T cells maintain immediate effector functions and high proliferative potential over time. Thus, GRAd vector is a valuable platform for genetic vaccine development, especially when robust CD8 response is needed., Competing Interests: Declaration of interests S. Capone, R. Camerini, R.D., F.G., S. Battella, A.M.C., G.P., S. Colloca, and A.F. are full employees of ReiThera Srl. S. Colloca and A.F. are founders and shareholders of Keires AG. S. Colloca is named inventor of the patent application no. 20183515.4 titled “GORILLA ADENOVIRUS NUCLEIC ACID- AND AMINO ACID-SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREOF.” L.V. is full employee of Exom, the CRO in charge of the COVITAR study management. S.L.C. received honoraria from Gilead, ViiV, GSK, Janssen, and MSD, has participated on the advisory boards of Gilead, ViiV, GSK, Janssen, and MSD, and has received support for attending meetings from Gilead. M. Lichtner received honoraria and support for attending meetings from Gilead, MSD, and ViiV, participated on the advisory boards of ViiV, Abbvie, and MSD, and received grants through the institution from Gilead and Abbvie. R. Carsetti was a member of the COVITAR study steering committee. C.I. received financial support from Exom for statistical analysis of the COVITAR study., (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.